

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, DC 20549

Form 10-Q

(Mark One)

☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d)
OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended December 31, 2022

OR

☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d)
OF THE SECURITIES EXCHANGE ACT OF 1934

COMMISSION FILE NUMBER: 1-33901

Oaktree Specialty Lending Corporation

(EXACT NAME OF REGISTRANT AS SPECIFIED IN ITS CHARTER)

Delaware
(State or jurisdiction of
incorporation or organization)

333 South Grand Avenue, 28th Floor
Los Angeles, CA
(Address of principal executive office)

26-1219283
(I.R.S. Employer
Identification No.)

90071
(Zip Code)

REGISTRANT'S TELEPHONE NUMBER, INCLUDING AREA CODE:
(213) 830-6300

SECURITIES REGISTERED PURSUANT TO SECTION 12(b) OF THE ACT:

Title of Each Class	Trading Symbol(s)	Name of Each Exchange on Which Registered
Common Stock, par value \$0.01 per share	OCSL	The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒ No ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of "large accelerated filer," "accelerated filer," "smaller reporting company" and "emerging growth company" in Rule 12b-2 of the Exchange Act.

Large accelerated filer ☒ Accelerated filer ☐ Non-accelerated filer ☐ Smaller reporting company ☐

Emerging growth company ☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act ☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act) Yes ☐ No ☒

The registrant had 77,079,805 shares of common stock outstanding as of February 6, 2023.

OAKTREE SPECIALTY LENDING CORPORATION
FORM 10-Q FOR THE QUARTER ENDED DECEMBER 31, 2022

TABLE OF CONTENTS

PART I — FINANCIAL INFORMATION

<u>Item 1.</u>	<u>Consolidated Financial Statements:</u>	
	<u>Consolidated Statements of Assets and Liabilities as of December 31, 2022 (unaudited) and September 30, 2022</u>	<u>2</u>
	<u>Consolidated Statements of Operations (unaudited) for the three months ended December 31, 2022 and 2021</u>	<u>3</u>
	<u>Consolidated Statements of Changes in Net Assets (unaudited) for the three months ended December 31, 2022 and 2021</u>	<u>4</u>
	<u>Consolidated Statements of Cash Flows (unaudited) for the three months ended December 31, 2022 and 2021</u>	<u>5</u>
	<u>Consolidated Schedule of Investments (unaudited) as of December 31, 2022</u>	<u>6</u>
	<u>Consolidated Schedule of Investments as of September 30, 2022</u>	<u>20</u>
	<u>Notes to Consolidated Financial Statements (unaudited)</u>	<u>33</u>
<u>Item 2.</u>	<u>Management's Discussion and Analysis of Financial Condition and Results of Operations</u>	<u>85</u>
<u>Item 3.</u>	<u>Quantitative and Qualitative Disclosures about Market Risk</u>	<u>104</u>
<u>Item 4.</u>	<u>Controls and Procedures</u>	<u>106</u>

PART II — OTHER INFORMATION

<u>Item 1.</u>	<u>Legal Proceedings</u>	<u>106</u>
<u>Item 1A.</u>	<u>Risk Factors</u>	<u>106</u>
<u>Item 2.</u>	<u>Unregistered Sales of Equity Securities and Use of Proceeds</u>	<u>106</u>
<u>Item 3.</u>	<u>Defaults Upon Senior Securities</u>	<u>106</u>
<u>Item 4.</u>	<u>Mine Safety Disclosures</u>	<u>106</u>
<u>Item 5.</u>	<u>Other Information</u>	<u>106</u>
<u>Item 6.</u>	<u>Exhibits</u>	<u>107</u>
<u>Signatures</u>		<u>108</u>

PART I — FINANCIAL INFORMATION

Item 1. Consolidated Financial Statements.

Oaktree Specialty Lending Corporation
Consolidated Statements of Assets and Liabilities
(in thousands, except per share amounts)

	December 31, 2022 (unaudited)	September 30, 2022
ASSETS		
Investments at fair value:		
Control investments (cost December 31, 2022: \$281,911; cost September 30, 2022: \$260,305)	\$ 232,462	\$ 214,165
Affiliate investments (cost December 31, 2022: \$24,327; cost September 30, 2022: \$27,353)	23,173	26,196
Non-control/Non-affiliate investments (cost December 31, 2022: \$2,471,776; cost September 30, 2022: \$2,330,096)	2,387,235	2,253,750
Total investments at fair value (cost December 31, 2022: \$2,778,014; cost September 30, 2022: \$2,617,754)	2,642,870	2,494,111
Cash and cash equivalents	17,382	23,528
Restricted cash	1,863	2,836
Interest, dividends and fees receivable	37,802	35,598
Due from portfolio companies	6,181	22,495
Receivables from unsettled transactions	8,657	4,692
Due from broker	39,760	45,530
Deferred financing costs	6,781	7,350
Deferred offering costs	32	32
Deferred tax asset, net	1,722	1,687
Derivative assets at fair value	—	6,789
Other assets	4,210	1,665
Total assets	\$ 2,767,260	\$ 2,646,313
LIABILITIES AND NET ASSETS		
Liabilities:		
Accounts payable, accrued expenses and other liabilities	\$ 3,035	\$ 3,701
Base management fee and incentive fee payable	16,871	15,940
Due to affiliate	3,260	3,180
Interest payable	13,368	7,936
Payables from unsettled transactions	20,974	26,981
Derivative liability at fair value	44,139	41,969
Credit facilities payable	860,000	700,000
Unsecured notes payable (net of \$4,650 and \$5,020 of unamortized financing costs as of December 31, 2022 and September 30, 2022, respectively)	603,624	601,043
Total liabilities	1,565,271	1,400,750
Commitments and contingencies (Note 13)		
Net assets:		
Common stock, \$0.01 par value per share, 250,000 shares authorized; 61,220 and 61,125 shares issued and outstanding as of December 31, 2022 and September 30, 2022, respectively (1)	612	611
Additional paid-in-capital	1,829,653	1,827,721
Accumulated overdistributed earnings	(628,276)	(582,769)
Total net assets (equivalent to \$19.63 and \$20.38 per common share as of December 31, 2022 and September 30, 2022, respectively) (Note 11) (1)	1,201,989	1,245,563
Total liabilities and net assets	\$ 2,767,260	\$ 2,646,313

1) As discussed in Note 2, the Company completed a 1-for-3 reverse stock split on January 20, 2023, effective as of the commencement of trading on January 23, 2023. The issued and outstanding shares and net asset value per share reflect the reverse stock split on a retroactive basis.

See notes to Consolidated Financial Statements.

Oaktree Specialty Lending Corporation
Consolidated Statements of Operations
(in thousands, except per share amounts)
(unaudited)

	Three months ended December 31, 2022	Three months ended December 31, 2021
Interest income:		
Control investments	\$ 4,567	\$ 3,480
Affiliate investments	641	334
Non-control/Non-affiliate investments	64,298	51,635
Interest on cash and cash equivalents	472	1
Total interest income	69,978	55,450
PIK interest income:		
Non-control/Non-affiliate investments	6,130	4,663
Total PIK interest income	6,130	4,663
Fee income:		
Control investments	13	13
Affiliate investments	5	5
Non-control/Non-affiliate investments	2,003	894
Total fee income	2,021	912
Dividend income:		
Control investments	1,050	3,916
Total dividend income	1,050	3,916
Total investment income	79,179	64,941
Expenses:		
Base management fee	9,917	9,952
Part I incentive fee	7,703	6,457
Part II incentive fee	—	1,751
Professional fees	1,500	1,322
Directors fees	160	123
Interest expense	20,719	9,400
Administrator expense	298	390
General and administrative expenses	746	693
Total expenses	41,043	30,088
Fees waived	(750)	(750)
Net expenses	40,293	29,338
Net investment income before taxes	38,886	35,603
(Provision) benefit for taxes on net investment income	—	(3,308)
Excise tax	(78)	—
Net investment income	38,808	32,295
Unrealized appreciation (depreciation):		
Control investments	(3,309)	(667)
Affiliate investments	3	(251)
Non-control/Non-affiliate investments	(8,675)	(2,831)
Foreign currency forward contracts	(11,001)	(837)
Net unrealized appreciation (depreciation)	(22,982)	(4,586)
Realized gains (losses):		
Control investments	—	1,868
Non-control/Non-affiliate investments	(7,651)	4,481
Foreign currency forward contracts	4,448	2,972
Net realized gains (losses)	(3,203)	9,321
(Provision) benefit for taxes on realized and unrealized gains (losses)	549	2,378
Net realized and unrealized gains (losses), net of taxes	(25,636)	7,113
Net increase (decrease) in net assets resulting from operations	\$ 13,172	\$ 39,408
Net investment income per common share — basic and diluted (1)	\$ 0.63	\$ 0.54
Earnings (loss) per common share — basic and diluted (Note 5) (1)	\$ 0.22	\$ 0.66
Weighted average common shares outstanding — basic and diluted (1)	61,142	60,127

(1) As discussed in Note 2, the Company completed a 1-for-3 reverse stock split on January 20, 2023, effective as of the commencement of trading on January 23, 2023. The weighted average common shares outstanding and per share information reflect the reverse stock split on a retroactive basis.

See notes to Consolidated Financial Statements.

Oaktree Specialty Lending Corporation
Consolidated Statements of Changes in Net Assets
(in thousands, except per share amounts)
(unaudited)

	Three months ended December 31, 2022	Three months ended December 31, 2021
Operations:		
Net investment income	\$ 38,808	\$ 32,295
Net unrealized appreciation (depreciation)	(22,982)	(4,586)
Net realized gains (losses)	(3,203)	9,321
(Provision) benefit for taxes on realized and unrealized gains (losses)	549	2,378
Net increase (decrease) in net assets resulting from operations	13,172	39,408
Stockholder transactions:		
Distributions to stockholders	(58,679)	(27,956)
Net increase (decrease) in net assets from stockholder transactions	(58,679)	(27,956)
Capital share transactions:		
Issuance of common stock under dividend reinvestment plan	1,933	786
Net increase (decrease) in net assets from capital share transactions	1,933	786
Total increase (decrease) in net assets	(43,574)	12,238
Net assets at beginning of period	1,245,563	1,312,823
Net assets at end of period	\$ 1,201,989	\$ 1,325,061
Net asset value per common share	\$ 19.63	\$ 22.03
Common shares outstanding at end of period	61,220	60,156

See notes to Consolidated Financial Statements.

Oaktree Specialty Lending Corporation
Consolidated Statements of Cash Flows
(in thousands)
(unaudited)

	Three months ended December 31, 2022	Three months ended December 31, 2021
Operating activities:		
Net increase (decrease) in net assets resulting from operations	\$ 13,172	\$ 39,408
Adjustments to reconcile net increase (decrease) in net assets resulting from operations to net cash provided by (used in) operating activities:		
Net unrealized (appreciation) depreciation	22,982	4,586
Net realized (gains) losses	3,203	(9,321)
PIK interest income	(6,130)	(4,663)
Accretion of original issue discount on investments	(5,127)	(7,076)
Accretion of original issue discount on unsecured notes payable	170	170
Amortization of deferred financing costs	828	924
Deferred taxes	(35)	(959)
Purchases of investments	(261,404)	(246,623)
Proceeds from the sales and repayments of investments	108,831	235,020
Changes in operating assets and liabilities:		
(Increase) decrease in interest, dividends and fees receivable	(1,842)	1,796
(Increase) decrease in due from portfolio companies	16,314	(803)
(Increase) decrease in receivables from unsettled transactions	(3,966)	(17,673)
(Increase) decrease in due from broker	5,770	(1,810)
(Increase) decrease in other assets	(2,546)	(564)
Increase (decrease) in accounts payable, accrued expenses and other liabilities	(554)	3,145
Increase (decrease) in base management fee and incentive fee payable	931	(6,459)
Increase (decrease) in due to affiliate	80	(854)
Increase (decrease) in interest payable	5,432	2,101
Increase (decrease) in payables from unsettled transactions	(6,007)	32,717
Increase (decrease) in director fees payable	—	123
Net cash provided by (used in) operating activities	(109,898)	23,185
Financing activities:		
Distributions paid in cash	(56,746)	(27,170)
Borrowings under credit facilities	202,000	70,000
Repayments of borrowings under credit facilities	(42,000)	(50,000)
Deferred financing costs paid	—	(334)
Net cash provided by (used in) financing activities	103,254	(7,504)
Effect of exchange rate changes on foreign currency	(475)	(1,259)
Net increase (decrease) in cash and cash equivalents and restricted cash	(7,119)	14,422
Cash and cash equivalents and restricted cash, beginning of period	26,364	31,635
Cash and cash equivalents and restricted cash, end of period	\$ 19,245	\$ 46,057
Supplemental information:		
Cash paid for interest	\$ 14,289	\$ 6,205
Non-cash financing activities:		
Issuance of shares of common stock under dividend reinvestment plan	\$ 1,933	\$ 786
Reconciliation to the Consolidated Statements of Assets and Liabilities	December 31, 2022	September 30, 2022
Cash and cash equivalents	\$ 17,382	\$ 23,528
Restricted cash	1,863	2,836
Total cash and cash equivalents and restricted cash	\$ 19,245	\$ 26,364

See notes to Consolidated Financial Statements.

Oaktree Specialty Lending Corporation
Consolidated Schedule of Investments
December 31, 2022
(dollar amounts in thousands)
(unaudited)

Portfolio Company/Type of Investment (1)(2)(3)(4)(5)	Cash Interest Rate (6)	Industry	Principal (7)	Cost	Fair Value	Notes
Control Investments						(8)(9)
C5 Technology Holdings, LLC						
		Data Processing & Outsourced Services				
829 Common Units			\$	—	\$	(15)
34,984,460.37 Preferred Units				34,984	27,638	(15)
				34,984	27,638	
Dominion Diagnostics, LLC						
		Health Care Services				
First Lien Term Loan, LIBOR+5.00% cash due 2/28/2024	9.73 %		\$ 14,297	14,297	14,297	(6)(15)
First Lien Revolver, LIBOR+5.00% cash due 2/28/2024			—	—	—	(6)(15)(19)
30,030.8 Common Units in DD Healthcare Services Holdings, LLC				15,222	4,227	(15)
				29,519	18,524	
OCSI Glick JV LLC						
		Multi-Sector Holdings				(14)
Subordinated Debt, LIBOR+4.50% cash due 10/20/2028	7.67 %		59,049	49,961	49,536	(6)(11)(15)(19)
87.5% equity interest				—	—	(11)(16)(19)
				49,961	49,536	
Senior Loan Fund JV I, LLC						
		Multi-Sector Holdings				(14)
Subordinated Debt, LIBOR+7.00% cash due 12/29/2028	10.17 %		112,656	112,656	112,656	(6)(11)(15)(19)
87.5% LLC equity interest				54,791	24,108	(11)(12)(16)(19)
				167,447	136,764	
Total Control Investments (19.3% of net assets)				\$ 281,911	\$ 232,462	
Affiliate Investments						
						(17)
Assembled Brands Capital LLC						
		Specialized Finance				
First Lien Revolver, LIBOR+6.75% cash due 10/17/2023	11.48 %		\$ 21,464	\$ 21,464	\$ 21,252	(6)(15)(19)
1,609,201 Class A Units				764	354	(15)
1,019,168.80 Preferred Units, 6%				1,019	1,243	(15)
70,424.5641 Class A Warrants (exercise price \$3.3778) expiration date 9/9/2029				—	—	(15)
				23,247	22,849	
Caregiver Services, Inc.						
		Health Care Services				
1,080,399 shares of Series A Preferred Stock, 10%				1,080	324	(15)
				1,080	324	
Total Affiliate Investments (1.9% of net assets)				\$ 24,327	\$ 23,173	
Non-Control/Non-Affiliate Investments						
						(18)
107 Fair Street LLC						
		Real Estate Development				
First Lien Delayed Draw Term Loan, 12.50% cash due 5/17/2024			\$ 1,174	\$ 1,111	\$ 1,108	(10)(15)(19)
				1,111	1,108	
112-126 Van Houten Real22 LLC						
		Real Estate Development				
First Lien Delayed Draw Term Loan, 12.00% cash due 5/4/2024			3,239	3,167	3,159	(10)(15)(19)
				3,167	3,159	
A.T. Holdings II Ltd.						
		Biotechnology				
First Lien Revenue Interest Financing Term Loan 14.25% cash due 9/13/2029			15,939	15,939	15,939	(11)(15)
				15,939	15,939	
A.T. Holdings II SÀRL						
		Biotechnology				
First Lien Term Loan, 12.50% PIK due 1/20/2023			15,643	15,640	15,722	(11)(15)
				15,640	15,722	
Access CIG, LLC						
		Diversified Support Services				
Second Lien Term Loan, LIBOR+7.75% cash due 2/27/2026	11.82 %		20,000	19,932	17,800	(6)(15)
				19,932	17,800	

Oaktree Specialty Lending Corporation
Consolidated Schedule of Investments
December 31, 2022
(dollar amounts in thousands)
(unaudited)

Portfolio Company/Type of Investment (1)(2)(3)(4)(5)	Cash Interest Rate (6)	Industry	Principal (7)	Cost	Fair Value	Notes
Accupac, Inc.						
First Lien Term Loan, SOFR+5.50% cash due 1/16/2026	10.16 %	Personal Products	\$ 15,935	\$ 15,668	\$ 15,903	(6)(15)
First Lien Delayed Draw Term Loan, SOFR+5.50% cash due 1/16/2026			—	—	(6)	(6)(15)(19)
First Lien Revolver, SOFR+5.50% cash due 1/16/2026	10.17 %		908	874	904	(6)(15)(19)
				16,542	16,801	
Acquia Inc.						
First Lien Term Loan, LIBOR+7.00% cash due 10/31/2025	10.74 %	Application Software	27,349	27,064	27,240	(6)(15)
First Lien Revolver, LIBOR+7.00% cash due 10/31/2025	12.18 %		1,317	1,296	1,308	(6)(15)(19)
				28,360	28,548	
ADB Companies, LLC						
First Lien Term Loan, SOFR+6.25% cash due 12/18/2025	11.34 %	Construction & Engineering	14,505	14,079	14,254	(6)(15)
				14,079	14,254	
ADC Therapeutics SA						
First Lien Term Loan, SOFR+7.50% cash due 8/15/2029	12.23 %	Biotechnology	6,589	6,269	6,274	(6)(11)(15)
First Lien Delayed Draw Term Loan, SOFR+7.50% cash due 8/15/2029			—	(38)	(35)	(6)(11)(15)(19)
28,948 Common Stock Warrants (exercise price \$8.297) expiration 8/15/2032				174	50	(11)(15)
				6,405	6,289	
Aden & Anais Merger Sub, Inc.						
		Apparel, Accessories & Luxury Goods		5,165	—	(15)
51,645 Common Units in Aden & Anais Holdings, Inc.				5,165	—	
AI Sirona (Luxembourg) Acquisition S.a.r.l.						
Second Lien Term Loan, EURIBOR+7.25% cash due 9/28/2026	9.15 %	Pharmaceuticals	€ 24,838	27,775	24,255	(6)(11)(15)
				27,775	24,255	
AIP RD Buyer Corp.						
Second Lien Term Loan, SOFR+7.75% cash due 12/23/2029	12.17 %	Distributors	\$ 14,414	14,163	13,960	(6)(15)
14,410 Common Units in RD Holding LP				1,352	1,528	(15)
				15,515	15,488	
AirStrip Technologies, Inc.						
5,715 Common Stock Warrants (exercise price \$139.99) expiration date 5/11/2025		Application Software		90	—	(15)
				90	—	
All Web Leads, Inc.						
First Lien Term Loan, LIBOR+1.00% cash 7.50% PIK due 12/29/2023	5.73 %	Advertising	23,562	22,547	22,354	(6)(15)
				22,547	22,354	
Altice France S.A.						
Fixed Rate Bond, 5.50% cash due 10/15/2029		Integrated Telecommunication Services	4,050	3,533	3,095	(11)
				3,533	3,095	
Alto Pharmacy Holdings, Inc.						
First Lien Term Loan, SOFR+8.00% cash 3.50% PIK due 10/14/2027	12.68 %	Health Care Technology	8,640	7,904	7,930	(6)(15)
166,414 Common Stock Warrants (exercise price \$15.46) expiration date 10/14/2032				642	629	(15)
				8,546	8,559	
Alvogen Pharma US, Inc.						
First Lien Term Loan, SOFR+7.50% cash due 6/30/2025	12.23 %	Pharmaceuticals	12,968	12,711	12,903	(6)(15)
				12,711	12,903	

Oaktree Specialty Lending Corporation
Consolidated Schedule of Investments
December 31, 2022
(dollar amounts in thousands)
(unaudited)

Portfolio Company/Type of Investment (1)(2)(3)(4)(5)	Cash Interest Rate (6)	Industry	Principal (7)	Cost	Fair Value	Notes
Alvotech Holdings S.A.		Biotechnology				(13)
Tranche A Fixed Rate Bond 8.50% cash 3.50% PIK due 11/16/2026			\$ 26,179	\$ 25,798	\$ 25,684	(11)(15)
Tranche B Fixed Rate Bond 8.50% cash 3.50% PIK due 11/16/2026			25,612	25,264	25,128	(11)(15)
587,930 Common Shares in Alvotech SA				5,308	5,879	(11)
124,780 Seller Earn Out Shares in Alvotech SA				485	418	(11)(15)
293,082 \$10.00 Put Options on Common Shares in Alvotech SA				—	580	(11)(15)
408,508 Common Stock Warrants (exercise price \$0.01) expiration 12/31/2027				—	4,081	(11)(15)
				56,855	61,770	
American Auto Auction Group, LLC		Consumer Finance				
Second Lien Term Loan, SOFR+8.75% cash due 1/2/2029	13.33 %		14,760	14,503	11,439	(6)(15)
				14,503	11,439	
American Tire Distributors, Inc.		Distributors				
First Lien Term Loan, LIBOR+6.25% cash due 10/20/2028	10.61 %		9,870	9,747	9,081	(6)
				9,747	9,081	
AMMC CLO 27		Multi-Sector Holdings				
Class E Notes, SOFR+8.89% cash due 1/20/2036	13.49 %		2,275	2,037	2,087	(6)(11)
				2,037	2,087	
Amplify Finco Pty Ltd.		Movies & Entertainment				
First Lien Term Loan, LIBOR+4.25% cash due 11/26/2026	8.98 %		15,181	14,014	14,637	(6)(11)(15)
Second Lien Term Loan, LIBOR+8.00% cash due 11/26/2027	12.73 %		12,500	12,188	11,833	(6)(11)(15)
				26,202	26,470	
Anastasia Parent, LLC		Personal Products				
First Lien Term Loan, LIBOR+3.75% cash due 8/11/2025	8.48 %		2,729	2,254	2,043	(6)
				2,254	2,043	
Ankura Consulting Group LLC		Research & Consulting Services				
Second Lien Term Loan, LIBOR+8.00% cash due 3/19/2029	12.36 %		2,996	2,951	2,558	(6)(15)
				2,951	2,558	
Apptio, Inc.		Application Software				
First Lien Term Loan, LIBOR+6.00% cash due 1/10/2025	9.94 %		34,458	33,818	33,769	(6)(15)
First Lien Revolver, LIBOR+6.00% cash due 1/10/2025	9.94 %		1,338	1,312	1,294	(6)(15)(19)
				35,130	35,063	
APX Group Inc.		Electrical Components & Equipment				
Fixed Rate Bond, 5.75% cash due 7/15/2029			2,075	1,742	1,721	(11)
				1,742	1,721	
Ardonagh Midco 3 PLC		Insurance Brokers				
First Lien Term Loan, EURIBOR+7.00% cash due 7/14/2026	8.00 %	€	1,964	2,176	2,103	(6)(11)(15)
First Lien Term Loan, SONIA+7.00% cash due 7/14/2026	10.43 %	£	18,636	23,058	22,485	(6)(11)(15)
First Lien Term Loan, LIBOR+5.75% cash due 7/14/2026	8.81 %	\$	10,519	10,368	10,561	(6)(11)(15)
First Lien Term Loan, SONIA+5.75% cash due 7/14/2026	7.48 %	£	3,649	3,666	3,908	(6)(11)(15)
				39,268	39,057	
Associated Asphalt Partners, LLC		Construction Materials				
First Lien Term Loan, LIBOR+5.25% cash due 4/5/2024	9.63 %	\$	2,493	2,353	1,928	(6)
				2,353	1,928	
Astra Acquisition Corp.		Application Software				
First Lien Term Loan, LIBOR+5.25% cash due 10/25/2028	9.63 %		5,640	5,489	5,006	(6)
				5,489	5,006	
athenahealth Group Inc.		Health Care Technology				
18,635 Shares of Series A Preferred Stock in Minerva Holdco, Inc., 10.75%				18,264	15,606	(15)
				18,264	15,606	
Athenex, Inc.		Pharmaceuticals				
First Lien Term Loan, 11.00% cash due 6/19/2026			12,556	12,191	12,036	(11)(15)
First Lien Revenue Interest Financing Term Loan due 5/31/2031			8,649	8,604	8,649	(11)(15)
328,149 Common Stock Warrants (exercise price \$0.4955) expiration date 6/19/2027				973	7	(11)(15)
				21,768	20,692	

Oaktree Specialty Lending Corporation
Consolidated Schedule of Investments
December 31, 2022
(dollar amounts in thousands)
(unaudited)

Portfolio Company/Type of Investment (1)(2)(3)(4)(5)	Cash Interest Rate (6)	Industry	Principal (7)	Cost	Fair Value	Notes
Aurora Lux Finco S.A.R.L.						
First Lien Term Loan, LIBOR+6.00% cash due 12/24/2026	10.32 %	Airport Services	\$ 22,368	\$ 22,050	\$ 21,274	(6)(11)(15)
				22,050	21,274	
Avalara, Inc.						
First Lien Term Loan, SOFR+7.25% cash due 10/19/2028	11.83 %	Application Software	41,467	40,466	40,430	(6)(15)
First Lien Revolver, SOFR+7.25% cash due 10/19/2028			—	(100)	(104)	(6)(15)(19)
				40,366	40,326	
The Avery						
		Real Estate Operating Companies				
First Lien Term Loan in T8 Urban Condo Owner, LLC, LIBOR+7.30% cash due 2/17/2023	11.69 %		15,301	15,279	15,391	(6)(15)
Subordinated Debt in T8 Senior Mezz LLC, LIBOR+12.50% cash due 2/17/2023	17.24 %		3,706	3,701	3,733	(6)(15)
				18,980	19,124	
BAART Programs, Inc.						
		Health Care Services				
First Lien Delayed Draw Term Loan, LIBOR+5.00% cash due 6/11/2027	9.73 %		2,541	2,497	2,420	(6)(15)(19)
Second Lien Term Loan, LIBOR+8.50% cash due 6/11/2028	13.23 %		7,166	7,059	6,944	(6)(15)
Second Lien Delayed Draw Term Loan, LIBOR+8.50% cash due 6/11/2028	13.23 %		5,197	5,042	4,854	(6)(15)(19)
				14,598	14,218	
Berner Food & Beverage, LLC						
		Soft Drinks				
First Lien Term Loan, LIBOR+5.50% cash due 7/30/2027	9.91 %		32,995	32,555	32,533	(6)(15)
First Lien Revolver, PRIME+4.50% cash due 7/30/2026	12.00 %		897	859	857	(6)(15)(19)
				33,414	33,390	
BioXcel Therapeutics, Inc.						
		Pharmaceuticals				
First Lien Term Loan, 8.00% cash 2.25% PIK due 4/19/2027			5,383	5,184	5,028	(11)(15)
First Lien Delayed Draw Term Loan, 8.00% cash 2.25% PIK due 4/19/2027			—	—	—	(11)(15)(19)
First Lien Revenue Interest Financing Term Loan due 9/30/2032			2,432	2,432	2,432	(11)(15)
First Lien Revenue Interest Financing Delayed Draw Term Loan due 9/30/2032			—	—	—	(11)(15)(19)
21,177 Common Stock Warrants (exercise price \$20.04) expiration date 4/19/2029				125	275	(11)(15)
				7,741	7,735	
Blackhawk Network Holdings, Inc.						
		Data Processing & Outsourced Services				
Second Lien Term Loan, LIBOR+7.00% cash due 6/15/2026	10.94 %		30,625	30,300	26,391	(6)
				30,300	26,391	
Blumenthal Temecula, LLC						
		Automotive Retail				
First Lien Term Loan, 9.00% cash due 9/24/2023			3,979	3,980	3,960	(15)
1,293,324 Preferred Units in Unstoppable Automotive AMV, LLC				1,293	1,267	(15)
298,460 Preferred Units in Unstoppable Automotive VMV, LLC				298	292	(15)
298,460 Common Units in Unstoppable Automotive AMV, LLC				298	379	(15)
				5,869	5,898	
Cadence Aerospace, LLC						
		Aerospace & Defense				
First Lien Term Loan, LIBOR+6.50% cash 2.00% PIK due 11/14/2023	10.92 %		14,332	13,700	13,178	(6)(15)
				13,700	13,178	
CircusTrix Holdings, LLC						
		Leisure Facilities				
First Lien Term Loan, LIBOR+5.50% cash due 7/16/2023	9.57 %		10,668	10,201	10,465	(6)(15)
				10,201	10,465	
Clear Channel Outdoor Holdings Inc.						
		Advertising				
Fixed Rate Bond, 7.50% cash due 6/1/2029			4,311	4,311	3,174	(11)
Fixed Rate Bond, 7.75% cash due 4/15/2028			676	649	494	(11)
				4,960	3,668	

Oaktree Specialty Lending Corporation
Consolidated Schedule of Investments
December 31, 2022
(dollar amounts in thousands)
(unaudited)

<u>Portfolio Company/Type of Investment (1)(2)(3)(4)(5)</u>	<u>Cash Interest Rate (6)</u>	<u>Industry</u>	<u>Principal (7)</u>	<u>Cost</u>	<u>Fair Value</u>	<u>Notes</u>
Condor Merger Sub Inc.						
Systems Software						
Fixed Rate Bond, 7.375% cash due 2/15/2030			\$ 8,420	\$ 8,248	\$ 6,785	
				8,248	6,785	
Continental Intermodal Group LP						
Oil & Gas Storage & Transportation						
First Lien Term Loan, LIBOR+8.50% cash due 1/28/2025	12.88 %		19,992	19,286	17,893	(6)(15)
Common Stock Warrants expiration date 7/28/2025				648	220	(15)
				19,934	18,113	
Convergeone Holdings, Inc.						
IT Consulting & Other Services						
First Lien Term Loan, LIBOR+5.00% cash due 1/4/2026	9.38 %		11,882	11,684	6,963	(6)
				11,684	6,963	
Conviva Inc.						
Application Software						
517,851 Shares of Series D Preferred Stock				605	894	(15)
				605	894	
CorEvitas, LLC						
Health Care Technology						
First Lien Term Loan, SOFR+6.125% cash due 12/13/2025	10.55 %		13,677	13,527	13,344	(6)(15)
First Lien Revolver, PRIME+4.75% cash due 12/13/2025	12.25 %		305	289	261	(6)(15)(19)
1,099 Class A2 Common Units in CorEvitas Holdings, L.P.				690	2,340	(15)
				14,506	15,945	
Covetrus, Inc.						
Health Care Distributors						
First Lien Term Loan, SOFR+5.00% cash due 9/20/2029	9.58 %		10,336	9,733	9,711	(6)
				9,733	9,711	
Coyote Buyer, LLC						
Specialty Chemicals						
First Lien Term Loan, LIBOR+6.00% cash due 2/6/2026	10.41 %		18,153	17,766	17,798	(6)(15)
First Lien Revolver, LIBOR+6.00% cash due 2/6/2025			—	(13)	(26)	(6)(15)(19)
				17,753	17,772	
Cuppa Bidco BV						
Soft Drinks						
First Lien Term Loan, EURIBOR+4.75% cash due 7/30/2029	7.50 %	€	12,340	10,521	10,997	(6)(11)
				10,521	10,997	
Delta Leasing SPV II LLC						
Specialized Finance						
Subordinated Delayed Draw Term Loan, 10.00% cash due 8/31/2029		\$	8,365	8,365	8,365	(11)(15)(19)
419 Series C Preferred Units in Delta Financial Holdings LLC				419	419	(11)(15)
2.09 Common Units in Delta Financial Holdings LLC				2	2	(11)(15)
31.37 Common Warrants (exercise price \$1.00)				—	—	(11)(15)
				8,786	8,786	
Delta Topco, Inc.						
Systems Software						
Second Lien Term Loan, LIBOR+7.25% cash due 12/1/2028	11.65 %		6,680	6,647	5,319	(6)
				6,647	5,319	
Dialyze Holdings, LLC						
Health Care Equipment						
First Lien Term Loan, LIBOR+9.00% cash due 8/4/2026	13.73 %		20,965	19,913	20,912	(6)(15)
Subordinated Term Loan, 8.00% PIK due 9/30/2027			520	520	494	(15)
5,403,823 Class A Warrants (exercise price \$1.00) expiration date 8/4/2028				1,405	1,297	(15)
				21,838	22,703	
Digital.AI Software Holdings, Inc.						
Application Software						
First Lien Term Loan, LIBOR+6.50% cash due 2/10/2027	11.09 %		9,877	9,593	9,768	(6)(15)
First Lien Revolver, LIBOR+7.00% cash due 2/10/2027	11.59 %		251	229	239	(6)(15)(19)
				9,822	10,007	
DirecTV Financing, LLC						
Cable & Satellite						
First Lien Term Loan, LIBOR+5.00% cash due 8/2/2027	9.38 %		8,166	8,012	7,968	(6)
				8,012	7,968	
Dryden 66 Euro CLO 2018						
Multi-Sector Holdings						
Class DR Notes, EURIBOR+3.35% cash due 1/18/2032	4.75 %	€	1,500	1,335	1,389	(6)(11)
				1,335	1,389	

Oaktree Specialty Lending Corporation
Consolidated Schedule of Investments
December 31, 2022
(dollar amounts in thousands)
(unaudited)

Portfolio Company/Type of Investment (1)(2)(3)(4)(5)	Cash Interest Rate (6)	Industry	Principal (7)	Cost	Fair Value	Notes
DTI Holdco, Inc.						
Research & Consulting Services						
First Lien Term Loan, SOFR+4.75% cash due 4/26/2029	8.84 %		\$ 4,988	\$ 4,897	\$ 4,607	(6)
				4,897	4,607	
Eagleview Technology Corporation						
Application Software						
Second Lien Term Loan, LIBOR+7.50% cash due 8/14/2026	12.23 %		8,974	8,884	7,897	(6)(15)
				8,884	7,897	
EOS Fitness Opco Holdings, LLC						
Leisure Facilities						
487.5 Class A Preferred Units, 12%				488	1,067	(15)
12,500 Class B Common Units				—	—	(15)
				488	1,067	
Establishment Labs Holdings Inc.						
Health Care Technology						
First Lien Term Loan, 3.00% cash 6.00% PIK due 4/21/2027			10,576	10,441	10,100	(11)(15)
First Lien Delayed Draw Term Loan, 3.00% cash 6.00% PIK due 4/21/2027			1,694	1,667	1,694	(11)(15)(19)
				12,108	11,794	
Fairbridge Strategic Capital Funding LLC						
Real Estate Operating Companies						
First Lien Delayed Draw Term Loan, 9.00% cash due 12/24/2028			31,000	31,000	31,000	(15)(19)
2,500 Warrant Units (exercise price \$0.01) expiration date 11/24/2031				—	3	(11)(15)
				31,000	31,003	
FINThrive Software Intermediate Holdings, Inc.						
Health Care Technology						
Second Lien Term Loan, LIBOR+6.75% cash due 12/17/2029	11.13 %		25,061	24,685	19,273	(6)
				24,685	19,273	
Fortress Biotech, Inc.						
Biotechnology						
First Lien Term Loan, 11.00% cash due 8/27/2025			9,466	9,106	8,922	(11)(15)
331,200 Common Stock Warrants (exercise price \$3.20) expiration date 8/27/2030				405	26	(11)(15)
				9,511	8,948	
Frontier Communications Holdings, LLC						
Integrated Telecommunication Services						
Fixed Rate Bond, 6.00% cash due 1/15/2030			4,881	4,432	3,841	(11)
				4,432	3,841	
GKD Index Partners, LLC						
Specialized Finance						
First Lien Term Loan, LIBOR+7.00% cash due 6/29/2023	11.73 %		24,819	24,682	24,641	(6)(15)
First Lien Revolver, LIBOR+7.00% cash due 6/29/2023	11.75 %		1,280	1,272	1,268	(6)(15)(19)
				25,954	25,909	
GoldenTree Loan Management EUR CLO 2						
Multi-Sector Holdings						
Class D Notes, EURIBOR+2.85% cash due 1/20/2032	4.31 %	€	1,000	865	899	(6)(11)
				865	899	
Grove Hotel Parcel Owner, LLC						
Hotels, Resorts & Cruise Lines						
First Lien Term Loan, SOFR+8.00% cash due 6/21/2027	12.33 %	\$	14,275	14,020	13,990	(6)(15)
First Lien Delayed Draw Term Loan, SOFR+8.00% cash due 6/21/2027			—	(51)	(57)	(6)(15)(19)
First Lien Revolver, SOFR+8.00% cash due 6/21/2027			—	(26)	(29)	(6)(15)(19)
				13,943	13,904	
Harbor Purchaser Inc.						
Education Services						
First Lien Term Loan, SOFR+5.25% cash due 4/9/2029	9.67 %		9,369	9,070	8,938	(6)
				9,070	8,938	
Hayfin Emerald CLO XI						
Multi-Sector Holdings						
Class E Notes, EURIBOR+8.12% cash due 1/25/2036	10.11 %	€	2,250	2,041	2,079	(6)(11)
				2,041	2,079	

Oaktree Specialty Lending Corporation
Consolidated Schedule of Investments
December 31, 2022
(dollar amounts in thousands)
(unaudited)

Portfolio Company/Type of Investment (1)(2)(3)(4)(5)	Cash Interest Rate (6)	Industry	Principal (7)	Cost	Fair Value	Notes
Horizon Aircraft Finance I						
Class A Notes, 4.458% cash due 12/15/2038		Specialized Finance	\$ 7,112	\$ 5,697	\$ 5,838	(6)(11)
				5,697	5,838	
iCIMs, Inc.						
		Application Software				
First Lien Term Loan, SOFR+3.375% cash 3.875% PIK due 8/18/2028	7.14 %		19,203	18,888	18,420	(6)(15)
First Lien Term Loan, SOFR+7.25% cash due 8/18/2028	11.52 %		2,944	2,895	2,885	(6)(15)
First Lien Delayed Draw Term Loan, SOFR+6.75% cash due 8/18/2028			—	—	—	(6)(15)(19)
First Lien Revolver, SOFR+6.75% cash due 8/18/2028			—	(30)	(75)	(6)(15)(19)
				21,753	21,230	
Immucor, Inc.						
		Health Care Supplies				
First Lien Term Loan, LIBOR+5.75% cash due 7/2/2025	10.48 %		8,547	8,395	8,635	(6)(15)
Second Lien Term Loan, LIBOR+8.00% cash 3.50% PIK due 10/2/2025	12.73 %		22,819	22,401	23,275	(6)(15)
				30,796	31,910	
Impel Neuropharma, Inc.						
		Health Care Technology				
First Lien Revenue Interest Financing Term Loan due 2/15/2031			13,482	13,482	13,428	(15)
First Lien Term Loan, SOFR+8.75% cash due 3/17/2027	13.20 %		12,161	11,956	11,876	(6)(15)
				25,438	25,304	
Innocoll Pharmaceuticals Limited						
		Health Care Technology				
First Lien Term Loan, 11.00% cash due 1/26/2027			6,817	6,569	6,336	(11)(15)
First Lien Delayed Draw Term Loan, 11.00% cash due 1/26/2027			—	—	—	(11)(15)(19)
56,999 Tranche A Warrant Shares (exercise price \$4.23) expiration date 1/26/2029				135	662	(11)(15)
				6,704	6,998	
Integral Development Corporation						
		Other Diversified Financial Services				
1,078,284 Common Stock Warrants (exercise price \$0.9274) expiration date 7/10/2024				113	—	(15)
				113	—	
Inventus Power, Inc.						
		Electrical Components & Equipment				
First Lien Term Loan, SOFR+5.00% cash due 3/29/2024	9.84 %		18,612	18,536	18,054	(6)(15)
Second Lien Term Loan, LIBOR+8.50% cash due 9/29/2024	13.23 %		13,674	13,535	13,195	(6)(15)
				32,071	31,249	
INW Manufacturing, LLC						
		Personal Products				
First Lien Term Loan, LIBOR+5.75% cash due 3/25/2027	10.48 %		35,156	34,394	30,059	(6)(15)
				34,394	30,059	
IPC Corp.						
		Application Software				
First Lien Term Loan, LIBOR+6.50% cash due 10/1/2026	9.44 %		34,357	33,660	32,553	(6)(15)
				33,660	32,553	
Ivanti Software, Inc.						
		Application Software				
Second Lien Term Loan, LIBOR+7.25% cash due 12/1/2028	12.01 %		10,247	10,196	5,994	(6)
				10,196	5,994	
Jazz Acquisition, Inc.						
		Aerospace & Defense				
First Lien Term Loan, LIBOR+7.50% cash due 1/29/2027	11.88 %		35,912	34,918	36,176	(6)(15)
Second Lien Term Loan, LIBOR+8.00% cash due 6/18/2027	12.38 %		528	480	483	(6)
				35,398	36,659	
Kings Buyer, LLC						
		Environmental & Facilities Services				
First Lien Term Loan, LIBOR+6.50% cash due 10/29/2027	11.23 %		13,589	13,453	13,153	(6)(15)
First Lien Revolver, LIBOR+6.50% cash due 10/29/2027	11.75 %		659	640	599	(6)(15)(19)
				14,093	13,752	

Oaktree Specialty Lending Corporation
Consolidated Schedule of Investments
December 31, 2022
(dollar amounts in thousands)
(unaudited)

Portfolio Company/Type of Investment (1)(2)(3)(4)(5)	Cash Interest Rate (6)	Industry	Principal (7)	Cost	Fair Value	Notes
Latam Airlines Group S.A.						
First Lien Term Loan, SOFR+9.50% cash due 11/3/2027	13.99 %	Airlines	\$ 26,205	\$ 24,034	\$ 25,864	(6)(11)
				24,034	25,864	
Lift Brands Holdings, Inc.						
2,000,000 Class A Common Units in Snap Investments, LLC		Leisure Facilities		1,399	—	(15)
				1,399	—	
Lightbox Intermediate, L.P.						
First Lien Term Loan, LIBOR+5.00% cash due 5/9/2026	9.73 %	Real Estate Services	36,913	36,233	35,621	(6)(15)
				36,233	35,621	
Liquid Environmental Solutions Corporation						
Second Lien Term Loan, LIBOR+8.50% cash due 11/30/2026	12.88 %	Environmental & Facilities Services	4,357	4,289	4,215	(6)(15)
Second Lien Delayed Draw Term Loan, LIBOR+8.50% cash due 11/30/2026	12.94 %		2,370	2,323	2,257	(6)(15)(19)
450.75 Class A2 Units in LES Group Holdings, L.P.				451	451	(15)
				7,063	6,923	
LSL Holdeo, LLC						
First Lien Term Loan, LIBOR+6.00% cash due 1/31/2028	10.38 %	Health Care Distributors	21,315	20,839	20,089	(6)(15)
First Lien Revolver, LIBOR+6.00% cash due 1/31/2028	10.38 %		2,137	2,101	2,014	(6)(15)
				22,940	22,103	
LTI Holdings, Inc.						
Second Lien Term Loan, LIBOR+6.75% cash due 9/6/2026	11.13 %	Electronic Components	2,140	2,095	1,712	(6)
				2,095	1,712	
Marinus Pharmaceuticals, Inc.						
First Lien Term Loan, 11.50% cash due 5/11/2026		Pharmaceuticals	17,203	16,972	16,573	(11)(15)
First Lien Delayed Draw Term Loan, 11.50% cash due 5/11/2026			—	—	—	(11)(15)(19)
				16,972	16,573	
Mesoblast, Inc.						
First Lien Term Loan, 8.00% cash 1.75% PIK due 11/19/2026		Biotechnology	7,247	6,717	6,474	(11)(15)
First Lien Delayed Draw Term Loan, 8.00% cash 1.75% PIK due 11/19/2026			—	1	—	(11)(15)(19)
209,588 Warrant Shares (exercise price \$7.26) expiration date 11/19/2028				480	222	(11)(15)
53,887 Warrant Shares (exercise price \$3.70) expiration 11/19/2028				—	81	(11)(15)
				7,198	6,777	
MHE Intermediate Holdings, LLC						
First Lien Term Loan, SOFR+6.00% cash due 7/21/2027	9.50 %	Diversified Support Services	18,344	18,057	17,678	(6)(15)
First Lien Revolver, SOFR+6.00% cash due 7/21/2027	10.94 %		200	178	148	(6)(15)(19)
				18,235	17,826	
Mindbody, Inc.						
First Lien Term Loan, LIBOR+7.00% cash due 2/14/2025	11.72 %	Internet Services & Infrastructure	45,487	44,616	44,486	(6)(15)
First Lien Revolver, LIBOR+8.00% cash due 2/14/2025			—	(48)	(88)	(6)(15)(19)
				44,568	44,398	
Mosaic Companies, LLC						
First Lien Term Loan, LIBOR+6.75% cash due 7/2/2026	10.93 %	Home Improvement Retail	45,907	45,266	45,127	(6)(15)
				45,266	45,127	
MRI Software LLC						
First Lien Term Loan, LIBOR+5.50% cash due 2/10/2026	10.23 %	Application Software	25,768	25,392	24,833	(6)(15)
First Lien Delayed Draw Term Loan, LIBOR+5.50% cash due 2/10/2026			—	(11)	(95)	(6)(15)(19)
First Lien Revolver, LIBOR+5.50% cash due 2/10/2026			—	(13)	(65)	(6)(15)(19)
				25,368	24,673	
Navisite, LLC						
Second Lien Term Loan, LIBOR+8.50% cash due 12/30/2026	13.23 %	Data Processing & Outsourced Services	22,560	22,260	21,545	(6)(15)
				22,260	21,545	

Oaktree Specialty Lending Corporation
Consolidated Schedule of Investments
December 31, 2022
(dollar amounts in thousands)
(unaudited)

Portfolio Company/Type of Investment (1)(2)(3)(4)(5)	Cash Interest Rate (6)	Industry	Principal (7)	Cost	Fair Value	Notes
NeuAG, LLC						
		Fertilizers & Agricultural Chemicals				
First Lien Term Loan, LIBOR+10.50% cash due 9/11/2024	15.23 %		\$ 50,276	\$ 49,271	\$ 52,292	(6)(15)
				49,271	52,292	
NFP Corp.						
		Other Diversified Financial Services				
Fixed Rate Bond 6.875% cash due 8/15/2028			10,191	9,787	8,423	
				9,787	8,423	
NN, Inc.						
		Industrial Machinery				
First Lien Term Loan, LIBOR+6.88% cash due 9/19/2026	11.26 %		58,564	57,577	55,958	(6)(11)(15)
				57,577	55,958	
OCP EURO CLO 2022-6						
		Multi-Sector Holdings				
Class D Notes, EURIBOR+6.06% cash due 1/20/2033	8.05 %		€ 2,500	2,503	2,576	(6)(11)
Class E Notes, EURIBOR+6.87% cash due 1/20/2033	8.86 %		3,000	2,677	2,728	(6)(11)
				5,180	5,304	
OEConnection LLC						
		Application Software				
First Lien Term Loan, SOFR+4.00% cash due 9/25/2026	8.42 %		\$ 3,315	3,165	3,167	(6)
Second Lien Term Loan, SOFR+7.00% cash due 9/25/2027	11.42 %		7,519	7,396	7,221	(6)(15)
				10,561	10,388	
OTG Management, LLC						
		Airport Services				
First Lien Term Loan, LIBOR+2.00% cash 8.00% PIK due 9/1/2025	6.76 %		21,993	21,728	21,993	(6)(15)
First Lien Delayed Draw Term Loan, LIBOR+2.00% cash 8.00% PIK due 9/1/2025			—	(30)	—	(6)(15)(19)
				21,698	21,993	
P & L Development, LLC						
		Pharmaceuticals				
Fixed Rate Bond, 7.75% cash due 11/15/2025			7,776	7,817	6,318	
				7,817	6,318	
Park Place Technologies, LLC						
		Internet Services & Infrastructure				
First Lien Term Loan, SOFR+5.00% cash due 11/10/2027	9.42 %		4,838	4,703	4,575	(6)
				4,703	4,575	
Performance Health Holdings, Inc.						
		Health Care Distributors				
First Lien Term Loan, LIBOR+6.00% cash due 7/12/2027	10.73 %		17,976	17,705	17,537	(6)(15)
				17,705	17,537	
PFNY Holdings, LLC						
		Leisure Facilities				
First Lien Term Loan, LIBOR+7.00% cash due 12/31/2026	10.74 %		26,088	25,674	25,632	(6)(15)
First Lien Delayed Draw Term Loan, LIBOR+7.00% cash due 12/31/2026	10.74 %		2,228	2,188	2,184	(6)(15)(19)
First Lien Revolver, LIBOR+7.00% cash due 12/31/2026	11.76 %		1,252	1,232	1,230	(6)(15)
				29,094	29,046	
Planview Parent, Inc.						
		Application Software				
Second Lien Term Loan, LIBOR+7.25% cash due 12/18/2028	11.98 %		28,627	28,198	25,693	(6)(15)
				28,198	25,693	
Pluralsight, LLC						
		Application Software				
First Lien Term Loan, LIBOR+8.00% cash due 4/6/2027	11.83 %		48,689	47,993	47,471	(6)(15)
First Lien Revolver, LIBOR+8.00% cash due 4/6/2027	12.36 %		1,766	1,716	1,678	(6)(15)(19)
				49,709	49,149	
PRGX Global, Inc.						
		Data Processing & Outsourced Services				
First Lien Term Loan, LIBOR+6.75% cash due 3/3/2026	11.50 %		31,186	30,466	30,578	(6)(15)
First Lien Revolver, LIBOR+6.75% cash due 3/3/2026			—	(31)	(49)	(6)(15)(19)
80,515 Class B Common Units				79	121	(15)
				30,514	30,650	
Profrac Holdings II, LLC						
		Industrial Machinery				
First Lien Term Loan, SOFR+7.25% cash due 3/4/2025	11.10 %		22,984	22,496	22,432	(6)(15)
				22,496	22,432	

Oaktree Specialty Lending Corporation
Consolidated Schedule of Investments
December 31, 2022
(dollar amounts in thousands)
(unaudited)

Portfolio Company/Type of Investment (1)(2)(3)(4)(5)	Cash Interest Rate (6)	Industry	Principal (7)	Cost	Fair Value	Notes
Project Boost Purchaser, LLC						
Second Lien Term Loan, LIBOR+8.00% cash due 5/31/2027	12.38 %	Application Software	\$ 5,250	\$ 5,173	\$ 4,955	(6)(15)
				5,173	4,955	
Quantum Bidco Limited						
First Lien Term Loan, SONIA+6.00% cash due 1/29/2028	9.63 %	Food Distributors	£ 3,501	\$ 4,655	\$ 3,599	(6)(11)(15)
				4,655	3,599	
QuorumLabs, Inc.						
64,887,669 Junior-2 Preferred Stock		Application Software		375	—	(15)
				375	—	
Radiology Partners Inc.						
First Lien Term Loan, LIBOR+4.25% cash due 7/9/2025	8.64 %	Health Care Distributors	\$ 3,400	3,221	2,870	(6)
Fixed Rate Bond, 9.25% cash due 2/1/2028			4,755	4,721	2,677	
				7,942	5,547	
Relativity ODA LLC						
First Lien Term Loan, LIBOR+7.50% PIK due 5/12/2027		Application Software	25,405	25,002	24,846	(6)(15)
First Lien Revolver, LIBOR+6.50% cash due 5/12/2027			—	(40)	(47)	(6)(15)(19)
				24,962	24,799	
Renaissance Holding Corp.						
Second Lien Term Loan, LIBOR+7.00% cash due 5/29/2026	11.38 %	Diversified Banks	3,542	3,515	3,315	(6)
				3,515	3,315	
RumbleOn, Inc.						
First Lien Term Loan, LIBOR+8.25% cash due 8/31/2026	12.98 %	Automotive Retail	36,092	34,407	34,540	(6)(11)(15)
First Lien Delayed Draw Term Loan, LIBOR+8.25% cash due 8/31/2026	12.98 %		10,920	10,185	10,243	(6)(11)(15)(19)
164,660 Class B Common Stock Warrants (exercise price \$31.50) expiration date 7/25/2023				1,202	—	(11)(15)
				45,794	44,783	
Salus Workers' Compensation, LLC						
First Lien Term Loan, SOFR+10.00% cash due 10/7/2026	14.32 %	Other Diversified Financial Services	27,848	26,787	26,804	(6)(15)
First Lien Revolver, SOFR+10.00% cash due 10/7/2026	14.32 %		931	812	814	(6)(15)(19)
991,019 Common Stock Warrants (exercise price \$4.83) expiration date 10/7/2032				327	307	(15)
				27,926	27,925	
SCP Eye Care Services, LLC						
Second Lien Term Loan, SOFR+8.75% cash due 10/7/2030	12.52 %	Health Care Services	8,010	7,777	7,778	(6)(15)
Second Lien Delayed Draw Term Loan, SOFR+8.75% cash due 10/7/2030			—	(35)	(68)	(6)(15)(19)
1,037 Units in Eyesouth Co-Investor FT Aggregator LLC				1,037	1,113	(15)
				8,779	8,823	
scPharmaceuticals Inc.						
First Lien Term Loan, SOFR+8.75% cash due 10/13/2027	11.75 %	Pharmaceuticals	5,212	4,945	4,957	(6)(15)
First Lien Delayed Draw Term Loan, SOFR+8.75% cash due 10/13/2027			—	—	—	(6)(15)(19)
53,700 Common Stock Warrants (exercise price \$5.40) expiration date 10/12/2029				175	262	(15)
				5,120	5,219	
ShareThis, Inc.						
345,452 Series C Preferred Stock Warrants (exercise price \$3.0395) expiration date 3/4/2024		Application Software		367	—	(15)
				367	—	
SiO2 Medical Products, Inc.						
First Lien Term Loan, 5.50% cash 8.50% PIK due 12/21/2026		Metal & Glass Containers	47,112	46,447	44,520	(15)
415.34 Common Stock Warrants (exercise price \$4,920.75) expiration date 7/31/2028				681	243	(15)
				47,128	44,763	
SM Wellness Holdings, Inc.						
First Lien Term Loan, LIBOR+4.75% cash due 4/17/2028	9.42 %	Health Care Services	3,395	2,784	2,767	(6)(15)
Second Lien Term Loan, LIBOR+8.00% cash due 4/16/2029	12.67 %		9,109	8,972	6,604	(6)(15)
				11,756	9,371	

Oaktree Specialty Lending Corporation
Consolidated Schedule of Investments
December 31, 2022
(dollar amounts in thousands)
(unaudited)

Portfolio Company/Type of Investment (1)(2)(3)(4)(5)	Cash Interest Rate (6)	Industry	Principal (7)	Cost	Fair Value	Notes
SonicWall US Holdings Inc.						
Second Lien Term Loan, LIBOR+7.50% cash due 5/18/2026	12.20 %	Technology Distributors	\$ 3,195	\$ 3,163	\$ 2,971	(6)(15)
				3,163	2,971	
Sorrento Therapeutics, Inc.						
50,000 Common Stock Units		Biotechnology		197	44	(11)
				197	44	
Spanx, LLC						
First Lien Term Loan, LIBOR+5.25% cash due 11/20/2028	9.64 %	Apparel Retail	4,523	4,447	4,415	(6)(15)
First Lien Revolver, LIBOR+5.25% cash due 11/18/2027	9.29 %		330	280	260	(6)(15)(19)
				4,727	4,675	
SPX Flow, Inc.						
First Lien Term Loan, SOFR+4.50% cash due 4/5/2029	8.92 %	Industrial Machinery	1,496	1,410	1,401	(6)
				1,410	1,401	
SumUp Holdings Luxembourg S.À.R.L.						
First Lien Term Loan, EURIBOR+8.50% cash due 3/10/2026	10.49 %	Other Diversified Financial Services	€ 16,911	19,415	17,732	(6)(11)(15)
				19,415	17,732	
Sunland Asphalt & Construction, LLC						
First Lien Term Loan, LIBOR+6.00% cash due 1/13/2026	11.15 %	Construction & Engineering	\$ 42,510	41,624	41,702	(6)(15)
				41,624	41,702	
Superior Industries International, Inc.						
First Lien Term Loan, SOFR+8.00% cash due 12/16/2028	12.32 %	Auto Parts & Equipment	39,774	38,591	38,581	(6)(15)
				38,591	38,581	
Supermoose Borrower, LLC						
First Lien Term Loan, LIBOR+3.75% cash due 8/29/2025	8.48 %	Application Software	3,457	3,162	2,994	(6)
				3,162	2,994	
SVP-Singer Holdings Inc.						
First Lien Term Loan, LIBOR+6.75% cash due 7/28/2028	11.48 %	Home Furnishings	20,714	19,554	17,917	(6)(15)
				19,554	17,917	
Swordfish Merger Sub LLC						
Second Lien Term Loan, LIBOR+6.75% cash due 2/2/2026	11.14 %	Auto Parts & Equipment	12,500	12,476	11,434	(6)(15)
				12,476	11,434	
Tacala, LLC						
Second Lien Term Loan, LIBOR+7.50% cash due 2/4/2028	11.88 %	Restaurants	9,448	9,343	8,610	(6)
				9,343	8,610	
Tahoe Bidco B.V.						
First Lien Term Loan, LIBOR+6.00% cash due 9/29/2028	10.29 %	Application Software	23,215	22,833	22,866	(6)(11)(15)
First Lien Revolver, LIBOR+6.00% cash due 10/1/2027			—	(28)	(26)	(6)(11)(15)(19)
				22,805	22,840	
Tecta America Corp.						
Second Lien Term Loan, SOFR+8.50% cash due 4/9/2029	12.94 %	Construction & Engineering	5,203	5,125	4,982	(6)(15)
				5,125	4,982	
Telestream Holdings Corporation						
First Lien Term Loan, SOFR+9.75% cash due 10/15/2025	13.67 %	Application Software	18,276	17,941	17,765	(6)(15)
First Lien Revolver, SOFR+9.75% cash due 10/15/2025	13.67 %		1,231	1,212	1,182	(6)(15)(19)
				19,153	18,947	
TerSera Therapeutics LLC						
Second Lien Term Loan, LIBOR+9.50% cash due 3/30/2026	13.88 %	Pharmaceuticals	29,663	29,375	29,057	(6)(15)
668,879 Common Units of TerSera Holdings LLC				2,028	4,662	(15)
				31,403	33,719	
TGNR HoldCo LLC						
Subordinated Debt, 11.50% cash due 5/14/2026		Integrated Oil & Gas	4,984	4,873	4,847	(10)(11)(15)
				4,873	4,847	

Oaktree Specialty Lending Corporation
Consolidated Schedule of Investments
December 31, 2022
(dollar amounts in thousands)
(unaudited)

Portfolio Company/Type of Investment (1)(2)(3)(4)(5)	Cash Interest Rate (6)	Industry	Principal (7)	Cost	Fair Value	Notes
Thrasio, LLC		Internet & Direct Marketing Retail				
First Lien Term Loan, LIBOR+7.00% cash due 12/18/2026	11.17 %		\$ 37,399	\$ 36,532	\$ 34,126	(6)(15)
8,434 Shares of Series C-3 Preferred Stock in Thrasio Holdings, Inc.				101	71	(15)
284,650.32 Shares of Series C-2 Preferred Stock in Thrasio Holdings, Inc.				2,409	1,882	(15)
48,352 Shares of Series D Preferred Stock in Thrasio Holdings, Inc.				979	852	(15)
25,780 Shares of Series X Preferred Stock in Thrasio Holdings, Inc.				25,564	29,070	(15)
				65,585	66,001	
TIBCO Software Inc.		Application Software				
First Lien Term Loan, SOFR+4.50% cash due 3/20/2029	9.18 %		12,032	10,986	10,775	(6)
				10,986	10,775	
Touchstone Acquisition, Inc.		Health Care Supplies				
First Lien Term Loan, LIBOR+6.00% cash due 12/29/2028	10.38 %		6,001	5,897	5,866	(6)(15)
				5,897	5,866	
Trinitas CLO XV		Multi-Sector Holdings				
Class E Notes, LIBOR+7.45% cash due 4/22/2034	11.77 %		1,000	810	846	(6)(11)
				810	846	
Uniti Group LP		Specialized REITs				
Fixed Rate Bond, 6.50% cash due 2/15/2029			4,500	4,074	2,990	(11)
Fixed Rate Bond, 4.75% cash due 4/15/2028			300	260	240	(11)
				4,334	3,230	
Win Brands Group LLC		Housewares & Specialties				
First Lien Term Loan, LIBOR+15.00% cash due 1/22/2026	20.75 %		2,238	2,217	2,137	(6)(15)
3,621 Class F Warrants in Brand Value Growth LLC (exercise price \$0.01) expiration date 1/25/2027				—	128	(15)
				2,217	2,265	
Windstream Services II, LLC		Integrated Telecommunication Services				
First Lien Term Loan, SOFR+6.25% cash due 9/21/2027	10.67 %		25,432	24,612	23,131	(6)
18,032 Shares of Common Stock in Windstream Holdings II, LLC				216	279	(15)
109,420 Warrants in Windstream Holdings II, LLC				1,842	1,695	(15)
				26,670	25,105	
WP CPP Holdings, LLC		Aerospace & Defense				
First Lien Term Loan, LIBOR+3.75% cash due 4/30/2025	8.17 %		7,545	7,029	6,598	(6)
Second Lien Term Loan, LIBOR+7.75% cash due 4/30/2026	12.17 %		6,000	5,866	5,055	(6)(15)
				12,895	11,653	
WPEngine, Inc.		Application Software				
First Lien Term Loan, LIBOR+6.00% cash due 3/27/2026	10.19 %		40,536	39,991	40,131	(6)(15)
				39,991	40,131	
WWEX Uni Topco Holdings, LLC		Air Freight & Logistics				
Second Lien Term Loan, LIBOR+7.00% cash due 7/26/2029	11.73 %		5,000	4,925	4,191	(6)(15)
				4,925	4,191	
Zayo Group Holdings, Inc.		Alternative Carriers				
Fixed Rate Bond, 4.00% cash due 3/1/2027			250	214	185	
				214	185	

Oaktree Specialty Lending Corporation
Consolidated Schedule of Investments
December 31, 2022
(dollar amounts in thousands)
(unaudited)

<u>Portfolio Company/Type of Investment (1)(2)(3)(4)(5)</u>	<u>Cash Interest Rate (6)</u>	<u>Industry</u>	<u>Principal (7)</u>	<u>Cost</u>	<u>Fair Value</u>	<u>Notes</u>
Zep Inc.		Specialty Chemicals				
Second Lien Term Loan, LIBOR+8.25% cash due 8/11/2025	12.98 %		\$ 19,578	\$ 19,545	\$ 13,704	(6)(15)
				19,545	13,704	
Zephyr Bidco Limited		Specialized Finance				
Second Lien Term Loan, SONIA+7.50% cash due 7/23/2026	10.96 %		£ 18,000	23,839	16,369	(6)(11)(15)
				23,839	16,369	
Total Non-Control/Non-Affiliate Investments (198.6% of net assets)				\$ 2,471,776	\$ 2,387,235	
Total Portfolio Investments (219.9% of net assets)				\$ 2,778,014	\$ 2,642,870	
Cash and Cash Equivalents and Restricted Cash						
JP Morgan Prime Money Market Fund, Institutional Shares				\$ 3,421	\$ 3,421	
Other cash accounts				15,824	15,824	
Total Cash and Cash Equivalents and Restricted Cash (1.6% of net assets)				\$ 19,245	\$ 19,245	
Total Portfolio Investments and Cash and Cash Equivalents and Restricted Cash (221.5% of net assets)				\$ 2,797,259	\$ 2,662,115	

<u>Derivative Instrument</u>	<u>Notional Amount to be Purchased</u>	<u>Notional Amount to be Sold</u>	<u>Maturity Date</u>	<u>Counterparty</u>	<u>Cumulative Unrealized Appreciation /(Depreciation)</u>
Foreign currency forward contract	\$ 44,825	€ 44,224	2/9/2023	JPMorgan Chase Bank, N.A.	\$ (2,499)
Foreign currency forward contract	\$ 46,412	£ 39,965	2/9/2023	JPMorgan Chase Bank, N.A.	(1,712)
					\$ (4,211)

<u>Derivative Instrument</u>	<u>Company Receives</u>	<u>Company Pays</u>	<u>Counterparty</u>	<u>Maturity Date</u>	<u>Notional Amount</u>	<u>Fair Value</u>
Interest rate swap	Fixed 2.7%	Floating 3-month LIBOR +1.658%	Royal Bank of Canada	1/15/2027	\$350,000	\$(39,928)

Oaktree Specialty Lending Corporation
Consolidated Schedule of Investments
December 31, 2022
(dollar amounts in thousands)
(unaudited)

- (1) All debt investments are income producing unless otherwise noted. All equity investments are non-income producing unless otherwise noted.
- (2) See Note 3 in the accompanying notes to the Consolidated Financial Statements for portfolio composition by geographic region.
- (3) Equity ownership may be held in shares or units of companies related to the portfolio companies.
- (4) Interest rates may be adjusted from period to period on certain term loans and revolvers. These rate adjustments may be either temporary in nature due to tier pricing arrangements or financial or payment covenant violations in the original credit agreements or permanent in nature per loan amendment or waiver documents.
- (5) Each of the Company's investments is pledged as collateral under one or more of its credit facilities. A single investment may be divided into parts that are individually pledged as collateral to separate credit facilities.
- (6) The interest rate on the principal balance outstanding for most of the floating rate loans is indexed to the London Interbank Offered Rate ("LIBOR") and/or an alternate base rate (e.g., prime rate), which typically resets semi-annually, quarterly, or monthly at the borrower's option. Certain loans may also be indexed to the secured overnight financing rate ("SOFR") or the sterling overnight index average ("SONIA"). The borrower may also elect to have multiple interest reset periods for each loan. For each of these loans, the Company has provided the applicable margin over the reference rate based on each respective credit agreement and the cash interest rate as of period end. All LIBOR shown above is in U.S. dollars unless otherwise noted. As of December 31, 2022, the reference rates for the Company's variable rate loans were the 30-day LIBOR at 4.38%, the 90-day LIBOR at 4.73%, the 180-day LIBOR at 5.15%, the PRIME at 7.50%, the 30-day SOFR at 4.32%, the 90-day SOFR at 4.58%, the 180-day SOFR at 4.79%, the SONIA at 3.43%, the 30-day EURIBOR at 1.90%, the 90-day EURIBOR at 1.99% and the 180-day EURIBOR at 0.38%. Most loans include an interest floor, which generally ranges from 0% to 2%. SOFR and SONIA based contracts may include a credit spread adjustment that is charged in addition to the base rate and the stated spread.
- (7) Principal includes accumulated payment in kind ("PIK") interest and is net of repayments, if any. "£" signifies the investment is denominated in British Pounds. "€" signifies the investment is denominated in Euros. All other investments are denominated in U.S. dollars.
- (8) Control Investments generally are defined by the Investment Company Act of 1940, as amended (the "Investment Company Act"), as investments in companies in which the Company owns more than 25% of the voting securities or maintains greater than 50% of the board representation.
- (9) As defined in the Investment Company Act, the Company is deemed to be both an "Affiliated Person" of and to "Control" these portfolio companies as the Company owns more than 25% of the portfolio company's outstanding voting securities or has the power to exercise control over management or policies of such portfolio company (including through a management agreement). See Schedule 12-14 in the accompanying notes to the Consolidated Financial Statements for transactions during the three months ended December 31, 2022 in which the issuer was both an Affiliated Person and a portfolio company that the Company is deemed to control.
- (10) This investment represents a participation interest in the underlying securities shown.
- (11) Investment is not a "qualifying asset" as defined under Section 55(a) of the Investment Company Act. Under the Investment Company Act, the Company may not acquire any non-qualifying asset unless, at the time the acquisition is made, qualifying assets represent at least 70% of the Company's total assets. As of December 31, 2022, qualifying assets represented 73.8% of the Company's total assets and non-qualifying assets represented 26.2% of the Company's total assets.
- (12) Income producing through payment of dividends or distributions.
- (13) One half of the Seller Earn Out Shares will vest if, at any time through June 16, 2027, the Alvotech SA common share price is at or above a volume weighted average price ("VWAP") of \$15.00 per share for any ten trading days within any twenty trading day period, and the other half will vest, if at any time during such period, the common share price is at or above a VWAP of \$20.00 per share for any ten trading days within any twenty trading day period.
- (14) See Note 3 in the accompanying notes to the Consolidated Financial Statements for portfolio composition.
- (15) As of December 31, 2022, these investments were categorized as Level 3 within the fair value hierarchy established by Financial Accounting Standards Board ("FASB") guidance under Accounting Standards Codification ("ASC") Topic 820, *Fair Value Measurements and Disclosures* ("ASC 820").
- (16) This investment was valued using net asset value as a practical expedient for fair value. Consistent with ASC 820, these investments are excluded from the hierarchical levels.
- (17) Affiliate Investments generally are defined by the Investment Company Act as investments in companies in which the Company owns between 5% and 25% of the voting securities.
- (18) Non-Control/Non-Affiliate Investments are investments that are neither Control Investments nor Affiliate Investments.
- (19) Investment had undrawn commitments. Unamortized fees are classified as unearned income which reduces cost basis, which may result in a negative cost basis. A negative fair value may result from the unfunded commitment being valued below par.

See notes to Consolidated Financial Statements.

Oaktree Specialty Lending Corporation
Consolidated Schedule of Investments
September 30, 2022
(dollar amounts in thousands)

Portfolio Company/Type of Investment (1)(2)(3)(4)(5)	Cash Interest Rate (6)	Industry	Principal (7)	Cost	Fair Value	Notes
Control Investments						(8)(9)
CS Technology Holdings, LLC						
		Data Processing & Outsourced Services				
829 Common Units			\$	—	\$	(15)
34,984,460.37 Preferred Units				34,984	27,638	(15)
				34,984	27,638	
Dominion Diagnostics, LLC						
		Health Care Services				
First Lien Term Loan, LIBOR+5.00% cash due 2/28/2024	8.68 %		\$ 14,333	14,333	14,333	(6)(15)
First Lien Revolver, LIBOR+5.00% cash due 2/28/2024			—	—	—	(6)(15)(19)
30,030.8 Common Units in DD Healthcare Services Holdings, LLC				15,222	4,946	(15)
				29,555	19,279	
OCSI Glick JV LLC						
		Multi-Sector Holdings				(14)
Subordinated Debt, LIBOR+4.50% cash due 10/20/2028	6.30 %		59,662	50,194	50,283	(6)(11)(15)(19)
87.5% equity interest				—	—	(11)(16)(19)
				50,194	50,283	
Senior Loan Fund JV I, LLC						
		Multi-Sector Holdings				(14)
Subordinated Debt, LIBOR+7.00% cash due 12/29/2028	8.80 %		96,250	96,250	96,250	(6)(11)(15)(19)
87.5% LLC equity interest				49,322	20,715	(11)(12)(16)(19)
				145,572	116,965	
Total Control Investments (17.2% of net assets)				\$ 260,305	\$ 214,165	
Affiliate Investments						
						(17)
Assembled Brands Capital LLC						
		Specialized Finance				
First Lien Revolver, LIBOR+6.75% cash due 10/17/2023	10.42 %		\$ 24,490	\$ 24,490	\$ 24,225	(6)(15)(19)
1,609,201 Class A Units				764	370	(15)
1,019,168.80 Preferred Units, 6%				1,019	1,223	(15)
70,424.5641 Class A Warrants (exercise price \$3.3778) expiration date 9/9/2029				—	—	(15)
				26,273	25,818	
Caregiver Services, Inc.						
		Health Care Services				
1,080,399 shares of Series A Preferred Stock, 10%				1,080	378	(15)
				1,080	378	
Total Affiliate Investments (2.1% of net assets)				\$ 27,353	\$ 26,196	
Non-Control/Non-Affiliate Investments						
						(18)
109 Montgomery Owner LLC						
		Real Estate Operating Companies				
First Lien Term Loan, LIBOR+7.00% cash due 2/2/2023	9.80 %		\$ 389	\$ 387	\$ 727	(6)(15)
First Lien Delayed Draw Term Loan, LIBOR+7.00% cash due 2/2/2023			—	(31)	—	(6)(15)(19)
				356	727	
A.T. Holdings II SÀRL						
		Biotechnology				
First Lien Term Loan, 10.50% PIK due 12/22/2022			33,997	33,960	34,891	(11)(15)
				33,960	34,891	
Access CIG, LLC						
		Diversified Support Services				
Second Lien Term Loan, LIBOR+7.75% cash due 2/27/2026	10.82 %		20,000	19,927	19,075	(6)
				19,927	19,075	
Accupac, Inc.						
		Personal Products				
First Lien Term Loan, SOFR+5.50% cash due 1/16/2026	9.12 %		15,976	15,686	15,944	(6)(15)
First Lien Delayed Draw Term Loan, SOFR+5.50% cash due 1/16/2026			—	—	(6)	(6)(15)(19)
First Lien Revolver, SOFR+5.50% cash due 1/16/2026	9.14 %		500	462	495	(6)(15)(19)
				16,148	16,433	

Oaktree Specialty Lending Corporation
Consolidated Schedule of Investments
September 30, 2022
(dollar amounts in thousands)

Portfolio Company/Type of Investment (1)(2)(3)(4)(5)	Cash Interest Rate (6)	Industry	Principal (7)	Cost	Fair Value	Notes
Acquia Inc.						
Application Software						
First Lien Term Loan, LIBOR+7.00% cash due 10/31/2025	9.63 %		\$ 27,349	\$ 27,038	\$ 27,158	(6)(15)
First Lien Revolver, LIBOR+7.00% cash due 10/31/2025	10.64 %		914	890	898	(6)(15)(19)
				27,928	28,056	
ADB Companies, LLC						
Construction & Engineering						
First Lien Term Loan, SOFR+6.25% cash due 12/18/2025	9.80 %		14,685	14,217	14,431	(6)(15)
				14,217	14,431	
ADC Therapeutics SA						
Biotechnology						
First Lien Term Loan, SOFR+7.50% cash due 8/15/2029	11.20 %		6,589	6,256	6,262	(6)(11)(15)
First Lien Delayed Draw Term Loan, SOFR+7.50% cash due 8/15/2029			—	(38)	(37)	(6)(11)(15)(19)
28,948 Common Stock Warrants (exercise price \$8.297) expiration 8/15/2032				174	73	(11)(15)
				6,392	6,298	
Aden & Anais Merger Sub, Inc.						
Apparel, Accessories & Luxury Goods						
51,645 Common Units in Aden & Anais Holdings, Inc.				5,165	—	(15)
				5,165	—	
AI Sirona (Luxembourg) Acquisition S.a.r.l.						
Pharmaceuticals						
Second Lien Term Loan, EURIBOR+7.25% cash due 9/28/2026	7.94 %		€ 24,838	27,752	22,143	(6)(11)(15)
				27,752	22,143	
AIP RD Buyer Corp.						
Distributors						
Second Lien Term Loan, SOFR+7.75% cash due 12/23/2029	10.88 %		\$ 14,414	14,154	13,910	(6)(15)
14,410 Common Units in RD Holding LP				1,352	1,291	(15)
				15,506	15,201	
AirStrip Technologies, Inc.						
Application Software						
5,715 Common Stock Warrants (exercise price \$139.99) expiration date 5/11/2025				90	—	(15)
				90	—	
All Web Leads, Inc.						
Advertising						
First Lien Term Loan, LIBOR+8.50% PIK due 12/29/2023			23,338	22,057	22,141	(6)(15)
				22,057	22,141	
Altice France S.A.						
Integrated Telecommunication Services						
Fixed Rate Bond, 5.50% cash due 10/15/2029			4,050	3,518	3,057	(11)
				3,518	3,057	
Alvogen Pharma US, Inc.						
Pharmaceuticals						
First Lien Term Loan, SOFR+7.50% cash due 6/30/2025	11.20 %		13,134	12,847	13,068	(6)(15)
				12,847	13,068	
Alvotech Holdings S.A.						
Biotechnology						(13)
Tranche A Fixed Rate Bond 10.00% cash due 6/24/2025			24,043	23,747	23,923	(11)(15)
Tranche B Fixed Rate Bond 10.00% cash due 6/24/2025			23,522	23,264	23,404	(11)(15)
587,930 Common Shares in Alvotech SA				5,308	3,974	(11)
124,780 Seller Earn Out Shares in Alvotech SA				485	212	(11)(15)
				52,804	51,513	
American Auto Auction Group, LLC						
Consumer Finance						
Second Lien Term Loan, SOFR+8.75% cash due 1/2/2029	12.30 %		14,760	14,492	13,284	(6)(15)
				14,492	13,284	
American Tire Distributors, Inc.						
Distributors						
First Lien Term Loan, LIBOR+6.25% cash due 10/20/2028	9.03 %		9,895	9,772	9,293	(6)
				9,772	9,293	
Amplify Finco Pty Ltd.						
Movies & Entertainment						
First Lien Term Loan, LIBOR+4.25% cash due 11/26/2026	7.92 %		15,220	13,973	14,687	(6)(11)(15)
Second Lien Term Loan, LIBOR+8.00% cash due 11/26/2027	11.67 %		12,500	12,188	11,958	(6)(11)(15)
				26,161	26,645	

Oaktree Specialty Lending Corporation
Consolidated Schedule of Investments
September 30, 2022
(dollar amounts in thousands)

Portfolio Company/Type of Investment (1)(2)(3)(4)(5)	Cash Interest Rate (6)	Industry	Principal (7)	Cost	Fair Value	Notes
Anastasia Parent, LLC						
Personal Products						
First Lien Term Loan, LIBOR+3.75% cash due 8/11/2025	7.42 %		\$ 2,736	\$ 2,260	\$ 2,189	(6)
				2,260	2,189	
Ankura Consulting Group LLC						
Research & Consulting Services						
Second Lien Term Loan, LIBOR+8.00% cash due 3/19/2029	10.78 %		4,346	4,281	3,813	(6)(15)
				4,281	3,813	
Apptio, Inc.						
Application Software						
First Lien Term Loan, LIBOR+6.00% cash due 1/10/2025	8.46 %		34,458	33,737	33,738	(6)(15)
First Lien Revolver, LIBOR+6.00% cash due 1/10/2025	8.46 %		892	863	846	(6)(15)(19)
				34,600	34,584	
APX Group Inc.						
Electrical Components & Equipment						
Fixed Rate Bond, 5.75% cash due 7/15/2029			2,075	1,733	1,645	(11)
				1,733	1,645	
Ardonagh Midco 3 PLC						
Insurance Brokers						
First Lien Term Loan, EURIBOR+7.00% cash due 7/14/2026	8.00 %		€ 1,964	2,176	1,927	(6)(11)(15)
First Lien Term Loan, SONIA+7.00% cash due 7/14/2026	9.19 %		£ 18,636	23,139	20,826	(6)(11)(15)
First Lien Term Loan, LIBOR+5.75% cash due 7/14/2026	8.81 %		\$ 10,519	10,357	10,328	(6)(11)(15)
First Lien Delayed Draw Term Loan, SONIA+5.75% cash due 7/14/2026			£ —	(44)	—	(6)(11)(15)(19)
				35,628	33,081	
ASP Unifrax Holdings, Inc.						
Trading Companies & Distributors						
Fixed Rate Bond, 7.50% cash due 9/30/2029			\$ 5,500	5,408	3,641	
Fixed Rate Bond, 5.25% cash due 9/30/2028			2,500	2,220	1,926	
				7,628	5,567	
Associated Asphalt Partners, LLC						
Construction Materials						
First Lien Term Loan, LIBOR+5.25% cash due 4/5/2024	8.06 %		2,501	2,331	1,934	(6)
				2,331	1,934	
Astra Acquisition Corp.						
Application Software						
First Lien Term Loan, LIBOR+5.25% cash due 10/25/2028	8.37 %		5,640	5,482	4,822	(6)
				5,482	4,822	
athenahealth Group Inc.						
Health Care Technology						
18,635 Shares of Series A Preferred Stock in Minerva Holdco, Inc., 10.75%				18,264	16,575	(15)
				18,264	16,575	
Athenex, Inc.						
Pharmaceuticals						
First Lien Term Loan, 11.00% cash due 6/19/2026			13,346	12,929	12,812	(11)(15)
First Lien Revenue Interest Financing Term Loan due 5/31/2031			8,309	8,264	8,309	(11)(15)
328,149 Common Stock Warrants (exercise price \$0.4955 expiration date 6/19/2027)				973	16	(11)(15)
				22,166	21,137	
Aurora Lux Finco S.À.R.L.						
Airport Services						
First Lien Term Loan, LIBOR+6.00% cash due 12/24/2026	8.78 %		22,425	22,086	21,326	(6)(11)(15)
				22,086	21,326	
The Avery						
Real Estate Operating Companies						
First Lien Term Loan in T8 Urban Condo Owner, LLC, LIBOR+7.30% cash due 2/17/2023	10.44 %		15,674	15,605	15,682	(6)(15)
Subordinated Debt in T8 Senior Mezz LLC, LIBOR+12.50% cash due 2/17/2023	16.17 %		3,789	3,774	3,800	(6)(15)
				19,379	19,482	
BAART Programs, Inc.						
Health Care Services						
First Lien Delayed Draw Term Loan, LIBOR+5.00% cash due 6/11/2027	8.12 %		2,546	2,503	2,395	(6)(15)(19)
Second Lien Term Loan, LIBOR+8.50% cash due 6/11/2028	11.62 %		7,166	7,059	6,915	(6)(15)
Second Lien Delayed Draw Term Loan, LIBOR+8.50% cash due 6/11/2028	11.62 %		4,227	4,070	3,839	(6)(15)(19)
				13,632	13,149	

Oaktree Specialty Lending Corporation
Consolidated Schedule of Investments
September 30, 2022
(dollar amounts in thousands)

Portfolio Company/Type of Investment (1)(2)(3)(4)(5)	Cash Interest Rate (6)	Industry	Principal (7)	Cost	Fair Value	Notes
Berner Food & Beverage, LLC						
		Soft Drinks				
First Lien Term Loan, LIBOR+5.50% cash due 7/30/2027	8.31 %		\$ 33,078	\$ 32,612	\$ 32,053	(6)(15)
First Lien Revolver, PRIME+4.50% cash due 7/30/2026	10.75 %		1,702	1,660	1,617	(6)(15)(19)
				34,272	33,670	
BioXcel Therapeutics, Inc.						
		Pharmaceuticals				
First Lien Term Loan, 10.25% cash due 4/19/2027			5,322	5,111	5,114	(11)(15)
First Lien Delayed Draw Term Loan, 10.25% cash due 4/19/2027			—	—	—	(11)(15)(19)
First Lien Revenue Interest Financing Term Loan due 9/30/2032			2,353	2,353	2,353	(11)(15)
First Lien Revenue Interest Financing Delayed Draw Term Loan due 9/30/2032			—	—	—	(11)(15)(19)
21,177 Common Stock Warrants (exercise price \$20.04) expiration date 4/19/2029				125	98	(11)(15)
				7,589	7,565	
Blackhawk Network Holdings, Inc.						
		Data Processing & Outsourced Services				
Second Lien Term Loan, LIBOR+7.00% cash due 6/15/2026	9.50 %		30,625	30,276	29,017	(6)
				30,276	29,017	
Blumenthal Temecula, LLC						
		Automotive Retail				
First Lien Term Loan, 9.00% cash due 9/24/2023			3,979	3,980	3,960	(15)
1,293,324 Preferred Units in Unstoppable Automotive AMV, LLC				1,293	1,280	(15)
298,460 Preferred Units in Unstoppable Automotive VMV, LLC				298	295	(15)
298,460 Common Units in Unstoppable Automotive AMV, LLC				298	349	(15)
				5,869	5,884	
Cadence Aerospace, LLC						
		Aerospace & Defense				
First Lien Term Loan, LIBOR+6.50% cash 2.00% PIK due 11/14/2023	9.31 %		14,294	13,471	13,143	(6)(15)
				13,471	13,143	
Carvana Co.						
		Automotive Retail				
Fixed Rate Bond, 5.625% cash due 10/1/2025			6,700	5,825	4,724	(11)
				5,825	4,724	
CCO Holdings LLC						
		Cable & Satellite				
Fixed Rate Bond, 4.50% cash due 5/1/2032			2,097	1,746	1,603	(11)
				1,746	1,603	
CircusTrix Holdings, LLC						
		Leisure Facilities				
First Lien Term Loan, LIBOR+5.50% cash due 7/16/2023	8.62 %		10,692	10,004	10,209	(6)(15)
				10,004	10,209	
CITGO Holding, Inc.						
		Oil & Gas Refining & Marketing				
Fixed Rate Bond, 9.25% cash due 8/1/2024			7,857	7,857	7,807	
				7,857	7,807	
CITGO Petroleum Corp.						
		Oil & Gas Refining & Marketing				
First Lien Term Loan, LIBOR+6.25% cash due 3/28/2024	9.37 %		795	770	797	(6)
				770	797	
Clear Channel Outdoor Holdings Inc.						
		Advertising				
Fixed Rate Bond, 7.50% cash due 6/1/2029			4,311	4,311	3,132	(11)
Fixed Rate Bond, 5.125% cash due 8/15/2027			1,374	1,229	1,163	(11)
Fixed Rate Bond, 7.75% cash due 4/15/2028			676	648	512	(11)
				6,188	4,807	
Condor Merger Sub Inc.						
		Systems Software				
Fixed Rate Bond, 7.375% cash due 2/15/2030			8,420	8,243	6,900	
				8,243	6,900	
Continental Intermodal Group LP						
		Oil & Gas Storage & Transportation				
First Lien Term Loan, LIBOR+8.50% cash due 1/28/2025	11.62 %		22,537	21,642	20,396	(6)(15)
Common Stock Warrants expiration date 7/28/2025				648	457	(15)
				22,290	20,853	

Oaktree Specialty Lending Corporation
Consolidated Schedule of Investments
September 30, 2022
(dollar amounts in thousands)

Portfolio Company/Type of Investment (1)(2)(3)(4)(5)	Cash Interest Rate (6)	Industry	Principal (7)	Cost	Fair Value	Notes
Convergeone Holdings, Inc.						
		IT Consulting & Other Services				
First Lien Term Loan, LIBOR+5.00% cash due 1/4/2026	8.12 %		\$ 11,913	\$ 11,697	\$ 8,596	(6)
				11,697	8,596	
Conviva Inc.						
		Application Software				
517,851 Shares of Series D Preferred Stock				605	894	(15)
				605	894	
CorEvitas, LLC						
		Health Care Technology				
First Lien Term Loan, SOFR+5.75% cash due 12/13/2025	8.88 %		13,712	13,554	13,583	(6)(15)
First Lien Revolver, PRIME+4.75% cash due 12/13/2025	11.00 %		916	898	898	(6)(15)(19)
1,099 Class A2 Common Units in CorEvitas Holdings, L.P.				690	2,340	(15)
				15,142	16,821	
Covetrus, Inc.						
		Health Care Distributors				
First Lien Term Loan, SOFR+5.00% cash due 9/20/2029	7.65 %		10,336	9,716	9,681	(6)
				9,716	9,681	
Coyote Buyer, LLC						
		Specialty Chemicals				
First Lien Term Loan, LIBOR+6.00% cash due 2/6/2026	8.81 %		18,200	17,790	17,843	(6)(15)
First Lien Revolver, LIBOR+6.00% cash due 2/6/2025			—	(13)	(26)	(6)(15)(19)
				17,777	17,817	
Delivery Hero FinCo LLC						
		Internet & Direct Marketing Retail				
First Lien Term Loan, SOFR+5.75% cash due 8/12/2027	8.49 %		4,988	4,882	4,757	(6)(11)
				4,882	4,757	
Delta Leasing SPV II LLC						
		Specialized Finance				
Subordinated Delayed Draw Term Loan, 10.00% cash due 8/31/2029			4,183	4,183	4,183	(11)(15)(19)
419 Series C Preferred Units in Delta Financial Holdings LLC				419	419	(11)(15)
2.09 Common Units in Delta Financial Holdings LLC				2	2	(11)(15)
31.37 Common Warrants (exercise price \$1.00)				—	—	(11)(15)
				4,604	4,604	
Delta Topco, Inc.						
		Systems Software				
Second Lien Term Loan, LIBOR+7.25% cash due 12/1/2028	9.34 %		6,680	6,647	5,934	(6)
				6,647	5,934	
Dialyze Holdings, LLC						
		Health Care Equipment				
First Lien Term Loan, LIBOR+9.00% cash 2.00% PIK due 8/4/2026	12.67 %		24,396	23,083	22,993	(6)(15)
First Lien Delayed Draw Term Loan, LIBOR+9.00% cash 2.00% PIK due 8/4/2026			—	(135)	(129)	(6)(15)(19)
5,403,823 Class A Warrants (exercise price \$1.00) expiration date 8/4/2028				1,405	1,297	(15)
				24,353	24,161	
Digital.AI Software Holdings, Inc.						
		Application Software				
First Lien Term Loan, LIBOR+7.00% cash due 2/10/2027	9.91 %		9,902	9,599	9,793	(6)(15)
First Lien Revolver, LIBOR+6.50% cash due 2/10/2027	9.41 %		251	228	239	(6)(15)(19)
				9,827	10,032	
DirecTV Financing, LLC						
		Cable & Satellite				
First Lien Term Loan, LIBOR+5.00% cash due 8/2/2027	8.12 %		19,242	18,970	17,973	(6)
				18,970	17,973	
DTI Holdco, Inc.						
		Research & Consulting Services				
First Lien Term Loan, SOFR+4.75% cash due 4/26/2029	7.33 %		5,000	4,906	4,760	(6)
				4,906	4,760	
Eagleview Technology Corporation						
		Application Software				
Second Lien Term Loan, LIBOR+7.50% cash due 8/14/2026	11.17 %		8,974	8,884	8,503	(6)(15)
				8,884	8,503	

Oaktree Specialty Lending Corporation
Consolidated Schedule of Investments
September 30, 2022
(dollar amounts in thousands)

Portfolio Company/Type of Investment (1)(2)(3)(4)(5)	Cash Interest Rate (6)	Industry	Principal (7)	Cost	Fair Value	Notes
EOS Fitness Opco Holdings, LLC						
487.5 Class A Preferred Units, 12%		Leisure Facilities		\$ 488	\$ 966	(15)
12,500 Class B Common Units				—	—	(15)
				488	966	
Establishment Labs Holdings Inc.						
First Lien Term Loan, 3.00% cash 6.00% PIK due 4/21/2027		Health Care Technology	\$ 10,418	10,275	10,231	(11)(15)
First Lien Delayed Draw Term Loan, 3.00% cash 6.00% PIK due 4/21/2027				3	—	(11)(15)(19)
				10,278	10,231	
Fairbridge Strategic Capital Funding LLC						
		Real Estate Operating Companies				(20)
First Lien Delayed Draw Term Loan, 9.00% cash due 12/24/2028			27,850	27,850	27,850	(15)(19)
2,500 Warrant Units (exercise price \$0.01) expiration date 11/24/2031				—	3	(11)(15)
				27,850	27,853	
FINThrive Software Intermediate Holdings, Inc.						
Second Lien Term Loan, LIBOR+6.75% cash due 12/17/2029	9.87 %	Health Care Technology	25,061	24,685	21,646	(6)
				24,685	21,646	
Fortress Biotech, Inc.						
First Lien Term Loan, 11.00% cash due 8/27/2025		Biotechnology	9,466	9,071	9,008	(11)(15)
331,200 Common Stock Warrants (exercise price \$3.20) expiration date 8/27/2030				405	66	(11)(15)
				9,476	9,074	
Frontier Communications Holdings, LLC						
		Integrated Telecommunication Services				
Fixed Rate Bond, 6.00% cash due 1/15/2030			4,881	4,420	3,845	(11)
				4,420	3,845	
GKD Index Partners, LLC						
		Specialized Finance				
First Lien Term Loan, LIBOR+7.00% cash due 6/29/2023	10.67 %		25,128	24,915	24,851	(6)(15)
First Lien Revolver, LIBOR+7.00% cash due 6/29/2023	10.60 %		1,280	1,268	1,262	(6)(15)(19)
				26,183	26,113	
Global Medical Response, Inc.						
First Lien Term Loan, LIBOR+4.25% cash due 3/14/2025	7.37 %	Health Care Services	5,572	5,435	4,848	(6)
				5,435	4,848	
Grove Hotel Parcel Owner, LLC						
		Hotels, Resorts & Cruise Lines				
First Lien Term Loan, SOFR+8.00% cash due 6/21/2027	11.04 %		14,311	14,041	14,060	(6)(15)
First Lien Delayed Draw Term Loan, SOFR+8.00% cash due 6/21/2027			—	(54)	(50)	(6)(15)(19)
First Lien Revolver, SOFR+8.00% cash due 6/21/2027			—	(27)	(25)	(6)(15)(19)
				13,960	13,985	
Harbor Purchaser Inc.						
		Education Services				
First Lien Term Loan, SOFR+5.25% cash due 4/9/2029	8.38 %		9,392	9,080	8,582	(6)
				9,080	8,582	
iCIMS, Inc.						
		Application Software				
First Lien Term Loan, SOFR+6.75% cash due 8/18/2028	9.49 %		19,203	18,874	18,867	(6)(15)
First Lien Delayed Draw Term Loan, SOFR+6.75% cash due 8/18/2028			—	—	—	(6)(15)(19)
First Lien Revolver, SOFR+6.75% cash due 8/18/2028			—	(31)	(32)	(6)(15)(19)
				18,843	18,835	
Immucor, Inc.						
		Health Care Supplies				
First Lien Term Loan, LIBOR+5.75% cash due 7/2/2025	9.42 %		8,569	8,401	8,407	(6)(15)
Second Lien Term Loan, LIBOR+8.00% cash 3.50% PIK due 10/2/2025	11.67 %		22,619	22,162	22,275	(6)(15)
				30,563	30,682	

Oaktree Specialty Lending Corporation
Consolidated Schedule of Investments
September 30, 2022
(dollar amounts in thousands)

Portfolio Company/Type of Investment (1)(2)(3)(4)(5)	Cash Interest Rate (6)	Industry	Principal (7)	Cost	Fair Value	Notes
Impel Neuropharma, Inc.						
Health Care Technology						
First Lien Revenue Interest Financing Term Loan due 2/15/2031			\$ 13,083	\$ 13,083	\$ 13,083	(15)
First Lien Term Loan, SOFR+8.75% cash due 3/17/2027	12.45 %		12,161	11,944	11,942	(6)(15)
				25,027	25,025	
Innocoll Pharmaceuticals Limited						
Health Care Technology						
First Lien Term Loan, 11.00% cash due 1/26/2027			6,817	6,553	6,408	(11)(15)
First Lien Delayed Draw Term Loan, 11.00% cash due 1/26/2027			—	—	—	(11)(15)(19)
56,999 Tranche A Warrant Shares (exercise price \$4.23) expiration date 1/26/2029				135	609	(11)(15)
				6,688	7,017	
Integral Development Corporation						
Other Diversified Financial Services						
1,078,284 Common Stock Warrants (exercise price \$0.9274) expiration date 7/10/2024				113	—	(15)
				113	—	
Inventus Power, Inc.						
Electrical Components & Equipment						
First Lien Term Loan, SOFR+5.00% cash due 3/29/2024	8.55 %		18,660	18,567	18,134	(6)(15)
Second Lien Term Loan, LIBOR+8.50% cash due 9/29/2024	12.17 %		13,674	13,514	13,154	(6)(15)
				32,081	31,288	
INW Manufacturing, LLC						
Personal Products						
First Lien Term Loan, LIBOR+5.75% cash due 3/25/2027	9.42 %		35,625	34,806	31,528	(6)(15)
				34,806	31,528	
IPC Corp.						
Application Software						
First Lien Term Loan, LIBOR+6.50% cash due 10/1/2026	9.44 %		34,357	33,612	32,639	(6)(15)
				33,612	32,639	
Ivanti Software, Inc.						
Application Software						
Second Lien Term Loan, LIBOR+7.25% cash due 12/1/2028	10.33 %		10,247	10,196	7,702	(6)
				10,196	7,702	
Jazz Acquisition, Inc.						
Aerospace & Defense						
First Lien Term Loan, LIBOR+7.50% cash due 1/29/2027	10.62 %		36,234	35,170	36,392	(6)(15)
Second Lien Term Loan, LIBOR+8.00% cash due 6/18/2027	11.12 %		528	478	481	(6)
				35,648	36,873	
Kings Buyer, LLC						
Environmental & Facilities Services						
First Lien Term Loan, LIBOR+6.50% cash due 10/29/2027	10.17 %		13,623	13,487	13,351	(6)(15)
First Lien Revolver, LIBOR+6.50% cash due 10/29/2027	10.17 %		329	311	292	(6)(15)(19)
				13,798	13,643	
LaserShip, Inc.						
Air Freight & Logistics						
Second Lien Term Loan, LIBOR+7.50% cash due 5/7/2029	10.38 %		2,394	2,370	1,867	(6)(15)
				2,370	1,867	
Lift Brands Holdings, Inc.						
Leisure Facilities						
2,000,000 Class A Common Units in Snap Investments, LLC				1,399	—	(15)
				1,399	—	
Lightbox Intermediate, L.P.						
Real Estate Services						
First Lien Term Loan, LIBOR+5.00% cash due 5/9/2026	8.67 %		41,008	40,243	39,573	(6)(15)
				40,243	39,573	
Liquid Environmental Solutions Corporation						
Environmental & Facilities Services						
Second Lien Term Loan, LIBOR+8.50% cash due 11/30/2026	11.38 %		4,357	4,285	4,226	(6)(15)
Second Lien Delayed Draw Term Loan, LIBOR+8.50% cash due 11/30/2026	11.38 %		2,370	2,323	2,265	(6)(15)(19)
450.75 Class A2 Units in LES Group Holdings, L.P.				451	451	(15)
				7,059	6,942	

Oaktree Specialty Lending Corporation
Consolidated Schedule of Investments
September 30, 2022
(dollar amounts in thousands)

Portfolio Company/Type of Investment (1)(2)(3)(4)(5)	Cash Interest Rate (6)	Industry	Principal (7)	Cost	Fair Value	Notes
LSL Holdco, LLC						
		Health Care Distributors				
First Lien Term Loan, LIBOR+6.00% cash due 1/31/2028	9.12 %		\$ 19,236	\$ 18,894	\$ 18,707	(6)(15)
First Lien Revolver, LIBOR+6.00% cash due 1/31/2028	9.12 %		1,710	1,672	1,651	(6)(15)(19)
				20,566	20,358	
LTI Holdings, Inc.						
		Electronic Components				
Second Lien Term Loan, LIBOR+6.75% cash due 9/6/2026	9.87 %		2,140	2,092	1,890	(6)
				2,092	1,890	
Marinus Pharmaceuticals, Inc.						
		Pharmaceuticals				
First Lien Term Loan, 11.50% cash due 5/11/2026			17,203	16,954	16,644	(11)(15)
First Lien Delayed Draw Term Loan, 11.50% cash due 5/11/2026			—	—	—	(11)(15)(19)
				16,954	16,644	
Mesoblast, Inc.						
		Biotechnology				
First Lien Term Loan, 8.00% cash 1.75% PIK due 11/19/2026			7,215	6,650	6,440	(11)(15)
First Lien Delayed Draw Term Loan, 8.00% cash 1.75% PIK due 11/19/2026			—	1	—	(11)(15)(19)
209,588 Warrant Shares (exercise price \$7.26) expiration date 11/19/2028				480	170	(11)(15)
				7,131	6,610	
MHE Intermediate Holdings, LLC						
		Diversified Support Services				
First Lien Term Loan, SOFR+6.00% cash due 7/21/2027	9.50 %		18,390	18,088	17,691	(6)(15)
First Lien Revolver, SOFR+6.00% cash due 7/21/2027			—	(23)	(54)	(6)(15)(19)
				18,065	17,637	
Mindbody, Inc.						
		Internet Services & Infrastructure				
First Lien Term Loan, LIBOR+7.00% cash 1.50% PIK due 2/14/2025	10.64 %		45,665	44,689	44,523	(6)(15)
First Lien Revolver, LIBOR+8.00% cash due 2/14/2025			—	(54)	(100)	(6)(15)(19)
				44,635	44,423	
Mosaic Companies, LLC						
		Home Improvement Retail				
First Lien Term Loan, LIBOR+6.75% cash due 7/2/2026	9.89 %		46,499	45,802	45,421	(6)(15)
				45,802	45,421	
MRI Software LLC						
		Application Software				
First Lien Term Loan, LIBOR+5.50% cash due 2/10/2026	9.17 %		29,565	29,128	28,734	(6)(15)
First Lien Delayed Draw Term Loan, LIBOR+5.50% cash due 2/10/2026			—	(12)	(96)	(6)(15)(19)
First Lien Revolver, LIBOR+5.50% cash due 2/10/2026			—	(13)	(51)	(6)(15)(19)
				29,103	28,587	
Navisite, LLC						
		Data Processing & Outsourced Services				
Second Lien Term Loan, LIBOR+8.50% cash due 12/30/2026	12.17 %		22,560	22,241	21,524	(6)(15)
				22,241	21,524	
NeuAG, LLC						
		Fertilizers & Agricultural Chemicals				
First Lien Term Loan, LIBOR+10.50% cash due 9/11/2024	14.17 %		50,459	49,301	51,972	(6)(15)
				49,301	51,972	
NFP Corp.						
		Other Diversified Financial Services				
Fixed Rate Bond 6.875% cash due 8/15/2028			10,191	9,773	7,966	
				9,773	7,966	
NN, Inc.						
		Industrial Machinery				
First Lien Term Loan, LIBOR+6.88% cash due 9/19/2026	9.99 %		58,713	57,655	56,805	(6)(11)(15)
				57,655	56,805	
OEConnection LLC						
		Application Software				
First Lien Term Loan, LIBOR+4.00% cash due 9/25/2026	7.12 %		3,323	3,162	3,207	(6)
Second Lien Term Loan, LIBOR+7.00% cash due 9/25/2027	10.05 %		7,519	7,389	7,237	(6)(15)
				10,551	10,444	

Oaktree Specialty Lending Corporation
Consolidated Schedule of Investments
September 30, 2022
(dollar amounts in thousands)

<u>Portfolio Company/Type of Investment (1)(2)(3)(4)(5)</u>	<u>Cash Interest Rate (6)</u>	<u>Industry</u>	<u>Principal (7)</u>	<u>Cost</u>	<u>Fair Value</u>	<u>Notes</u>
OTG Management, LLC						
First Lien Term Loan, LIBOR+2.00% cash 8.00% PIK due 9/1/2025	5.08 %	Airport Services	\$ 21,557	\$ 21,267	\$ 21,557	(6)(15)
First Lien Delayed Draw Term Loan, LIBOR+2.00% cash 8.00% PIK due 9/1/2025			—	(31)	—	(6)(15)(19)
				21,236	21,557	
P & L Development, LLC						
Fixed Rate Bond, 7.75% cash due 11/15/2025		Pharmaceuticals	7,776	7,820	5,846	
				7,820	5,846	
Park Place Technologies, LLC						
First Lien Term Loan, SOFR+5.00% cash due 11/10/2027	8.13 %	Internet Services & Infrastructure	9,850	9,460	9,374	(6)
				9,460	9,374	
Performance Health Holdings, Inc.						
First Lien Term Loan, LIBOR+6.00% cash due 7/12/2027	8.88 %	Health Care Distributors	17,976	17,690	17,537	(6)(15)
				17,690	17,537	
PFNY Holdings, LLC						
First Lien Term Loan, LIBOR+7.00% cash due 12/31/2026	9.28 %	Leisure Facilities	26,154	25,712	25,893	(6)(15)
First Lien Delayed Draw Term Loan, LIBOR+7.00% cash due 12/31/2026	9.25 %		2,228	2,186	2,203	(6)(15)(19)
First Lien Revolver, LIBOR+7.00% cash due 12/31/2026			—	(21)	(13)	(6)(15)(19)
				27,877	28,083	
Planview Parent, Inc.						
Second Lien Term Loan, LIBOR+7.25% cash due 12/18/2028	10.92 %	Application Software	28,627	28,198	27,482	(6)(15)
				28,198	27,482	
Pluralsight, LLC						
First Lien Term Loan, LIBOR+8.00% cash due 4/6/2027	10.68 %	Application Software	48,689	47,951	47,155	(6)(15)
First Lien Revolver, LIBOR+8.00% cash due 4/6/2027			—	(53)	(111)	(6)(15)(19)
				47,898	47,044	
PRGX Global, Inc.						
First Lien Term Loan, LIBOR+6.75% cash due 3/3/2026	10.42 %	Data Processing & Outsourced Services	33,775	32,931	33,116	(6)(15)
First Lien Revolver, LIBOR+6.75% cash due 3/3/2026			—	(34)	(49)	(6)(15)(19)
80,515 Class B Common Units				79	89	(15)
				32,976	33,156	
Profrac Holdings II, LLC						
First Lien Term Loan, SOFR+8.50% cash due 3/4/2025	10.01 %	Industrial Machinery	23,275	22,722	22,810	(6)(15)
				22,722	22,810	
Project Boost Purchaser, LLC						
Second Lien Term Loan, LIBOR+8.00% cash due 5/31/2027	11.12 %	Application Software	5,250	5,168	5,047	(6)(15)
				5,168	5,047	
Quantum Bidco Limited						
First Lien Term Loan, SONIA+6.00% cash due 1/29/2028	8.39 %	Food Distributors	£ 3,501	4,646	3,367	(6)(11)(15)
				4,646	3,367	
QuorumLabs, Inc.						
64,887,669 Junior-2 Preferred Stock		Application Software		375	—	(15)
				375	—	
Radiology Partners Inc.						
First Lien Term Loan, LIBOR+4.25% cash due 7/9/2025	7.33 %	Health Care Distributors	\$ 3,400	3,202	2,880	(6)
Fixed Rate Bond, 9.25% cash due 2/1/2028			4,755	4,720	3,109	
				7,922	5,989	
Relativity ODA LLC						
First Lien Term Loan, LIBOR+7.50% PIK due 5/12/2027		Application Software	24,692	24,265	24,101	(6)(15)
First Lien Revolver, LIBOR+6.50% cash due 5/12/2027			—	(43)	(64)	(6)(15)(19)
				24,222	24,037	
Renaissance Holding Corp.						
Second Lien Term Loan, LIBOR+7.00% cash due 5/29/2026	10.12 %	Diversified Banks	3,542	3,515	3,402	(6)
				3,515	3,402	

Oaktree Specialty Lending Corporation
Consolidated Schedule of Investments
September 30, 2022
(dollar amounts in thousands)

Portfolio Company/Type of Investment (1)(2)(3)(4)(5)	Cash Interest Rate (6)	Industry	Principal (7)	Cost	Fair Value	Notes
RP Escrow Issuer LLC						
Fixed Rate Bond, 5.25% cash due 12/15/2025		Health Care Distributors	\$ 1,325	\$ 1,218	\$ 1,097	
				1,218	1,097	
RumbleOn, Inc.						
		Automotive Retail				
First Lien Term Loan, LIBOR+8.25% cash due 8/31/2026	11.92 %		37,656	35,775	36,187	(6)(11)(15)
First Lien Delayed Draw Term Loan, LIBOR+8.25% cash due 8/31/2026	11.92 %		11,393	10,583	10,760	(6)(11)(15)(19)
164,660 Class B Common Stock Warrants (exercise price \$33.00) expiration date 2/28/2023				1,202	74	(11)(15)
				47,560	47,021	
Sabert Corporation						
		Metal & Glass Containers				
First Lien Term Loan, LIBOR+4.50% cash due 12/10/2026	7.63 %		1,691	1,610	1,623	(6)
				1,610	1,623	
ShareThis, Inc.						
		Application Software				
345,452 Series C Preferred Stock Warrants (exercise price \$3.0395) expiration date 3/4/2024				367	—	(15)
				367	—	
SiO2 Medical Products, Inc.						
		Metal & Glass Containers				
First Lien Term Loan, 5.50% cash 8.50% PIK due 12/21/2026			46,121	45,413	45,295	(15)
415.34 Common Stock Warrants (exercise price \$4,920.75) expiration date 7/31/2028				681	681	(15)
				46,094	45,976	
SM Wellness Holdings, Inc.						
		Health Care Services				
Second Lien Term Loan, LIBOR+8.00% cash due 4/16/2029	10.74 %		9,109	8,972	8,289	(6)(15)
				8,972	8,289	
SonicWall US Holdings Inc.						
		Technology Distributors				
Second Lien Term Loan, LIBOR+7.50% cash due 5/18/2026	10.48 %		3,195	3,163	2,997	(6)(15)
				3,163	2,997	
Sorrento Therapeutics, Inc.						
		Biotechnology				
50,000 Common Stock Units				197	79	(11)
				197	79	
Spanx, LLC						
		Apparel Retail				
First Lien Term Loan, LIBOR+5.25% cash due 11/20/2028	8.30 %		4,534	4,455	4,427	(6)(15)
First Lien Revolver, LIBOR+5.25% cash due 11/18/2027	8.03 %		866	813	796	(6)(15)(19)
				5,268	5,223	
SPX Flow, Inc.						
		Industrial Machinery				
First Lien Term Loan, SOFR+4.50% cash due 4/5/2029	7.63 %		1,500	1,410	1,393	(6)
				1,410	1,393	
SumUp Holdings Luxembourg S.À.R.L.						
		Other Diversified Financial Services				
First Lien Term Loan, EURIBOR+8.50% cash due 3/10/2026	10.00 %		€ 16,911	19,414	16,360	(6)(11)(15)
				19,414	16,360	
Sunland Asphalt & Construction, LLC						
		Construction & Engineering				
First Lien Term Loan, LIBOR+6.00% cash due 1/13/2026	8.88 %		\$ 42,618	41,654	41,723	(6)(15)
				41,654	41,723	
Supermoose Borrower, LLC						
		Application Software				
First Lien Term Loan, LIBOR+3.75% cash due 8/29/2025	7.42 %		3,466	3,141	3,056	(6)
				3,141	3,056	
SVP-Singer Holdings Inc.						
		Home Furnishings				
First Lien Term Loan, LIBOR+6.75% cash due 7/28/2028	10.42 %		20,766	19,550	18,188	(6)(15)
				19,550	18,188	
Swordfish Merger Sub LLC						
		Auto Parts & Equipment				
Second Lien Term Loan, LIBOR+6.75% cash due 2/2/2026	9.81 %		12,500	12,474	11,469	(6)(15)
				12,474	11,469	

Oaktree Specialty Lending Corporation
Consolidated Schedule of Investments
September 30, 2022
(dollar amounts in thousands)

Portfolio Company/Type of Investment (1)(2)(3)(4)(5)	Cash Interest Rate (6)	Industry	Principal (7)	Cost	Fair Value	Notes
Tacala, LLC						
Second Lien Term Loan, LIBOR+7.50% cash due 2/4/2028	10.62 %	Restaurants	\$ 9,448	\$ 9,338	\$ 8,692	(6)
				9,338	8,692	
Tahoe Bidco B.V.						
		Application Software				
First Lien Term Loan, LIBOR+6.00% cash due 9/29/2028	8.68 %		23,215	22,815	22,843	(6)(11)(15)
First Lien Revolver, LIBOR+6.00% cash due 10/1/2027			—	(29)	(28)	(6)(11)(15)(19)
				22,786	22,815	
Tecta America Corp.						
		Construction & Engineering				
Second Lien Term Loan, LIBOR+8.50% cash due 4/9/2029	11.62 %		5,203	5,125	5,034	(6)(15)
				5,125	5,034	
Telestream Holdings Corporation						
		Application Software				
First Lien Term Loan, SOFR+9.25% cash due 10/15/2025	12.11 %		18,323	17,956	17,865	(6)(15)
First Lien Revolver, SOFR+9.25% cash due 10/15/2025	12.20 %		1,231	1,210	1,187	(6)(15)(19)
				19,166	19,052	
TerSera Therapeutics LLC						
		Pharmaceuticals				
Second Lien Term Loan, LIBOR+9.50% cash due 3/30/2026	13.17 %		29,663	29,352	29,031	(6)(15)
668,879 Common Units of TerSera Holdings LLC				2,028	4,077	(15)
				31,380	33,108	
TGNR HoldCo LLC						
		Integrated Oil & Gas				
Subordinated Debt, 11.50% cash due 5/14/2026			4,984	4,866	4,872	(10)(11)(15)
				4,866	4,872	
Thrasio, LLC						
		Internet & Direct Marketing Retail				
First Lien Term Loan, LIBOR+7.00% cash due 12/18/2026	11.17 %		37,494	36,569	35,807	(6)(15)
8,434 Shares of Series C-3 Preferred Stock in Thrasio Holdings, Inc.				101	69	(15)
284,650.32 Shares of Series C-2 Preferred Stock in Thrasio Holdings, Inc.				2,409	2,320	(15)
48,352 Shares of Series D Preferred Stock in Thrasio Holdings, Inc.				979	979	(15)
23,201 Shares of Series X Preferred Stock in Thrasio Holdings, Inc.				22,986	26,487	(15)(19)
				63,044	65,662	
TIBCO Software Inc.						
		Application Software				
First Lien Term Loan, SOFR+4.50% cash due 3/20/2029	8.15 %		12,032	10,949	10,827	(6)
				10,949	10,827	
Touchstone Acquisition, Inc.						
		Health Care Supplies				
First Lien Term Loan, LIBOR+6.00% cash due 12/29/2028	9.12 %		6,016	5,908	5,895	(6)(15)
				5,908	5,895	
Uniti Group LP						
		Specialized REITs				
Fixed Rate Bond, 6.50% cash due 2/15/2029			4,500	4,060	3,026	(11)
Fixed Rate Bond, 4.75% cash due 4/15/2028			300	258	238	(11)
				4,318	3,264	
Win Brands Group LLC						
		Housewares & Specialties				
First Lien Term Loan, LIBOR+15.00% cash due 1/22/2026	19.64 %		2,316	2,293	2,264	(6)(15)
3,621 Class F Warrants in Brand Value Growth LLC (exercise price \$0.01) expiration date 1/25/2027				—	192	(15)
				2,293	2,456	

Oaktree Specialty Lending Corporation
Consolidated Schedule of Investments
September 30, 2022
(dollar amounts in thousands)

Portfolio Company/Type of Investment (1)(2)(3)(4)(5)	Cash Interest Rate (6)	Industry	Principal (7)	Cost	Fair Value	Notes
Windstream Services II, LLC		Integrated Telecommunication Services				
First Lien Term Loan, LIBOR+6.25% cash due 9/21/2027	9.37 %		\$ 25,499	\$ 24,632	\$ 23,204	(6)
18,032 Shares of Common Stock in Windstream Holdings II, LLC				216	296	(15)
109,420 Warrants in Windstream Holdings II, LLC				1,842	1,799	(15)
				26,690	25,299	
WP CPP Holdings, LLC		Aerospace & Defense				
First Lien Term Loan, LIBOR+3.75% cash due 4/30/2025	6.56 %		7,564	6,989	6,795	(6)
Second Lien Term Loan, LIBOR+7.75% cash due 4/30/2026	10.56 %		6,000	5,855	5,070	(6)(15)
				12,844	11,865	
WPEngine, Inc.		Application Software				
First Lien Term Loan, LIBOR+6.00% cash due 3/27/2026	10.19 %		40,536	39,947	40,131	(6)(15)
				39,947	40,131	
WWEX Uni Topco Holdings, LLC		Air Freight & Logistics				
Second Lien Term Loan, LIBOR+7.00% cash due 7/26/2029	10.67 %		5,000	4,925	4,538	(6)(15)
				4,925	4,538	
Zayo Group Holdings, Inc.		Alternative Carriers				
Fixed Rate Bond, 4.00% cash due 3/1/2027			250	212	201	
				212	201	
Zep Inc.		Specialty Chemicals				
Second Lien Term Loan, LIBOR+8.25% cash due 8/11/2025	11.92 %		19,578	19,542	16,152	(6)(15)
				19,542	16,152	
Zephyr Bidco Limited		Specialized Finance				
Second Lien Term Loan, SONIA+7.50% cash due 7/23/2026	9.72 %		£ 18,000	23,804	16,552	(6)(11)(15)
				23,804	16,552	
Total Non-Control/Non-Affiliate Investments (180.9% of net assets)				\$ 2,330,096	\$ 2,253,750	
Total Portfolio Investments (200.2% of net assets)				\$ 2,617,754	\$ 2,494,111	
Cash and Cash Equivalents and Restricted Cash						
JP Morgan Prime Money Market Fund, Institutional Shares				\$ 5,261	\$ 5,261	
Other cash accounts				21,103	21,103	
Total Cash and Cash Equivalents and Restricted Cash (2.1% of net assets)				\$ 26,364	\$ 26,364	
Total Portfolio Investments and Cash and Cash Equivalents and Restricted Cash (202.4% of net assets)				\$ 2,644,118	\$ 2,520,475	

Derivative Instrument	Notional Amount to be Purchased	Notional Amount to be Sold	Maturity Date	Counterparty	Cumulative Unrealized Appreciation / (Depreciation)
Foreign currency forward contract	\$ 43,179	€ 41,444	11/10/2022	JPMorgan Chase Bank, N.A.	\$ 2,466
Foreign currency forward contract	\$ 45,692	£ 37,033	11/10/2022	JPMorgan Chase Bank, N.A.	4,323
					\$ 6,789

Derivative Instrument	Company Receives	Company Pays	Counterparty	Maturity Date	Notional Amount	Fair Value
Interest rate swap	Fixed 2.7%	Floating 3-month LIBOR +1.658%	Royal Bank of Canada	1/15/2027	\$350,000	\$(41,969)

Oaktree Specialty Lending Corporation
Consolidated Schedule of Investments
September 30, 2022
(dollar amounts in thousands)

- (1) All debt investments are income producing unless otherwise noted. All equity investments are non-income producing unless otherwise noted.
- (2) See Note 3 in the accompanying notes to the Consolidated Financial Statements for portfolio composition by geographic region.
- (3) Equity ownership may be held in shares or units of companies related to the portfolio companies.
- (4) Interest rates may be adjusted from period to period on certain term loans and revolving. These rate adjustments may be either temporary in nature due to tier pricing arrangements or financial or payment covenant violations in the original credit agreements or permanent in nature per loan amendment or waiver documents.
- (5) Each of the Company's investments is pledged as collateral under one or more of its credit facilities. A single investment may be divided into parts that are individually pledged as collateral to separate credit facilities.
- (6) The interest rate on the principal balance outstanding for most of the floating rate loans is indexed to LIBOR and/or an alternate base rate (e.g., prime rate), which typically resets semi-annually, quarterly, or monthly at the borrower's option. Certain loans may also be indexed to SOFR or SONIA. The borrower may also elect to have multiple interest reset periods for each loan. For each of these loans, the Company has provided the applicable margin over the reference rate based on each respective credit agreement and the cash interest rate as of period end. All LIBOR shown above is in U.S. dollars unless otherwise noted. As of September 30, 2022, the reference rates for the Company's variable rate loans were the 30-day LIBOR at 3.12%, the 90-day LIBOR at 3.67%, the 180-day LIBOR at 4.17%, the 360-day LIBOR at 4.78%, the PRIME at 6.25%, the 30-day SOFR at 3.03%, the 90-day SOFR at 3.55%, the SONIA at 1.69%, the 30-day EURIBOR at 0.69%, the 90-day EURIBOR at 0.99% and the 180-day EURIBOR at 0.38%. Most loans include an interest floor, which generally ranges from 0% to 1%. SOFR and SONIA based contracts may include a credit spread adjustment that is charged in addition to the base rate and the stated spread.
- (7) Principal includes accumulated PIK interest and is net of repayments, if any. "£" signifies the investment is denominated in British Pounds. "€" signifies the investment is denominated in Euros. All other investments are denominated in U.S. dollars.
- (8) Control Investments generally are defined by the Investment Company Act as investments in companies in which the Company owns more than 25% of the voting securities or maintains greater than 50% of the board representation.
- (9) As defined in the Investment Company Act, the Company is deemed to be both an "Affiliated Person" of and to "Control" these portfolio companies as the Company owns more than 25% of the portfolio company's outstanding voting securities or has the power to exercise control over management or policies of such portfolio company (including through a management agreement). See Schedule 12-14 in the accompanying notes to the Consolidated Financial Statements for transactions during the year ended September 30, 2022 in which the issuer was both an Affiliated Person and a portfolio company that the Company is deemed to control.
- (10) This investment represents a participation interest in the underlying securities shown.
- (11) Investment is not a "qualifying asset" as defined under Section 55(a) of the Investment Company Act. Under the Investment Company Act, the Company may not acquire any non-qualifying asset unless, at the time the acquisition is made, qualifying assets represent at least 70% of the Company's total assets. As of September 30, 2022, qualifying assets represented 75.7% of the Company's total assets and non-qualifying assets represented 24.3% of the Company's total assets.
- (12) Income producing through payment of dividends or distributions.
- (13) One half of the Seller Earn Out Shares will vest if, at any time through June 16, 2027, the Alvotech SA common share price is at or above a VWAP of \$15.00 per share for any ten trading days within any twenty trading day period, and the other half will vest, if at any time during such period, the common share price is at or above a VWAP of \$20.00 per share for any ten trading days within any twenty trading day period.
- (14) See Note 3 in the accompanying notes to the Consolidated Financial Statements for portfolio composition.
- (15) As of September 30, 2022, these investments were categorized as Level 3 within the fair value hierarchy established by FASB guidance under ASC 820.
- (16) This investment was valued using net asset value as a practical expedient for fair value. Consistent with ASC 820, these investments are excluded from the hierarchical levels.
- (17) Affiliate Investments generally are defined by the Investment Company Act as investments in companies in which the Company owns between 5% and 25% of the voting securities.
- (18) Non-Control/Non-Affiliate Investments are investments that are neither Control Investments nor Affiliate Investments.
- (19) Investment had undrawn commitments. Unamortized fees are classified as unearned income which reduces cost basis, which may result in a negative cost basis. A negative fair value may result from the unfunded commitment being valued below par.
- (20) This investment was renamed during the three months ended March 31, 2022. For periods prior to March 31, 2022, this investment was referenced as Realfi Strategic Capital Funding LLC.

See notes to Consolidated Financial Statements.

OAKTREE SPECIALTY LENDING CORPORATION
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
(in thousands, except share and per share amounts, percentages and as otherwise indicated)

Note 1. Organization

Oaktree Specialty Lending Corporation (together with its consolidated subsidiaries, the "Company") is a specialty finance company that looks to provide customized, one-stop credit solutions to companies with limited access to public or syndicated capital markets. The Company was formed in late 2007 and operates as a closed-end, externally managed, non-diversified management investment company that has elected to be regulated as a Business Development Company under the Investment Company Act. The Company has qualified and elected to be treated as a regulated investment company ("RIC") under the Internal Revenue Code of 1986, as amended (the "Code"), for U.S. federal income tax purposes.

The Company's investment objective is to generate current income and capital appreciation by providing companies with flexible and innovative financing solutions, including first and second lien loans, unsecured and mezzanine loans, bonds, preferred equity and certain equity co-investments. The Company may also seek to generate capital appreciation and income through secondary investments at discounts to par in either private or syndicated transactions.

The Company is externally managed by Oaktree Fund Advisors, LLC ("Oaktree"), pursuant to an investment advisory agreement between the Company and Oaktree (as amended and restated, the "Investment Advisory Agreement"). Oaktree is an affiliate of Oaktree Capital Management, L.P. ("OCM"), the Company's external investment adviser from October 17, 2017 through May 3, 2020. Oaktree Fund Administration, LLC ("Oaktree Administrator"), a subsidiary of OCM, provides certain administrative and other services necessary for the Company to operate pursuant to an administration agreement between the Company and Oaktree Administrator (the "Administration Agreement"). See Note 10. In 2019, Brookfield Corporation (f/k/a Brookfield Asset Management Inc.) ("Brookfield") acquired a majority economic interest in Oaktree Capital Group, LLC. Oaktree and its affiliates operate as an independent business within Brookfield, with their own product offerings and investment, marketing and support teams.

On March 19, 2021, the Company acquired Oaktree Strategic Income Corporation ("OCSI"), pursuant to that certain Agreement and Plan of Merger (the "OCSI Merger Agreement"), dated as of October 28, 2020, by and among OCSI, the Company, Lion Merger Sub, Inc., a wholly-owned subsidiary of the Company, and, solely for the limited purposes set forth therein, Oaktree. Pursuant to the OCSI Merger Agreement, OCSI was merged with and into the Company in a two-step transaction, with the Company as the surviving company (the "OCSI Merger").

On January 23, 2023, the Company acquired Oaktree Strategic Income II, Inc. ("OSI2") pursuant to that certain Agreement and Plan of Merger (the "OSI2 Merger Agreement"), dated as of September 14, 2022, by and among OSI2, the Company, Project Superior Merger Sub, Inc., a wholly-owned subsidiary of the Company, and, solely for the limited purposes set forth therein, Oaktree. Pursuant to the OSI2 Merger Agreement, OSI2 was merged with and into the Company in a two-step transaction with the Company as the surviving company (the "OSI2 Merger"). See Note 14.

Note 2. Significant Accounting Policies

Basis of Presentation:

The Consolidated Financial Statements of the Company have been prepared in accordance with GAAP and pursuant to the requirements for reporting on Form 10-Q and Regulation S-X. In the opinion of management, all adjustments of a normal recurring nature considered necessary for the fair presentation of the Consolidated Financial Statements have been made. All intercompany balances and transactions have been eliminated. The Company is an investment company following the accounting and reporting guidance in ASC Topic 946, *Financial Services - Investment Companies* ("ASC 946").

Certain prior period amounts have been reclassified to conform to the current period presentation. All per share amounts and common shares outstanding as of and for the three months ended December 31, 2022 and all prior periods reflect the Company's 1-for-3 reverse stock split completed on January 20, 2023 and effective as of the commencement of trading on January 23, 2023.

Use of Estimates:

The preparation of the financial statements in conformity with accounting principles generally accepted in the United States ("GAAP") requires management to make certain estimates and assumptions affecting amounts reported in the financial statements and accompanying notes. These estimates are based on the information that is currently available to the Company and on various other assumptions that the Company believes to be reasonable under the circumstances. Changes in the economic and political environments, financial markets and any other parameters used in determining these estimates could cause actual results to differ and such differences could be material. Significant estimates include the valuation of investments and revenue recognition.

OAKTREE SPECIALTY LENDING CORPORATION
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
(in thousands, except share and per share amounts, percentages and as otherwise indicated)

Consolidation:

The accompanying Consolidated Financial Statements include the accounts of Oaktree Specialty Lending Corporation and its consolidated subsidiaries. Each consolidated subsidiary is wholly-owned and, as such, consolidated into the Consolidated Financial Statements. Certain subsidiaries that hold investments are treated as pass through entities for U.S. federal income tax purposes. The assets of certain of the consolidated subsidiaries are not directly available to satisfy the claims of the creditors of Oaktree Specialty Lending Corporation or any of its other subsidiaries.

As an investment company, portfolio investments held by the Company are not consolidated into the Consolidated Financial Statements but rather are included on the Statements of Assets and Liabilities as investments at fair value.

Fair Value Measurements:

The Company values its investments in accordance with ASC 820, which defines fair value as the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. A liability's fair value is defined as the amount that would be paid to transfer the liability to a new obligor, not the amount that would be paid to settle the liability with the creditor. ASC 820 prioritizes the use of observable market prices over entity-specific inputs. Where observable prices or inputs are not available or reliable, valuation techniques are applied. These valuation techniques involve some level of management estimation and judgment, the degree of which is dependent on the price transparency for the investments or market and the investments' complexity.

Hierarchical levels, defined by ASC 820 and directly related to the amount of subjectivity associated with the inputs to fair valuation of these assets and liabilities, are as follows:

- Level 1 — Unadjusted, quoted prices in active markets for identical assets or liabilities as of the measurement date.
- Level 2 — Observable inputs other than Level 1 prices, such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data at the measurement date for substantially the full term of the assets or liabilities.
- Level 3 — Unobservable inputs that reflect Oaktree's best estimate of what market participants would use in pricing the asset or liability at the measurement date. Consideration is given to the risk inherent in the valuation technique and the risk inherent in the inputs to the model.

If inputs used to measure fair value fall into different levels of the fair value hierarchy, an investment's level is based on the lowest level of input that is significant to the fair value measurement. Oaktree's assessment of the significance of a particular input to the fair value measurement in its entirety requires judgment and considers factors specific to the investment. This includes investment securities that are valued using "bid" and "ask" prices obtained from independent third party pricing services or directly from brokers. These investments may be classified as Level 3 because the quoted prices may be indicative in nature for securities that are in an inactive market, may be for similar securities or may require adjustments for investment-specific factors or restrictions.

Financial instruments with readily available quoted prices generally will have a higher degree of market price observability and a lesser degree of judgment inherent in measuring fair value. As such, Oaktree obtains and analyzes readily available market quotations provided by pricing vendors and brokers for all of the Company's investments for which quotations are available. In determining the fair value of a particular investment, pricing vendors and brokers use observable market information, including both binding and non-binding indicative quotations.

Oaktree seeks to obtain at least two quotations for the subject or similar securities, typically from pricing vendors. If Oaktree is unable to obtain two quotes from pricing vendors, or if the prices obtained from pricing vendors are not within Oaktree's set threshold, Oaktree seeks to obtain a quote directly from a broker making a market for the asset. Oaktree evaluates the quotations provided by pricing vendors and brokers based on available market information, including trading activity of the subject or similar securities, or by performing a comparable security analysis to ensure that fair values are reasonably estimated. Oaktree also performs back-testing of valuation information obtained from pricing vendors and brokers against actual prices received in transactions. In addition to ongoing monitoring and back-testing, Oaktree performs due diligence procedures over pricing vendors to understand their methodology and controls to support their use in the valuation process. Generally, Oaktree does not adjust any of the prices received from these sources.

If the quotations obtained from pricing vendors or brokers are determined to not be reliable or are not readily available, Oaktree values such investments using any of three different valuation techniques. The first valuation technique is the transaction precedent technique, which utilizes recent or expected future transactions of the investment to determine fair value, to the extent applicable. The second valuation technique is an analysis of the enterprise value ("EV") of the portfolio company. EV means the entire value of the portfolio company to a market participant, including the sum of the values of debt and equity securities used to capitalize the enterprise at a point in time. The EV analysis is typically performed to determine (i) the value of

OAKTREE SPECIALTY LENDING CORPORATION
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
(in thousands, except share and per share amounts, percentages and as otherwise indicated)

equity investments, (ii) whether there is credit impairment for debt investments and (iii) the value for debt investments that the Company is deemed to control under the Investment Company Act. To estimate the EV of a portfolio company, Oaktree analyzes various factors, including the portfolio company's historical and projected financial results, macroeconomic impacts on the company and competitive dynamics in the company's industry. Oaktree also utilizes some or all of the following information based on the individual circumstances of the portfolio company: (i) valuations of comparable public companies, (ii) recent sales of private and public comparable companies in similar industries or having similar business or earnings characteristics, (iii) purchase prices as a multiple of their earnings or cash flow, (iv) the portfolio company's ability to meet its forecasts and its business prospects, (v) a discounted cash flow analysis, (vi) estimated liquidation or collateral value of the portfolio company's assets and (vii) offers from third parties to buy the portfolio company. Oaktree may probability weight potential sale outcomes with respect to a portfolio company when uncertainty exists as of the valuation date. The third valuation technique is a market yield technique, which is typically performed for non-credit impaired debt investments. In the market yield technique, a current price is imputed for the investment based upon an assessment of the expected market yield for a similarly structured investment with a similar level of risk, and Oaktree considers the current contractual interest rate, the capital structure and other terms of the investment relative to risk of the company and the specific investment. A key determinant of risk, among other things, is the leverage through the investment relative to the EV of the portfolio company. As debt investments held by the Company are substantially illiquid with no active transaction market, Oaktree depends on primary market data, including newly funded transactions and industry specific market movements, as well as secondary market data with respect to high yield debt instruments and syndicated loans, as inputs in determining the appropriate market yield, as applicable.

In accordance with ASC 820-10, certain investments that qualify as investment companies in accordance with ASC 946 may be valued using net asset value as a practical expedient for fair value. Consistent with FASB guidance under ASC 820, these investments are excluded from the hierarchical levels. These investments are generally not redeemable.

Oaktree estimates the fair value of certain privately held warrants using a Black Scholes pricing model, which includes an analysis of various factors and subjective assumptions, including the current stock price (by using an EV analysis as described above), the expected period until exercise, expected volatility of the underlying stock price, expected dividends and the risk free rate. Changes in the subjective input assumptions can materially affect the fair value estimates.

Rule 2a-5 under the Investment Company Act permits boards of directors of registered investment companies and Business Development Companies to either (i) choose to determine fair value in good faith or (ii) designate a valuation designee tasked with determining fair value in good faith, subject to the board's oversight. The Company's Board of Directors has designated Oaktree to serve as its valuation designee effective September 8, 2022.

Oaktree undertakes a multi-step valuation process each quarter in connection with determining the fair value of the Company's investments:

- The quarterly valuation process begins with each portfolio company or investment being initially valued by Oaktree's valuation team;
- Preliminary valuations are then reviewed and discussed with management of Oaktree;
- Separately, independent valuation firms prepare valuations of the Company's investments, on a selected basis, for which market quotations are not readily available or are readily available but deemed not reflective of the fair value of the investment, and submit the reports to the Company and provide such reports to Oaktree;
- Oaktree compares and contrasts its preliminary valuations to the valuations of the independent valuation firms and prepares a valuation report for the Audit Committee;
- The Audit Committee reviews the valuation report with Oaktree, and Oaktree responds and supplements the valuation report to reflect any discussions between Oaktree and the Audit Committee; and
- Oaktree, as valuation designee, determines the fair value of each investment in the Company's portfolio.

The fair value of the Company's investments as of December 31, 2022 and September 30, 2022 was determined by Oaktree, as the Company's valuation designee. The Company has and will continue to engage independent valuation firms to provide assistance regarding the determination of the fair value of a portion of its portfolio securities for which market quotations are not readily available or are readily available but deemed not reflective of the fair value of the investment each quarter.

Due to the inherent uncertainty of determining the fair value of investments that do not have a readily available market value, the fair value of the Company's investments may fluctuate from period to period. Because of the inherent uncertainty of valuation, these estimated values may differ significantly from the values that would have been reported had a ready market for the investments existed, and it is reasonably possible that the difference could be material.

OAKTREE SPECIALTY LENDING CORPORATION
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
(in thousands, except share and per share amounts, percentages and as otherwise indicated)

With the exception of the line items entitled "deferred financing costs," "deferred offering costs," "other assets," "deferred tax asset, net," "credit facilities payable" and "unsecured notes payable," which are reported at amortized cost, all assets and liabilities approximate fair value on the Consolidated Statements of Assets and Liabilities. The carrying value of the line items titled "interest, dividends and fees receivable," "due from portfolio companies," "receivables from unsettled transactions," "due from broker," "accounts payable, accrued expenses and other liabilities," "base management fee and incentive fee payable," "due to affiliate," "interest payable" and "payables from unsettled transactions" approximate fair value due to their short maturities.

Foreign Currency Translation:

The accounting records of the Company are maintained in U.S. dollars. All assets and liabilities denominated in foreign currencies are translated into U.S. dollars based on the prevailing foreign exchange rate on the reporting date. The Company does not isolate that portion of the results of operations resulting from changes in foreign exchange rates on investments from the fluctuations arising from changes in market prices of securities held. The Company's investments in foreign securities may involve certain risks, including foreign exchange restrictions, expropriation, taxation or other political, social or economic risks, all of which could affect the market and/or credit risk of the investment. In addition, changes in the relationship of foreign currencies to the U.S. dollar can significantly affect the value of these investments and therefore the earnings of the Company.

Derivative Instruments:

Foreign Currency Forward Contracts

The Company uses foreign currency forward contracts to reduce the Company's exposure to fluctuations in the value of foreign currencies. In a foreign currency forward contract, the Company agrees to receive or deliver a fixed quantity of one currency for another at a pre-determined price at a future date. Foreign currency forward contracts are marked-to-market at the applicable forward rate. Unrealized appreciation (depreciation) on foreign currency forward contracts is recorded within derivative assets or derivative liabilities on the Consolidated Statements of Assets and Liabilities by counterparty on a net basis, not taking into account collateral posted which is recorded separately, if applicable. Purchases and settlements of foreign currency forward contracts having the same settlement date and counterparty are generally settled net and any realized gains or losses are recognized on the settlement date. The Company does not utilize hedge accounting with respect to foreign currency forward contracts and as such, the Company recognizes its foreign currency forward contracts at fair value with changes included in the net unrealized appreciation (depreciation) on the Consolidated Statements of Operations.

Interest Rate Swaps

The Company uses an interest rate swap to hedge some of the Company's fixed rate debt. The Company designated the interest rate swap as the hedging instrument in an effective hedge accounting relationship, and therefore the periodic payments are recognized as components of interest expense in the Consolidated Statements of Operations. Depending on the nature of the balance at period end, the fair value of the interest rate swap is either included as a derivative asset or derivative liability on the Company's Consolidated Statements of Assets and Liabilities. The change in fair value of the interest rate swap is offset by a change in the carrying value of the fixed rate debt. Any amounts paid to the counterparty to cover collateral obligations under the terms of the interest rate swap agreement are included in due from broker on the Company's Consolidated Statements of Assets and Liabilities.

Investment Income:

Interest Income

Interest income, adjusted for accretion of original issue discount ("OID"), is recorded on an accrual basis to the extent that such amounts are expected to be collected. The Company stops accruing interest on investments when it is determined that interest is no longer collectible. Investments that are expected to pay regularly scheduled interest in cash are generally placed on non-accrual status when there is reasonable doubt that principal or interest cash payments will be collected. Cash interest payments received on investments may be recognized as income or a return of capital depending upon management's judgment. A non-accrual investment is restored to accrual status if past due principal and interest are paid in cash and the portfolio

OAKTREE SPECIALTY LENDING CORPORATION
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
(in thousands, except share and per share amounts, percentages and as otherwise indicated)

company, in management's judgment, is likely to continue timely payment of its remaining obligations. As of each of December 31, 2022 and September 30, 2022, there were no investments on non-accrual status.

In connection with its investment in a portfolio company, the Company sometimes receives nominal cost equity that is valued as part of the negotiation process with the portfolio company. When the Company receives nominal cost equity, the Company allocates its cost basis in the investment between debt securities and the nominal cost equity at the time of origination. Any resulting discount from recording the loan, or otherwise purchasing a security at a discount, is accreted into interest income over the life of the loan.

PIK Interest Income

The Company's investments in debt securities may contain PIK interest provisions. PIK interest, which generally represents contractually deferred interest added to the loan balance that is generally due at the end of the loan term, is generally recorded on the accrual basis to the extent such amounts are expected to be collected. The Company generally ceases accruing PIK interest if there is insufficient value to support the accrual or if the Company does not expect the portfolio company to be able to pay all principal and interest due. The Company's decision to cease accruing PIK interest on a loan or debt security involves subjective judgments and determinations based on available information about a particular portfolio company, including whether the portfolio company is current with respect to its payment of principal and interest on its loans and debt securities; financial statements and financial projections for the portfolio company; the Company's assessment of the portfolio company's business development success; information obtained by the Company in connection with periodic formal update interviews with the portfolio company's management and, if appropriate, the private equity sponsor; and information about the general economic and market conditions in which the portfolio company operates. The Company's determination to cease accruing PIK interest is generally made well before the Company's full write-down of a loan or debt security. In addition, if it is subsequently determined that the Company will not be able to collect any previously accrued PIK interest, the fair value of the loans or debt securities would be reduced by the amount of such previously accrued, but uncollectible, PIK interest. The accrual of PIK interest on the Company's debt investments increases the recorded cost bases of these investments in the Consolidated Financial Statements including for purposes of computing the capital gains incentive fee payable by the Company to Oaktree. To maintain its status as a RIC, certain income from PIK interest may be required to be distributed to the Company's stockholders, even though the Company has not yet collected the cash and may never do so.

Fee Income

Oaktree or its affiliates may provide financial advisory services to portfolio companies and, in return, the Company may receive fees for capital structuring services. These fees are generally non-recurring and are recognized by the Company upon the investment closing date. The Company may also receive additional fees in the ordinary course of business, including servicing, amendment and prepayment fees, which are classified as fee income and recognized as they are earned or the services are rendered.

The Company has also structured exit fees across certain of its portfolio investments to be received upon the future exit of those investments. These fees are typically paid to the Company upon the earliest to occur of (i) a sale of the borrower or substantially all of the assets of the borrower, (ii) the maturity date of the loan or (iii) the date when full prepayment of the loan occurs. The receipt of such fees is contingent upon the occurrence of one of the events listed above for each of the investments. These fees are included in net investment income over the life of the loan.

Dividend Income

The Company generally recognizes dividend income on the ex-dividend date for public securities and the record date for private equity investments. Distributions received from private equity investments are evaluated to determine if the distribution should be recorded as dividend income or a return of capital. Generally, the Company will not record distributions from private equity investments as dividend income unless there are sufficient earnings at the portfolio company prior to the distribution. Distributions that are classified as a return of capital are recorded as a reduction in the cost basis of the investment.

Cash and Cash Equivalents and Restricted Cash:

Cash and cash equivalents consist of demand deposits and highly liquid investments with maturities of three months or less when acquired. The Company places its cash and cash equivalents and restricted cash with financial institutions and, at times, cash held in bank accounts may exceed the Federal Deposit Insurance Corporation ("FDIC") insurance limit. Cash and cash equivalents are included on the Company's Consolidated Schedule of Investments and cash equivalents are classified as Level 1 assets.

OAKTREE SPECIALTY LENDING CORPORATION
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
(in thousands, except share and per share amounts, percentages and as otherwise indicated)

As of December 31, 2022 and September 30, 2022, included in restricted cash was \$1.9 million and \$2.8 million, respectively, that was held at Wells Fargo Bank, N.A. in connection with the Citibank Facility (as defined in Note 6. Borrowings). Pursuant to the terms of the Citibank Facility, the Company was restricted in terms of access to \$1.9 million and \$2.8 million as of December 31, 2022 and September 30, 2022, respectively, until the occurrence of the periodic distribution dates and, in connection therewith, the Company's submission of its required periodic reporting schedules and verifications of the Company's compliance with the terms of the Citibank Facility.

Due from Portfolio Companies:

Due from portfolio companies consists of amounts payable to the Company from its portfolio companies, including proceeds from the sale of portfolio companies not yet received or being held in escrow and excluding those amounts attributable to interest, dividends or fees receivable. These amounts are recognized as they become payable to the Company (*e.g.*, principal payments on the scheduled amortization payment date).

Receivables/Payables from Unsettled Transactions:

Receivables/payables from unsettled transactions consist of amounts receivable to or payable by the Company for transactions that have not settled at the reporting date.

Deferred Financing Costs:

Deferred financing costs consist of fees and expenses paid in connection with the closing or amending of credit facilities and debt offerings. Deferred financing costs in connection with credit facilities are capitalized as an asset when incurred. Deferred financing costs in connection with all other debt arrangements are a direct deduction from the related debt liability when incurred. Deferred financing costs are amortized using the effective interest method over the term of the respective debt arrangement. This amortization expense is included in interest expense in the Company's Consolidated Statements of Operations. Upon early termination or modification of a credit facility, all or a portion of unamortized fees related to such facility may be accelerated into interest expense. For extinguishments of the Company's unsecured notes payable, any unamortized deferred financing costs are deducted from the carrying amount of the debt in determining the gain or loss from the extinguishment.

Deferred Offering Costs:

Legal fees and other costs incurred in connection with the Company's shelf registration statement are capitalized as deferred offering costs in the Consolidated Statements of Assets and Liabilities. To the extent any such costs relate to equity offerings, these costs are charged as a reduction of capital upon utilization. To the extent any such costs relate to debt offerings, these costs are treated as deferred financing costs and are amortized over the term of the respective debt arrangement. Any deferred offering costs that remain at the expiration of the shelf registration statement or when it becomes probable that an offering will not be completed are expensed.

Income Taxes:

The Company has elected to be subject to tax as a RIC under Subchapter M of the Code and operates in a manner so as to qualify for the tax treatment applicable to RICs. In order to be subject to tax as a RIC, among other things, the Company is required to meet certain source of income and asset diversification requirements and timely distribute dividends to its stockholders of an amount generally at least equal to 90% of investment company taxable income, as defined by the Code and determined without regard to any deduction for dividends paid, for each taxable year. As a RIC, the Company is not subject to U.S. federal income tax on the portion of its taxable income and gains distributed currently to stockholders as a dividend. Depending on the level of taxable income earned during a taxable year, the Company may choose to retain taxable income in excess of current year dividend distributions and would distribute such taxable income in the next taxable year. The Company would then incur a 4% excise tax on such income, as required. To the extent that the Company determines that its estimated current year annual taxable income, determined on a calendar year basis, could exceed estimated current calendar year dividend distributions, the Company accrues excise tax, if any, on estimated excess taxable income as taxable income is earned. The Company anticipates timely distribution of its taxable income within the tax rules under Subchapter M of the Code. The Company did not incur a U.S. federal excise tax for calendar year 2021. For the calendar year 2022, the Company incurred \$0.1 million of excise tax. The Company does not expect to incur a U.S. federal excise tax for calendar year 2023.

The Company holds certain portfolio investments through taxable subsidiaries. The purpose of the Company's taxable subsidiaries is to permit the Company to hold equity investments in portfolio companies which are "pass through" entities for U.S. federal income tax purposes in order to comply with the RIC tax requirements. The taxable subsidiaries are consolidated for financial reporting purposes, and portfolio investments held by them are included in the Company's Consolidated Financial

OAKTREE SPECIALTY LENDING CORPORATION
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
(in thousands, except share and per share amounts, percentages and as otherwise indicated)

Statements as portfolio investments and recorded at fair value. The taxable subsidiaries are not consolidated with the Company for U.S. federal income tax purposes and may generate income tax expense, or benefit, and the related tax assets and liabilities, as a result of their ownership of certain portfolio investments. This income tax expense, if any, would be reflected in the Company's Consolidated Statements of Operations. The Company uses the liability method to account for its taxable subsidiaries' income taxes. Using this method, the Company recognizes deferred tax assets and liabilities for the estimated future tax effects attributable to temporary differences between financial reporting and tax bases of assets and liabilities. In addition, the Company recognizes deferred tax benefits associated with net operating loss carry forwards that it may use to offset future tax obligations. The Company measures deferred tax assets and liabilities using the enacted tax rates expected to apply to taxable income in the years in which it expects to recover or settle those temporary differences.

FASB ASC Topic 740, *Accounting for Uncertainty in Income Taxes* ("ASC 740"), provides guidance for how uncertain tax positions should be recognized, measured, presented and disclosed in the Company's Consolidated Financial Statements. ASC 740 requires the evaluation of tax positions taken or expected to be taken in the course of preparing the Company's tax returns to determine whether the tax positions are "more-likely-than-not" of being sustained by the applicable tax authority. Tax positions not deemed to meet the more-likely-than-not threshold are recorded as a tax benefit or expense in the current year. Management's determinations regarding ASC 740 may be subject to review and adjustment at a later date based upon factors including an ongoing analysis of tax laws, regulations and interpretations thereof. The Company recognizes the tax benefits of uncertain tax positions only where the position is "more-likely-than-not" to be sustained assuming examination by tax authorities. Management has analyzed the Company's tax positions and has concluded that no liability for unrecognized tax benefits should be recorded related to uncertain tax positions taken on returns filed for open tax years 2019, 2020 and 2021. The Company identifies its major tax jurisdictions as U.S. Federal and California, and the Company is not aware of any tax positions for which it is reasonably possible that the total amounts of unrecognized tax benefits will change materially in the next 12 months.

Recently Adopted Accounting Pronouncements

In March 2020, the FASB issued ASU 2020-04, Reference Rate Reform (Topic 848) Facilitation of the Effects of Reference Rate Reform on Financial Reporting, which provides optional expedients and exceptions for applying GAAP to contracts, hedging relationships, and other transactions to ease the potential burden in accounting for (or recognizing the effects of) reference rate reform on financial reporting if certain criteria are met. The guidance is effective from March 12, 2020 through December 31, 2022. As of December 31, 2022, the adoption of this guidance did not have an impact on the Company's Consolidated Financial Statements.

Note 3. Portfolio Investments

As of December 31, 2022, 219.9% of net assets at fair value, or \$2.6 billion, was invested in 156 portfolio companies, including (i) \$136.8 million in subordinated notes and limited liability company ("LLC") equity interests of Senior Loan Fund JV I, LLC ("SLF JV I"), a joint venture through which the Company and Trinity Universal Insurance Company, a subsidiary of Kemper Corporation ("Kemper"), co-invest in senior secured loans of middle-market companies and other corporate debt securities and (ii) \$49.5 million in subordinated notes and LLC equity interests of OCSI Glick JV LLC ("Glick JV" and, together with SLF JV I, the "JVs"), a joint venture through which the Company and GF Equity Funding 2014 LLC ("GF Equity Funding") co-invest primarily in senior secured loans of middle-market companies. As of December 31, 2022, 1.6% of net assets at fair value, or \$19.2 million, was invested in cash and cash equivalents (including \$1.9 million of restricted cash). In comparison, as of September 30, 2022, 200.2% of net assets at fair value, or \$2.5 billion, was invested in 149 portfolio investments, including (i) \$117.0 million in subordinated notes and LLC equity interests of SLF JV I and (ii) \$50.3 million in subordinated notes and LLC equity interests of Glick JV. As of September 30, 2022, 2.1% of net assets at fair value, or \$26.4 million, was invested in cash and cash equivalents (including \$2.8 million of restricted cash). As of December 31, 2022, 86.3% of the Company's portfolio at fair value consisted of senior secured debt investments and 8.5% consisted of subordinated debt investments, including the debt investments in the JVs. As of September 30, 2022, 86.9% of the Company's portfolio at fair value consisted of senior secured debt investments and 8.1% consisted of subordinated debt investments, including the debt investments in the JVs.

The Company also held equity investments in certain of its portfolio companies consisting of common stock, preferred stock, warrants, limited partnership interests or LLC equity interests. These instruments generally do not produce a current return but are held for potential investment appreciation and capital gain.

During the three months ended December 31, 2022 and 2021, the Company recorded net realized gains (losses) of \$(3.2) million and \$9.3 million, respectively. During the three months ended December 31, 2022 and 2021, the Company recorded net unrealized depreciation of \$23.0 million and \$4.6 million, respectively.

OAKTREE SPECIALTY LENDING CORPORATION
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
(in thousands, except share and per share amounts, percentages and as otherwise indicated)

The composition of the Company's investments as of December 31, 2022 and September 30, 2022 at cost and fair value was as follows:

	December 31, 2022		September 30, 2022	
	Cost	Fair Value	Cost	Fair Value
Investments in debt securities	\$ 2,428,251	\$ 2,343,380	\$ 2,294,392	\$ 2,223,329
Investments in equity securities	132,355	113,190	127,596	103,534
Debt investments in the JVs	162,617	162,192	146,444	146,533
Equity investments in the JVs	54,791	24,108	49,322	20,715
Total	\$ 2,778,014	\$ 2,642,870	\$ 2,617,754	\$ 2,494,111

The following table presents the composition of the Company's debt investments as of December 31, 2022 and September 30, 2022 at fixed rates and floating rates:

	December 31, 2022		September 30, 2022	
	Fair Value	% of Debt Portfolio	Fair Value	% of Debt Portfolio
Floating rate debt securities, including the debt investments in the JVs	\$ 2,188,193	87.33 %	\$ 2,049,644	86.49 %
Fixed rate debt securities	317,379	12.67	320,218	13.51
Total	\$ 2,505,572	100.00 %	\$ 2,369,862	100.00 %

The following table presents the financial instruments carried at fair value as of December 31, 2022 on the Company's Consolidated Statement of Assets and Liabilities for each of the three levels of hierarchy established by ASC 820:

	Level 1	Level 2	Level 3	Measured at Net Asset Value (a)	Total
Investments in debt securities (senior secured)	\$ —	\$ 233,393	\$ 2,047,842	\$ —	\$ 2,281,235
Investments in debt securities (subordinated, including the debt investments in the JVs)	—	44,706	179,631	—	224,337
Investments in equity securities (preferred)	—	—	80,625	—	80,625
Investments in equity securities (common and warrants, including LLC equity interests of the JVs)	5,923	—	26,642	24,108	56,673
Total investments at fair value	5,923	278,099	2,334,740	24,108	2,642,870
Cash equivalents	3,421	—	—	—	3,421
Total assets at fair value	\$ 9,344	\$ 278,099	\$ 2,334,740	\$ 24,108	\$ 2,646,291
Derivative liability	\$ —	\$ 44,139	\$ —	\$ —	\$ 44,139
Total liabilities at fair value	\$ —	\$ 44,139	\$ —	\$ —	\$ 44,139

- (a) In accordance with ASC 820-10, certain investments that are measured using the net asset value per share (or its equivalent) as a practical expedient for fair value have not been classified in the fair value hierarchy. These investments are generally not redeemable. The fair value amounts presented in this table are intended to permit reconciliation of the fair value hierarchy to the amounts presented in the Consolidated Statements of Assets and Liabilities.

OAKTREE SPECIALTY LENDING CORPORATION
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
(in thousands, except share and per share amounts, percentages and as otherwise indicated)

The following table presents the financial instruments carried at fair value as of September 30, 2022 on the Company's Consolidated Statement of Assets and Liabilities for each of the three levels of hierarchy established by ASC 820:

	Level 1	Level 2	Level 3	Measured at Net Asset Value (a)	Total
Investments in debt securities (senior secured)	\$ —	\$ 255,803	\$ 1,910,606	\$ —	\$ 2,166,409
Investments in debt securities (subordinated, including the debt investments in the JVs)	—	44,065	159,388	—	203,453
Investments in equity securities (preferred)	—	—	79,523	—	79,523
Investments in equity securities (common and warrants, including LLC equity interests of the JVs)	4,053	—	19,958	20,715	44,726
Total investments at fair value	4,053	299,868	2,169,475	20,715	2,494,111
Cash equivalents	5,261	—	—	—	5,261
Derivative assets	—	6,789	—	—	6,789
Total assets at fair value	\$ 9,314	\$ 306,657	\$ 2,169,475	\$ 20,715	\$ 2,506,161
Derivative liability	\$ —	\$ 41,969	\$ —	\$ —	\$ 41,969
Total liabilities at fair value	\$ —	\$ 41,969	\$ —	\$ —	\$ 41,969

(a) In accordance with ASC 820-10, certain investments that are measured using the net asset value per share (or its equivalent) as a practical expedient for fair value have not been classified in the fair value hierarchy. These investments are generally not redeemable. The fair value amounts presented in this table are intended to permit reconciliation of the fair value hierarchy to the amounts presented in the Consolidated Statements of Assets and Liabilities.

When a determination is made to classify a financial instrument within Level 3 of the valuation hierarchy, the determination is based upon the fact that the unobservable factors are significant to the overall fair value measurement. However, Level 3 financial instruments typically have both unobservable or Level 3 components and observable components (i.e. components that are actively quoted and can be validated by external sources). Accordingly, the appreciation (depreciation) in the tables below includes changes in fair value due in part to observable factors that are part of the valuation methodology. Transfers between levels are recognized at the beginning of the reporting period.

The following table provides a roll-forward in the changes in fair value from September 30, 2022 to December 31, 2022 for all investments for which the Company determined fair value using unobservable (Level 3) factors:

	Investments				
	Senior Secured Debt	Subordinated Debt (including debt investments in the JVs)	Preferred Equity	Common Equity and Warrants	Total
Fair value as of September 30, 2022	\$ 1,910,606	\$ 159,388	\$ 79,523	\$ 19,958	\$ 2,169,475
Purchases	177,599	21,104	2,579	2,181	203,463
Sales and repayments	(55,885)	(699)	—	(48)	(56,632)
Transfers in (a)	19,075	—	—	—	19,075
Capitalized PIK interest income	5,763	6	—	—	5,769
Accretion of OID	4,114	398	—	—	4,512
Net unrealized appreciation (depreciation)	(12,271)	(566)	(1,477)	4,505	(9,809)
Net realized gains (losses)	(1,159)	—	—	46	(1,113)
Fair value as of December 31, 2022	\$ 2,047,842	\$ 179,631	\$ 80,625	\$ 26,642	\$ 2,334,740
Net unrealized appreciation (depreciation) relating to Level 3 investments still held as of December 31, 2022 and reported within net unrealized appreciation (depreciation) in the Consolidated Statement of Operations for the three months ended December 31, 2022	\$ (12,398)	\$ (566)	\$ (1,477)	\$ 4,505	\$ (9,936)

(a) There was a transfer into Level 3 from Level 2 for an investment during the three months ended December 31, 2022 as a result of a change in the number of market quotes available and/or a change in market liquidity.

OAKTREE SPECIALTY LENDING CORPORATION
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
(in thousands, except share and per share amounts, percentages and as otherwise indicated)

The following table provides a roll-forward in the changes in fair value from September 30, 2021 to December 31, 2021 for all investments for which the Company determined fair value using unobservable (Level 3) factors:

	Investments				
	Senior Secured Debt	Subordinated Debt (including debt investments in the JVs)	Preferred Equity	Common Equity and Warrants	Total
Fair value as of September 30, 2021	\$ 1,878,536	\$ 176,317	\$ 63,565	\$ 43,163	\$ 2,161,581
Purchases	191,087	3,589	979	1,441	197,096
Sales and repayments	(131,946)	(20,185)	—	(6,503)	(158,634)
Transfers in (a)	3,178	—	—	—	3,178
Transfers out (a)	(17,070)	—	—	—	(17,070)
Capitalized PIK interest income	6,172	313	—	—	6,485
Accretion of OID	5,378	819	—	—	6,197
Net unrealized appreciation (depreciation)	(9,877)	516	1,006	6,636	(1,719)
Net realized gains (losses)	8,638	—	—	(2,795)	5,843
Fair value as of December 31, 2021	\$ 1,934,096	\$ 161,369	\$ 65,550	\$ 41,942	\$ 2,202,957
Net unrealized appreciation (depreciation) relating to Level 3 investments still held as of December 31, 2021 and reported within net unrealized appreciation (depreciation) in the Consolidated Statement of Operations for the three months ended December 31, 2021	\$ (717)	\$ 368	\$ 1,006	\$ 1,139	\$ 1,796

(a) There were transfers into/out of Level 3 from/to Level 2 for certain investments during the three months ended December 31, 2021 as a result of a change in the number of market quotes available and/or a change in market liquidity.

Significant Unobservable Inputs for Level 3 Investments

The following table provides quantitative information related to the significant unobservable inputs for Level 3 investments, which are carried at fair value, as of December 31, 2022:

Asset	Fair Value	Valuation Technique	Unobservable Input	Range	Weighted Average (a)
Senior Secured Debt	\$ 1,692,264	Market Yield	Market Yield	(b) 9.0% - 33.0%	14.0%
	14,297	Enterprise Value	EBITDA Multiple	(c) 5.0x - 7.0x	6.0x
	38,581	Transaction Precedent	Transaction Price	(d) N/A - N/A	N/A
	302,700	Broker Quotations	Broker Quoted Price	(e) N/A - N/A	N/A
Subordinated Debt	13,706	Market Yield	Market Yield	(b) 10.0% - 20.0%	11.4%
	3,733	Broker Quotations	Broker Quoted Price	(c) N/A - N/A	N/A
Debt Investments in the JVs	162,192	Enterprise Value	N/A	(f) N/A - N/A	N/A
Preferred & Common Equity	30,226	Enterprise Value	Revenue Multiple	(c) 0.1x - 4.3x	0.5x
	73,822	Enterprise Value	EBITDA Multiple	(c) 3.0x - 20.0x	14.6x
	1,600	Enterprise Value	Asset Multiple	(c) 0.9x - 1.1x	1.0x
	1,619	Transaction Precedent	Transaction Price	(d) N/A - N/A	N/A
Total	\$ 2,334,740				

- (a) Weighted averages are calculated based on fair value of investments.
(b) Used when market participants would take into account market yield when pricing the investment.
(c) Used when market participants would use such multiples when pricing the investment.
(d) Used when there is an observable transaction or pending event for the investment.
(e) Oaktree generally uses prices provided by an independent pricing service which are non-binding indicative prices on or near the valuation date as the primary basis for the fair value determinations for quoted senior secured debt investments. Since these prices are non-binding, they may not be indicative of fair value. Oaktree evaluates the quotations provided by pricing vendors and brokers based on available market information, including trading activity of the subject or similar securities, or by performing a comparable security analysis to ensure that fair values are reasonably estimated.
(f) Oaktree determined the value of its subordinated notes of each JV based on the total assets less the total liabilities senior to the subordinated notes held at such JV in an amount not exceeding par under the EV technique.

OAKTREE SPECIALTY LENDING CORPORATION
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
(in thousands, except share and per share amounts, percentages and as otherwise indicated)

The following table provides quantitative information related to the significant unobservable inputs for Level 3 investments, which are carried at fair value, as of September 30, 2022:

Asset	Fair Value	Valuation Technique	Unobservable Input	Range	Weighted Average (a)
Senior Secured Debt	\$ 1,599,148	Market Yield	Market Yield	(b) 9.0% - 30.0%	13.7%
	14,333	Enterprise Value	EBITDA Multiple	(c) 5.0x - 7.0x	6.0x
	297,125	Broker Quotations	Broker Quoted Price	(e) N/A - N/A	N/A
Subordinated Debt	12,855	Market Yield	Market Yield	(b) 10.0% - 19.0%	13.8%
Debt Investments in the JVs	146,533	Enterprise Value	N/A	(f) N/A - N/A	N/A
Preferred & Common Equity	61,693	Enterprise Value	Revenue Multiple	(c) 0.4x - 10.1x	4.3x
	36,913	Enterprise Value	EBITDA Multiple	(c) 3.0x - 20.0x	11.4x
	3	Enterprise Value	Asset Multiple	(c) 0.9x - 1.1x	1.0x
	872	Transaction Precedent	Transaction Price	(d) N/A - N/A	N/A
Total	\$ 2,169,475				

- (a) Weighted averages are calculated based on fair value of investments.
(b) Used when market participants would take into account market yield when pricing the investment.
(c) Used when market participants would use such multiples when pricing the investment.
(d) Used when there is an observable transaction or pending event for the investment.
(e) Oaktree generally uses prices provided by an independent pricing service which are non-binding indicative prices on or near the valuation date as the primary basis for the fair value determinations for quoted senior secured debt investments. Since these prices are non-binding, they may not be indicative of fair value. Oaktree evaluates the quotations provided by pricing vendors and brokers based on available market information, including trading activity of the subject or similar securities, or by performing a comparable security analysis to ensure that fair values are reasonably estimated.
(f) Oaktree determined the value of its subordinated notes of each JV based on the total assets less the total liabilities senior to the subordinated notes held at such JV in an amount not exceeding par under the EV technique.

Under the market yield technique, the significant unobservable input used in the fair value measurement of the Company's investments in debt securities is the market yield. Increases or decreases in the market yield may result in a lower or higher fair value measurement, respectively.

Under the EV technique, the significant unobservable input used in the fair value measurement of the Company's investments in debt or equity securities is the earnings before interest, taxes, depreciation and amortization ("EBITDA"), revenue or asset multiple, as applicable. Increases or decreases in the valuation multiples in isolation may result in a higher or lower fair value measurement, respectively.

Financial Instruments Disclosed, But Not Carried, At Fair Value

The following table presents the carrying value and fair value of the Company's financial liabilities disclosed, but not carried, at fair value as of December 31, 2022 and the level of each financial liability within the fair value hierarchy:

	Carrying Value	Fair Value	Level 1	Level 2	Level 3
Syndicated Facility payable	\$ 695,000	\$ 695,000	\$ —	\$ —	\$ 695,000
Citibank Facility payable	165,000	165,000	—	—	165,000
2025 Notes payable (carrying value is net of unamortized financing costs and unaccreted discount)	297,303	286,734	—	286,734	—
2027 Notes payable (carrying value is net of unamortized financing costs, unaccreted discount and interest rate swap fair value adjustment)	306,321	296,835	—	296,835	—
Total	\$ 1,463,624	\$ 1,443,569	\$ —	\$ 583,569	\$ 860,000

OAKTREE SPECIALTY LENDING CORPORATION
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
(in thousands, except share and per share amounts, percentages and as otherwise indicated)

The following table presents the carrying value and fair value of the Company's financial liabilities disclosed, but not carried, at fair value as of September 30, 2022 and the level of each financial liability within the fair value hierarchy:

	Carrying Value	Fair Value	Level 1	Level 2	Level 3
Syndicated Facility payable	\$ 540,000	\$ 540,000	\$ —	\$ —	\$ 540,000
Citibank Facility payable	160,000	160,000	—	—	160,000
2025 Notes payable (carrying value is net of unamortized financing costs and unaccreted discount)	296,991	283,077	—	283,077	—
2027 Notes payable (carrying value is net of unamortized financing costs, unaccreted discount and interest rate swap fair value adjustment)	304,052	294,028	—	294,028	—
Total	\$ 1,301,043	\$ 1,277,105	\$ —	\$ 577,105	\$ 700,000

The principal values of the credit facilities payable approximate fair value due to their variable interest rates and are included in Level 3 of the hierarchy. Oaktree used market quotes as of the valuation date to estimate the fair value of the Company's 3.500% notes due 2025 (the "2025 Notes") and 2.700% notes due 2027 (the "2027 Notes"), which are included in Level 2 of the hierarchy.

Portfolio Composition

Summaries of the composition of the Company's portfolio at cost as a percentage of total investments and at fair value as a percentage of total investments and net assets are shown in the following tables:

Cost:	December 31, 2022		September 30, 2022	
		% of Total Investments		% of Total Investments
Senior secured debt	\$ 2,359,295	84.94 %	\$ 2,227,245	85.08 %
Debt investments in the JVs	162,617	5.85 %	146,444	5.59 %
Preferred equity	87,878	3.16 %	85,300	3.26 %
Subordinated debt	68,956	2.48 %	67,147	2.57 %
LLC equity interests of the JVs	54,791	1.97 %	49,322	1.88 %
Common equity and warrants	44,477	1.60 %	42,296	1.62 %
Total	\$ 2,778,014	100.00 %	\$ 2,617,754	100.00 %

Fair Value:	December 31, 2022		September 30, 2022	
		% of Total Investments % of Net Assets		% of Total Investments % of Net Assets
Senior secured debt	\$ 2,281,235	86.32 % 189.78 %	\$ 2,166,409	86.86 % 173.93 %
Debt investments in the JVs	162,192	6.14 % 13.49 %	146,533	5.88 % 11.77 %
Preferred equity	80,625	3.05 % 6.71 %	79,523	3.19 % 6.38 %
Subordinated debt	62,145	2.35 % 5.17 %	56,920	2.28 % 4.57 %
Common equity and warrants	32,565	1.23 % 2.71 %	24,011	0.96 % 1.93 %
LLC equity interests of the JVs	24,108	0.91 % 2.01 %	20,715	0.83 % 1.66 %
Total	\$ 2,642,870	100.00 % 219.87 %	\$ 2,494,111	100.00 % 200.24 %

OAKTREE SPECIALTY LENDING CORPORATION
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
(in thousands, except share and per share amounts, percentages and as otherwise indicated)

The geographic composition is determined by the location of the corporate headquarters of the portfolio company, which may not be indicative of the primary source of the portfolio company's business. The following tables show the composition of the Company's portfolio by geographic region at cost as a percentage of total investments and at fair value as a percentage of total investments and net assets:

	December 31, 2022		September 30, 2022	
		% of Total Investments		% of Total Investments
Cost:				
Northeast	\$ 772,197	27.78 %	\$ 747,420	28.55 %
Midwest	403,393	14.52 %	373,236	14.26 %
Southeast	397,717	14.32 %	356,041	13.60 %
West	351,871	12.67 %	358,306	13.69 %
International	350,510	12.62 %	301,242	11.51 %
Southwest	204,143	7.35 %	221,308	8.45 %
South	164,094	5.91 %	168,819	6.45 %
Northwest	134,089	4.83 %	91,382	3.49 %
Total	\$ 2,778,014	100.00 %	\$ 2,617,754	100.00 %

	December 31, 2022			September 30, 2022		
		% of Total Investments	% of Net Assets		% of Total Investments	% of Net Assets
Fair Value:						
Northeast	\$ 716,827	27.12 %	59.63 %	\$ 696,368	27.93 %	55.90 %
Midwest	384,219	14.54 %	31.97 %	356,934	14.31 %	28.66 %
Southeast	380,276	14.39 %	31.64 %	344,567	13.82 %	27.66 %
International	342,447	12.96 %	28.49 %	279,646	11.21 %	22.45 %
West	330,698	12.51 %	27.51 %	345,251	13.84 %	27.72 %
Southwest	195,818	7.41 %	16.29 %	214,984	8.62 %	17.26 %
South	160,150	6.06 %	13.32 %	166,230	6.66 %	13.35 %
Northwest	132,435	5.01 %	11.02 %	90,131	3.61 %	7.24 %
Total	\$ 2,642,870	100.00 %	219.87 %	\$ 2,494,111	100.00 %	200.24 %

OAKTREE SPECIALTY LENDING CORPORATION
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
(in thousands, except share and per share amounts, percentages and as otherwise indicated)

The following tables show the composition of the Company's portfolio by industry at cost as a percentage of total investments and at fair value as a percentage of total investments and net assets as of December 31, 2022 and September 30, 2022:

Cost:	December 31, 2022		September 30, 2022	
		% of Total Investments		% of Total Investments
Application Software	\$ 435,165	15.66 %	\$ 391,938	14.98 %
Multi-Sector Holdings (1)	229,676	8.27	195,766	7.48
Pharmaceuticals	131,307	4.73	126,508	4.83
Data Processing & Outsourced Services	118,058	4.25	120,477	4.60
Biotechnology	111,745	4.02	109,960	4.20
Health Care Technology	110,251	3.97	100,084	3.82
Specialized Finance	87,523	3.15	80,864	3.09
Industrial Machinery	81,483	2.93	81,787	3.12
Health Care Services	65,732	2.37	58,674	2.24
Internet & Direct Marketing Retail	65,585	2.36	67,926	2.59
Aerospace & Defense	61,993	2.23	61,963	2.37
Construction & Engineering	60,828	2.19	60,996	2.33
Health Care Distributors	58,320	2.10	57,112	2.18
Other Diversified Financial Services	57,241	2.06	29,300	1.12
Personal Products	53,190	1.91	53,214	2.03
Automotive Retail	51,663	1.86	59,254	2.26
Auto Parts & Equipment	51,067	1.84	12,474	0.48
Real Estate Operating Companies	49,980	1.80	47,585	1.82
Fertilizers & Agricultural Chemicals	49,271	1.77	49,301	1.88
Internet Services & Infrastructure	49,271	1.77	54,095	2.07
Metal & Glass Containers	47,128	1.70	47,704	1.82
Home Improvement Retail	45,266	1.63	45,802	1.75
Soft Drinks	43,935	1.58	34,272	1.31
Airport Services	43,748	1.57	43,322	1.65
Leisure Facilities	41,182	1.48	39,768	1.52
Insurance Brokers	39,268	1.41	35,628	1.36
Diversified Support Services	38,167	1.37	37,992	1.45
Specialty Chemicals	37,298	1.34	37,319	1.43
Health Care Supplies	36,693	1.32	36,471	1.39
Real Estate Services	36,233	1.30	40,243	1.54
Integrated Telecommunication Services	34,635	1.25	34,628	1.32
Electrical Components & Equipment	33,813	1.22	33,814	1.29
Advertising	27,507	0.99	28,245	1.08
Movies & Entertainment	26,202	0.94	26,161	1.00
Distributors	25,262	0.91	25,278	0.97
Airlines	24,034	0.87	—	—
Health Care Equipment	21,838	0.79	24,353	0.93
Environmental & Facilities Services	21,156	0.76	20,857	0.80
Oil & Gas Storage & Transportation	19,934	0.72	22,290	0.85
Home Furnishings	19,554	0.70	19,550	0.75
Systems Software	14,895	0.54	14,890	0.57
Consumer Finance	14,503	0.52	14,492	0.55
Hotels, Resorts & Cruise Lines	13,943	0.50	13,960	0.53
IT Consulting & Other Services	11,684	0.42	11,697	0.45
Restaurants	9,343	0.34	9,338	0.36
Education Services	9,070	0.33	9,080	0.35
Cable & Satellite	8,012	0.29	20,716	0.79
Research & Consulting Services	7,848	0.28	9,187	0.35
Apparel, Accessories & Luxury Goods	5,165	0.19	5,165	0.20
Air Freight & Logistics	4,925	0.18	7,295	0.28
Integrated Oil & Gas	4,873	0.18	4,866	0.19
Apparel Retail	4,727	0.17	5,268	0.20
Food Distributors	4,655	0.17	4,646	0.18
Specialized REITs	4,334	0.16	4,318	0.16
Real Estate Development	4,278	0.15	—	—
Diversified Banks	3,515	0.13	3,515	0.13
Technology Distributors	3,163	0.11	3,163	0.12
Construction Materials	2,353	0.08	2,331	0.09
Housewares & Specialties	2,217	0.08	2,293	0.09
Electronic Components	2,095	0.08	2,092	0.08
Alternative Carriers	214	0.01	212	0.01
Oil & Gas Refining & Marketing	—	—	8,627	0.33
Trading Companies & Distributors	—	—	7,628	0.29
	<u>\$ 2,778,014</u>	<u>100.00 %</u>	<u>\$ 2,617,754</u>	<u>100.00 %</u>

OAKTREE SPECIALTY LENDING CORPORATION
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
(in thousands, except share and per share amounts, percentages and as otherwise indicated)

Fair Value:	December 31, 2022			September 30, 2022		
		% of Total Investments	% of Net Assets		% of Total Investments	% of Net Assets
Application Software	\$ 422,862	15.95 %	35.18 %	\$ 384,589	15.43 %	30.87 %
Multi-Sector Holdings (1)	198,904	7.53	16.55	167,248	6.71	13.43
Pharmaceuticals	127,414	4.82	10.60	119,511	4.79	9.59
Biotechnology	115,489	4.37	9.61	108,465	4.35	8.71
Data Processing & Outsourced Services	106,224	4.02	8.84	111,335	4.46	8.94
Health Care Technology	103,479	3.92	8.61	97,315	3.90	7.81
Industrial Machinery	79,791	3.02	6.64	81,008	3.25	6.50
Specialized Finance	79,751	3.02	6.63	73,087	2.93	5.87
Internet & Direct Marketing Retail	66,001	2.50	5.49	70,419	2.82	5.65
Aerospace & Defense	61,490	2.33	5.12	61,881	2.48	4.97
Construction & Engineering	60,938	2.31	5.07	61,188	2.45	4.91
Health Care Distributors	54,898	2.08	4.57	54,662	2.19	4.39
Other Diversified Financial Services	54,080	2.05	4.50	24,326	0.98	1.95
Fertilizers & Agricultural Chemicals	52,292	1.98	4.35	51,972	2.08	4.17
Health Care Services	51,260	1.94	4.26	45,943	1.84	3.69
Automotive Retail	50,681	1.92	4.22	57,629	2.31	4.63
Real Estate Operating Companies	50,127	1.90	4.17	48,062	1.93	3.86
Auto Parts & Equipment	50,015	1.89	4.16	11,469	0.46	0.92
Internet Services & Infrastructure	48,973	1.85	4.07	53,797	2.16	4.32
Personal Products	48,903	1.85	4.07	50,150	2.01	4.03
Home Improvement Retail	45,127	1.71	3.75	45,421	1.82	3.65
Metal & Glass Containers	44,763	1.69	3.72	47,599	1.91	3.82
Soft Drinks	44,387	1.68	3.69	33,670	1.35	2.70
Airport Services	43,267	1.64	3.60	42,883	1.72	3.44
Leisure Facilities	40,578	1.54	3.38	39,258	1.57	3.15
Insurance Brokers	39,057	1.48	3.25	33,081	1.33	2.66
Health Care Supplies	37,776	1.43	3.14	36,577	1.47	2.94
Diversified Support Services	35,626	1.35	2.96	36,712	1.47	2.95
Real Estate Services	35,621	1.35	2.96	39,573	1.59	3.18
Electrical Components & Equipment	32,970	1.25	2.74	32,933	1.32	2.64
Integrated Telecommunication Services	32,041	1.21	2.67	32,201	1.29	2.59
Specialty Chemicals	31,476	1.19	2.62	33,969	1.36	2.73
Movies & Entertainment	26,470	1.00	2.20	26,645	1.07	2.14
Advertising	26,022	0.98	2.16	26,948	1.08	2.16
Airlines	25,864	0.98	2.15	—	—	—
Distributors	24,569	0.93	2.04	24,494	0.98	1.97
Health Care Equipment	22,703	0.86	1.89	24,161	0.97	1.94
Environmental & Facilities Services	20,675	0.78	1.72	20,585	0.83	1.65
Oil & Gas Storage & Transportation	18,113	0.69	1.51	20,853	0.84	1.67
Home Furnishings	17,917	0.68	1.49	18,188	0.73	1.46
Hotels, Resorts & Cruise Lines	13,904	0.53	1.16	13,985	0.56	1.12
Systems Software	12,104	0.46	1.01	12,834	0.51	1.03
Consumer Finance	11,439	0.43	0.95	13,284	0.53	1.07
Education Services	8,938	0.34	0.74	8,582	0.34	0.69
Restaurants	8,610	0.33	0.72	8,692	0.35	0.70
Cable & Satellite	7,968	0.30	0.66	19,576	0.78	1.57
Research & Consulting Services	7,165	0.27	0.60	8,573	0.34	0.69
IT Consulting & Other Services	6,963	0.26	0.58	8,596	0.34	0.69
Integrated Oil & Gas	4,847	0.18	0.40	4,872	0.20	0.39
Apparel Retail	4,675	0.18	0.39	5,223	0.21	0.42
Real Estate Development	4,267	0.16	0.35	—	—	—
Air Freight & Logistics	4,191	0.16	0.35	6,405	0.26	0.51
Food Distributors	3,599	0.14	0.30	3,367	0.13	0.27
Diversified Banks	3,315	0.13	0.28	3,402	0.14	0.27
Specialized REITs	3,230	0.12	0.27	3,264	0.13	0.26
Technology Distributors	2,971	0.11	0.25	2,997	0.12	0.24
Housewares & Specialties	2,265	0.09	0.19	2,456	0.10	0.20
Construction Materials	1,928	0.07	0.16	1,934	0.08	0.16
Electronic Components	1,712	0.06	0.14	1,890	0.08	0.15
Alternative Carriers	185	0.01	0.02	201	0.01	0.02
Oil & Gas Refining & Marketing	—	—	—	8,604	0.34	0.69
Trading Companies & Distributors	—	—	—	5,567	0.22	0.45
Total	\$ 2,642,870	100.00 %	219.87 %	\$ 2,494,111	100.00 %	200.24 %

(1) This industry includes the Company's investments in the JVs.

As of December 31, 2022 and September 30, 2022, the Company had no single investment that represented greater than 10% of the total investment portfolio at fair value. Income, consisting of interest, dividends, fees, other investment income and realization of gains or losses, may fluctuate and in any given period can be highly concentrated among several investments.

OAKTREE SPECIALTY LENDING CORPORATION
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
(in thousands, except share and per share amounts, percentages and as otherwise indicated)

Senior Loan Fund JV I, LLC

In May 2014, the Company entered into an LLC agreement with Kemper to form SLF JV I. The Company co-invests in senior secured loans of middle-market companies and other corporate debt securities with Kemper through its investment in SLF JV I. SLF JV I is managed by a four person Board of Directors, two of whom are selected by the Company and two of whom are selected by Kemper. All portfolio decisions and investment decisions in respect of SLF JV I must be approved by the SLF JV I investment committee, which consists of one representative selected by the Company and one representative selected by Kemper (with approval from a representative of each required). Since the Company does not have a controlling financial interest in SLF JV I, the Company does not consolidate SLF JV I.

SLF JV I is capitalized pro rata with LLC equity interests as transactions are completed and may be capitalized with additional subordinated notes issued to the Company and Kemper by SLF JV I. The subordinated notes issued by SLF JV I (the "SLF JV I Notes") are senior in right of payment to SLF JV I LLC equity interests and subordinated in right of payment to SLF JV I's secured debt. As of December 31, 2022 and September 30, 2022, the Company and Kemper owned, in the aggregate, 87.5% and 12.5%, respectively, of the LLC equity interests of SLF JV I and the outstanding SLF JV I Notes. SLF JV I is not an "eligible portfolio company" as defined in section 2(a)(46) of the Investment Company Act.

SLF JV I has a senior revolving credit facility with Deutsche Bank AG, New York Branch (as amended, the "SLF JV I Deutsche Bank Facility"), which permitted up to \$260.0 million of borrowings (subject to borrowing base and other limitations) as of each of December 31, 2022 and September 30, 2022. Borrowings under the SLF JV I Deutsche Bank Facility are secured by all of the assets of SLF JV I Funding LLC, a special purpose financing subsidiary of SLF JV I. As of December 31, 2022, the reinvestment period of the SLF JV I Deutsche Bank Facility was scheduled to expire May 3, 2023 and the maturity date was May 3, 2028. As of December 31, 2022, borrowings under the SLF JV I Deutsche Bank Facility accrued interest at a rate equal to 3-month LIBOR plus 2.00% per annum during the reinvestment period, 3-month LIBOR plus 2.15% per annum for the first year after the reinvestment period, 3-month LIBOR plus 2.25% for the following year and 3-month LIBOR plus 2.50% thereafter, in each case with a 0.125% LIBOR floor. \$226.0 million and \$230.0 million of borrowings were outstanding under the SLF JV I Deutsche Bank Facility as of December 31, 2022 and September 30, 2022, respectively.

As of December 31, 2022 and September 30, 2022, SLF JV I had total assets of \$409.4 million and \$385.2 million, respectively. SLF JV I's portfolio primarily consisted of senior secured loans to 59 and 60 portfolio companies as of December 31, 2022 and September 30, 2022, respectively. The portfolio companies in SLF JV I are in industries similar to those in which the Company may invest directly. As of December 31, 2022, the Company's investment in SLF JV I consisted of LLC equity interests and SLF JV I Notes of \$136.8 million in aggregate, at fair value. As of September 30, 2022, the Company's investment in SLF JV I consisted of LLC equity interests and SLF JV I Notes of \$117.0 million in aggregate, at fair value.

As of December 31, 2022, the Company and Kemper had funded approximately \$190.5 million to SLF JV I, of which \$166.7 million was from the Company. As of September 30, 2022, the Company and Kemper had funded approximately \$165.5 million to SLF JV I, of which \$144.8 million was from the Company. As of December 31, 2022, the Company had aggregate commitments to fund SLF JV I of \$13.1 million, of which approximately \$9.8 million was to fund additional SLF JV I Notes and approximately \$3.3 million was to fund LLC equity interests in SLF JV I. During the three months ended December 31, 2022, the Company contributed \$16.4 million to fund additional SLF JV I Notes and approximately \$5.5 million to fund additional LLC equity interests in SLF JV I. As of September 30, 2022, the Company had aggregate commitments to fund SLF JV I of \$35.0 million, of which approximately \$26.2 million was to fund additional SLF JV I Notes and approximately \$8.8 million was to fund LLC equity interests in SLF JV I.

OAKTREE SPECIALTY LENDING CORPORATION
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
(in thousands, except share and per share amounts, percentages and as otherwise indicated)

Below is a summary of SLF JV I's portfolio, followed by a listing of the individual loans in SLF JV I's portfolio as of December 31, 2022 and September 30, 2022:

	December 31, 2022	September 30, 2022
Senior secured loans (1)	\$382,148	\$383,194
Weighted average interest rate on senior secured loans (2)	9.55%	8.33%
Number of borrowers in SLF JV I	59	60
Largest exposure to a single borrower (1)	\$11,337	\$10,093
Total of five largest loan exposures to borrowers (1)	\$51,990	\$48,139

(1) At principal amount.

(2) Computed using the weighted average annual interest rate on accruing senior secured loans at fair value.

OAKTREE SPECIALTY LENDING CORPORATION
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
(in thousands, except share and per share amounts, percentages and as otherwise indicated)

SLF JV I Portfolio as of December 31, 2022

<u>Portfolio Company</u>	<u>Investment Type</u>	<u>Cash Interest Rate (1)(2)</u>	<u>Industry</u>	<u>Principal</u>	<u>Cost</u>	<u>Fair Value (3)</u>	<u>Notes</u>
Access CIG, LLC	First Lien Term Loan, LIBOR+3.75% cash due 2/27/2025	7.82 %	Diversified Support Services	\$ 10,067	\$ 10,008	\$ 9,883	
ADB Companies, LLC	First Lien Term Loan, SOFR+6.25% cash due 12/18/2025	11.34 %	Construction & Engineering	8,413	8,296	8,267	(4)
Altice France S.A.	First Lien Term Loan, LIBOR+4.00% cash due 8/14/2026	8.65 %	Integrated Telecommunication Services	2,992	2,844	2,791	
Alvogen Pharma US, Inc.	First Lien Term Loan, SOFR+7.50% cash due 6/30/2025	12.23 %	Pharmaceuticals	9,150	9,060	9,104	(4)
American Rock Salt Company LLC	First Lien Term Loan, LIBOR+4.00% cash due 6/9/2028	8.38 %	Diversified Metals & Mining	1,995	1,836	1,883	
American Tire Distributors, Inc.	First Lien Term Loan, LIBOR+6.25% cash due 10/20/2028	10.61 %	Distributors	4,860	4,800	4,471	(4)
Amplify Finco Pty Ltd.	First Lien Term Loan, LIBOR+4.25% cash due 11/26/2026	8.98 %	Movies & Entertainment	7,780	7,702	7,501	(4)
Anastasia Parent, LLC	First Lien Term Loan, LIBOR+3.75% cash due 8/11/2025	8.48 %	Personal Products	1,535	1,200	1,149	(4)
Apptio, Inc.	First Lien Term Loan, LIBOR+6.00% cash due 1/10/2025	9.94 %	Application Software	4,615	4,584	4,523	(4)
Apptio, Inc.	First Lien Revolver, LIBOR+6.00% cash due 1/10/2025	9.94 %	Application Software	231	228	223	(4)(5)
Total Apptio, Inc.				4,846	4,812	4,746	
ASP-R-PAC Acquisition Co LLC	First Lien Term Loan, LIBOR+6.00% cash due 12/29/2027	10.38 %	Paper Packaging	4,166	4,097	4,012	
ASP-R-PAC Acquisition Co LLC	First Lien Revolver, LIBOR+6.00% cash due 12/29/2027		Paper Packaging	—	(8)	(18)	(5)
Total ASP-R-PAC Acquisition Co LLC				4,166	4,089	3,994	
Astra Acquisition Corp.	First Lien Term Loan, LIBOR+5.25% cash due 10/25/2028	9.63 %	Application Software	5,052	4,866	4,484	(4)
Asurion, LLC	First Lien Term Loan, SOFR+4.00% cash due 8/19/2028	8.68 %	Property & Casualty Insurance	4,988	4,752	4,463	
Asurion, LLC	Second Lien Term Loan, LIBOR+5.25% cash due 1/20/2029	9.63 %	Property & Casualty Insurance	4,346	3,995	3,404	
Total Asurion, LLC				9,334	8,747	7,867	
athenahealth Group Inc.	First Lien Term Loan, SOFR+3.50% cash due 2/15/2029	7.82 %	Health Care Technology	2,558	2,353	2,316	
athenahealth Group Inc.	First Lien Delayed Draw Term Loan, SOFR+3.50% cash due 2/15/2029	7.82 %	Health Care Technology	109	74	68	(5)
Total athenahealth Group Inc.				2,667	2,427	2,384	
Aurora Lux Finco S.À.R.L.	First Lien Term Loan, LIBOR+6.00% cash due 12/24/2026	10.32 %	Airport Services	6,321	6,232	6,012	(4)
BAART Programs, Inc.	First Lien Term Loan, LIBOR+5.00% cash due 6/11/2027	9.07 %	Health Care Services	6,354	6,295	6,176	
BAART Programs, Inc.	First Lien Delayed Draw Term Loan, LIBOR+5.00% cash due 6/11/2027	9.73 %	Health Care Services	1,767	1,747	1,682	(4)(5)
Total BAART Programs, Inc.				8,121	8,042	7,858	
Blackhawk Network Holdings, Inc.	First Lien Term Loan, LIBOR+3.00% cash due 6/15/2025	7.08 %	Data Processing & Outsourced Services	9,550	9,542	9,331	
Boxer Parent Company Inc.	First Lien Term Loan, LIBOR+3.75% cash due 10/2/2025	8.13 %	Systems Software	1,994	1,917	1,914	
BYJU's Alpha, Inc.	First Lien Term Loan, LIBOR+6.00% cash due 11/24/2026	10.70 %	Application Software	7,425	7,335	5,988	
C5 Technology Holdings, LLC	171 Common Units		Data Processing & Outsourced Services		—	—	(4)
C5 Technology Holdings, LLC	7,193,539.63 Preferred Units		Data Processing & Outsourced Services		7,194	5,683	(4)
Total C5 Technology Holdings, LLC					7,194	5,683	
Cengage Learning, Inc.	First Lien Term Loan, LIBOR+4.75% cash due 7/14/2026	7.81 %	Education Services	2,992	2,734	2,698	

OAKTREE SPECIALTY LENDING CORPORATION
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
(in thousands, except share and per share amounts, percentages and as otherwise indicated)

<u>Portfolio Company</u>	<u>Investment Type</u>	<u>Cash Interest Rate (1)(2)</u>	<u>Industry</u>	<u>Principal</u>	<u>Cost</u>	<u>Fair Value (3)</u>	<u>Notes</u>
Centerline Communications, LLC	First Lien Term Loan, SOFR+5.50% cash due 8/10/2023	10.43 %	Wireless Telecommunication Services	\$ 6,345	\$ 6,242	\$ 6,231	
Centerline Communications, LLC	First Lien Revolver, SOFR+5.50% cash due 8/10/2027		Wireless Telecommunication Services	—	(10)	(10)	(5)
Total Centerline Communications, LLC				6,345	6,232	6,221	
Convergeone Holdings, Inc.	First Lien Term Loan, LIBOR+5.00% cash due 1/4/2026	9.38 %	IT Consulting & Other Services	7,354	7,200	4,309	(4)
Covetrus, Inc.	First Lien Term Loan, SOFR+5.00% cash due 9/20/2029	9.58 %	Health Care Distributors	5,375	5,053	5,050	(4)
Curium Bidco S.à.r.l.	First Lien Term Loan, LIBOR+4.00% cash due 7/9/2026	8.73 %	Biotechnology	7,800	7,726	7,644	
Curium Bidco S.à.r.l.	First Lien Term Loan, LIBOR+4.25% cash due 12/2/2027	8.98 %	Biotechnology	997	978	975	
Total Curium Bidco S.à.r.l.				8,797	8,704	8,619	
DirecTV Financing, LLC	First Lien Term Loan, LIBOR+5.00% cash due 8/2/2027	9.38 %	Cable & Satellite	6,277	6,178	6,124	(4)
Domtar Corporation	First Lien Term Loan, LIBOR+5.50% cash due 11/30/2028	9.79 %	Paper Products	4,090	4,055	3,926	
DTI Holdco, Inc.	First Lien Term Loan, SOFR+4.75% cash due 4/26/2029	8.84 %	Research & Consulting Services	7,980	7,835	7,372	(4)
eResearch Technology, Inc.	First Lien Term Loan, LIBOR+4.50% cash due 2/4/2027	8.88 %	Application Software	7,811	7,681	6,915	
Gibson Brands, Inc.	First Lien Term Loan, LIBOR+5.00% cash due 8/11/2028	9.13 %	Leisure Products	7,425	7,351	5,495	
Global Medical Response, Inc.	First Lien Term Loan, LIBOR+4.25% cash due 10/2/2025	8.42 %	Health Care Services	1,260	1,246	891	
Harbor Purchaser Inc.	First Lien Term Loan, SOFR+5.25% cash due 4/9/2029	9.67 %	Education Services	7,980	7,764	7,613	(4)
Indivior Finance S.À.R.L.	First Lien Term Loan, SOFR+5.25% cash due 6/30/2026	10.09 %	Pharmaceuticals	7,388	7,282	7,277	
INW Manufacturing, LLC	First Lien Term Loan, LIBOR+5.75% cash due 3/25/2027	10.48 %	Personal Products	9,375	9,172	8,016	(4)
Iris Holding, Inc.	First Lien Term Loan, SOFR+4.75% cash due 6/28/2028	8.94 %	Metal & Glass Containers	4,988	4,630	4,548	
LABL, Inc.	First Lien Term Loan, LIBOR+5.00% cash due 10/29/2028	9.38 %	Office Services & Supplies	2,992	2,858	2,848	
LaserAway Intermediate Holdings II, LLC	First Lien Term Loan, LIBOR+5.75% cash due 10/14/2027	9.76 %	Health Care Services	7,425	7,306	7,295	
Lightbox Intermediate, L.P.	First Lien Term Loan, LIBOR+5.00% cash due 5/9/2026	9.73 %	Real Estate Services	11,337	11,152	10,941	(4)
LogMeIn, Inc.	First Lien Term Loan, LIBOR+4.75% cash due 8/31/2027	9.14 %	Application Software	7,840	7,736	5,080	
LTI Holdings, Inc.	First Lien Term Loan, LIBOR+3.50% cash due 9/6/2025	7.88 %	Electronic Components	7,347	7,270	7,050	
McAfee Corp.	First Lien Term Loan, SOFR+3.75% cash due 3/1/2029	7.97 %	Systems Software	1,995	1,876	1,862	
Mindbody, Inc.	First Lien Term Loan, LIBOR+7.00% cash due 2/14/2025	11.72 %	Internet Services & Infrastructure	4,668	4,636	4,566	(4)
Mindbody, Inc.	First Lien Revolver, LIBOR+8.00% cash due 2/14/2025		Internet Services & Infrastructure	—	(3)	(10)	(4)(5)
Total Mindbody, Inc.				4,668	4,633	4,556	
MRI Software LLC	First Lien Term Loan, LIBOR+5.50% cash due 2/10/2026	10.23 %	Application Software	10,611	10,416	10,227	(4)
MRI Software LLC	First Lien Revolver, LIBOR+5.50% cash due 2/10/2026		Application Software	—	(3)	(12)	(4)(5)
Total MRI Software LLC				10,611	10,413	10,215	
Northern Star Industries Inc.	First Lien Term Loan, LIBOR+4.50% cash due 3/31/2025	9.23 %	Electrical Components & Equipment	6,668	6,657	6,467	
OEConnection LLC	First Lien Term Loan, SOFR+4.00% cash due 9/25/2026	8.42 %	Application Software	7,757	7,721	7,411	(4)

OAKTREE SPECIALTY LENDING CORPORATION
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
(in thousands, except share and per share amounts, percentages and as otherwise indicated)

<u>Portfolio Company</u>	<u>Investment Type</u>	<u>Cash Interest Rate (1)(2)</u>	<u>Industry</u>	<u>Principal</u>	<u>Cost</u>	<u>Fair Value (3)</u>	<u>Notes</u>
Park Place Technologies, LLC	First Lien Term Loan, SOFR+5.00% cash due 11/10/2027	9.42 %	Internet Services & Infrastructure	\$ 9,900	\$ 9,504	\$ 9,362	(4)
Planview Parent, Inc.	First Lien Term Loan, LIBOR+4.00% cash due 12/17/2027	8.73 %	Application Software	2,435	2,294	2,274	
Planview Parent, Inc.	Second Lien Term Loan, LIBOR+7.25% cash due 12/18/2028	11.98 %	Application Software	4,503	4,435	4,041	(4)
Total Planview Parent, Inc.				6,938	6,729	6,315	
Pluralsight, LLC	First Lien Term Loan, LIBOR+8.00% cash due 4/6/2027	11.83 %	Application Software	6,796	6,698	6,626	(4)
Pluralsight, LLC	First Lien Revolver, LIBOR+8.00% cash due 4/6/2027		Application Software	212	206	201	(4)(5)
Total Pluralsight, LLC				7,008	6,904	6,827	
RevSpring, Inc.	First Lien Term Loan, LIBOR+4.00% cash due 10/11/2025	8.73 %	Commercial Printing	9,600	9,583	9,288	
SHO Holding I Corporation	First Lien Term Loan, LIBOR+5.25% cash due 4/27/2024	9.66 %	Footwear	8,179	8,173	6,339	
SHO Holding I Corporation	First Lien Term Loan, LIBOR+5.23% cash due 4/27/2024	9.64 %	Footwear	138	138	120	
Total SHO Holding I Corporation				8,317	8,311	6,459	
Sorenson Communications, LLC	First Lien Term Loan, LIBOR+5.50% cash due 3/17/2026	10.23 %	Communications Equipment	2,478	2,454	2,374	
Spanx, LLC	First Lien Term Loan, LIBOR+5.25% cash due 11/20/2028	9.64 %	Apparel Retail	8,910	8,760	8,699	(4)
SPX Flow, Inc.	First Lien Term Loan, SOFR+4.50% cash due 4/5/2029	8.92 %	Industrial Machinery	10,075	9,610	9,436	(4)
Supermoose Borrower, LLC	First Lien Term Loan, LIBOR+3.75% cash due 8/29/2025	8.48 %	Application Software	7,723	7,482	6,688	(4)
Surgery Center Holdings, Inc.	First Lien Term Loan, LIBOR+3.75% cash due 8/31/2026	8.05 %	Health Care Facilities	3,044	3,034	3,014	
TIBCO Software Inc.	First Lien Term Loan, SOFR+4.50% cash due 3/20/2029	9.18 %	Application Software	6,256	5,712	5,602	(4)
Touchstone Acquisition, Inc.	First Lien Term Loan, LIBOR+6.00% cash due 12/29/2028	10.38 %	Health Care Supplies	7,267	7,142	7,104	(4)
Veritas US Inc.	First Lien Term Loan, LIBOR+5.00% cash due 9/1/2025	9.73 %	Application Software	6,354	6,286	4,515	
Windstream Services II, LLC	First Lien Term Loan, SOFR+6.25% cash due 9/21/2027	10.67 %	Integrated Telecommunication Services	7,798	7,587	7,092	(4)
WP CPP Holdings, LLC	Second Lien Term Loan, LIBOR+7.75% cash due 4/30/2026	12.17 %	Aerospace & Defense	6,000	5,974	5,055	(4)
WP CPP Holdings, LLC	First Lien Term Loan, LIBOR+3.75% cash due 4/30/2025	8.17 %	Aerospace & Defense	1,980	1,913	1,732	(4)
Total WP CPP Holdings, LLC				7,980	7,887	6,787	
Zayo Group Holdings, Inc.	First Lien Term Loan, LIBOR+3.00% cash due 3/9/2027	7.38 %	Alternative Carriers	2,155	2,009	1,756	
Total Portfolio Investments				\$ 382,148	\$ 380,682	\$ 355,427	

(1) Represents the interest rate as of December 31, 2022. All interest rates are payable in cash, unless otherwise noted.

(2) The interest rate on the principal balance outstanding for most of the floating rate loans is indexed to LIBOR and/or an alternate base rate (e.g., prime rate), which typically resets semi-annually, quarterly, or monthly at the borrower's option. Certain loans may also be indexed to SOFR. The borrower may also elect to have multiple interest reset periods for each loan. For each of these loans, the Company has provided the applicable margin over the reference rates based on each respective credit agreement and the cash interest rate as of period end. All the LIBOR shown above is in U.S. dollars. As of December 31, 2022, the reference rates for SLF JV I's variable rate loans were the 30-day LIBOR at 4.38%, the 90-day LIBOR at 4.73%, the 30-day SOFR at 4.32%, the 90-day SOFR at 4.58% and the 180-day SOFR at 4.79%. Most loans include an interest floor, which generally ranges from 0% to 1%. SOFR based contracts may include a credit spread adjustment that is charged in addition to the base rate and the stated spread.

(3) Represents the current determination of fair value as of December 31, 2022 utilizing a similar technique as the Company in accordance with ASC 820. However, the determination of such fair value is not included in the valuation process described elsewhere herein.

(4) This investment was held by both the Company and SLF JV I as of December 31, 2022.

(5) Investment had undrawn commitments. Unamortized fees are classified as unearned income which reduces cost basis, which may result in a negative cost basis. A negative fair value may result from the unfunded commitment being valued below par.

OAKTREE SPECIALTY LENDING CORPORATION
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
(in thousands, except share and per share amounts, percentages and as otherwise indicated)

SLF JV I Portfolio as of September 30, 2022

<u>Portfolio Company</u>	<u>Investment Type</u>	<u>Cash Interest Rate (1)(2)</u>	<u>Industry</u>	<u>Principal</u>	<u>Cost</u>	<u>Fair Value (3)</u>	<u>Notes</u>
Access CIG, LLC	First Lien Term Loan, LIBOR+3.75% cash due 2/27/2025	6.82 %	Diversified Support Services	\$ 10,093	\$ 10,028	\$ 9,692	
ADB Companies, LLC	First Lien Term Loan, SOFR+6.25% cash due 12/18/2025	9.80 %	Construction & Engineering	8,518	8,389	8,371	(4)
Altice France S.A.	First Lien Term Loan, LIBOR+4.00% cash due 8/14/2026	6.91 %	Integrated Telecommunication Services	3,000	2,841	2,730	
Alvogen Pharma US, Inc.	First Lien Term Loan, SOFR+7.50% cash due 6/30/2025	11.20 %	Pharmaceuticals	9,267	9,166	9,221	(4)
American Tire Distributors, Inc.	First Lien Term Loan, LIBOR+6.25% cash due 10/20/2028	9.03 %	Distributors	4,873	4,812	4,576	(4)
Amplify Finco Pty Ltd.	First Lien Term Loan, LIBOR+4.25% cash due 11/26/2026	7.92 %	Movies & Entertainment	7,800	7,722	7,527	(4)
Anastasia Parent, LLC	First Lien Term Loan, LIBOR+3.75% cash due 8/11/2025	7.42 %	Personal Products	1,539	1,203	1,232	(4)
Apptio, Inc.	First Lien Term Loan, LIBOR+6.00% cash due 1/10/2025	8.46 %	Application Software	4,615	4,580	4,519	(4)
Apptio, Inc.	First Lien Revolver, LIBOR+6.00% cash due 1/10/2025	8.46 %	Application Software	154	151	146	(4)(5)
Total Apptio, Inc.				4,769	4,731	4,665	
ASP-R-PAC Acquisition Co LLC	First Lien Term Loan, LIBOR+6.00% cash due 12/29/2027	9.67 %	Paper Packaging	4,176	4,103	4,080	
ASP-R-PAC Acquisition Co LLC	First Lien Revolver, LIBOR+6.00% cash due 12/29/2027		Paper Packaging	—	(9)	(11)	(5)
Total ASP-R-PAC Acquisition Co LLC				4,176	4,094	4,069	
Astra Acquisition Corp.	First Lien Term Loan, LIBOR+5.25% cash due 10/25/2028	8.37 %	Application Software	5,052	4,858	4,319	(4)
Asurion, LLC	First Lien Term Loan, SOFR+4.00% cash due 8/19/2028	7.70 %	Property & Casualty Insurance	5,000	4,753	4,276	
Asurion, LLC	Second Lien Term Loan, LIBOR+5.25% cash due 1/20/2029	8.37 %	Property & Casualty Insurance	4,346	3,981	3,347	
Total Asurion, LLC				9,346	8,734	7,623	
Aurora Lux Finco S.À.R.L.	First Lien Term Loan, LIBOR+6.00% cash due 12/24/2026	8.78 %	Airport Services	6,338	6,242	6,027	(4)
BAART Programs, Inc.	First Lien Term Loan, LIBOR+5.00% cash due 6/11/2027	8.12 %	Health Care Services	6,371	6,311	6,148	
BAART Programs, Inc.	First Lien Delayed Draw Term Loan, LIBOR+5.00% cash due 6/11/2027	8.12 %	Health Care Services	1,771	1,751	1,664	(4)(5)
Total BAART Programs, Inc.				8,142	8,062	7,812	
Blackhawk Network Holdings, Inc.	First Lien Term Loan, LIBOR+3.00% cash due 6/15/2025	6.03 %	Data Processing & Outsourced Services	9,575	9,566	8,977	
BYJU's Alpha, Inc.	First Lien Term Loan, LIBOR+6.00% cash due 11/24/2026	8.98 %	Application Software	7,444	7,347	5,455	
C5 Technology Holdings, LLC	171 Common Units		Data Processing & Outsourced Services		—	—	(4)
C5 Technology Holdings, LLC	7,193,539.63 Preferred Units		Data Processing & Outsourced Services		7,194	5,683	(4)
Total C5 Technology Holdings, LLC					7,194	5,683	
Centerline Communications, LLC	First Lien Term Loan, SOFR+5.50% cash due 8/10/2027	9.12 %	Wireless Telecommunication Services	4,358	4,286	4,280	
Centerline Communications, LLC	First Lien Delayed Draw Term Loan, SOFR+5.50% cash due 8/10/2027	9.12 %	Wireless Telecommunication Services	449	432	413	(5)
Centerline Communications, LLC	First Lien Revolver, SOFR+5.50% cash due 8/10/2027		Wireless Telecommunication Services	—	(10)	(11)	(5)
Total Centerline Communications, LLC				4,807	4,708	4,682	

OAKTREE SPECIALTY LENDING CORPORATION
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
(in thousands, except share and per share amounts, percentages and as otherwise indicated)

<u>Portfolio Company</u>	<u>Investment Type</u>	<u>Cash Interest Rate (1)(2)</u>	<u>Industry</u>	<u>Principal</u>	<u>Cost</u>	<u>Fair Value (3)</u>	<u>Notes</u>
CITGO Petroleum Corp.	First Lien Term Loan, LIBOR+6.25% cash due 3/28/2024	9.37 %	Oil & Gas Refining & Marketing	\$ 7,038	\$ 6,967	\$ 7,057	(4)
City Football Group Limited	First Lien Term Loan, LIBOR+3.50% cash due 7/21/2028	6.48 %	Movies & Entertainment	6,451	6,419	6,166	
Convergeone Holdings, Inc.	First Lien Term Loan, LIBOR+5.00% cash due 1/4/2026	8.12 %	IT Consulting & Other Services	7,373	7,206	5,320	(4)
Covetrus, Inc.	First Lien Term Loan, SOFR+5.00% cash due 9/20/2029	7.65 %	Health Care Distributors	5,375	5,053	5,035	(4)
Curium Bidco S.à.r.l.	First Lien Term Loan, LIBOR+4.00% cash due 7/9/2026	7.67 %	Biotechnology	5,820	5,776	5,587	
Dealer Tire, LLC	First Lien Term Loan, LIBOR+4.25% cash due 12/12/2025	7.37 %	Distributors	2,992	2,935	2,924	
Delivery Hero FinCo LLC	First Lien Term Loan, SOFR+5.75% cash due 8/12/2027	8.49 %	Internet & Direct Marketing Retail	6,035	5,876	5,756	(4)
DirecTV Financing, LLC	First Lien Term Loan, LIBOR+5.00% cash due 8/2/2027	8.12 %	Cable & Satellite	6,436	6,332	6,012	(4)
Domtar Corporation	First Lien Term Loan, LIBOR+5.50% cash due 11/30/2028	8.26 %	Paper Products	4,100	4,065	3,921	
DTI Holdco, Inc.	First Lien Term Loan, SOFR+4.75% cash due 4/26/2029	7.33 %	Research & Consulting Services	8,000	7,849	7,616	(4)
Eagle Parent Corp.	First Lien Term Loan, SOFR+4.25% cash due 4/1/2029	7.80 %	Industrial Machinery	4,478	4,373	4,367	
eResearch Technology, Inc.	First Lien Term Loan, LIBOR+4.50% cash due 2/4/2027	7.62 %	Application Software	7,331	7,258	6,859	
Gibson Brands, Inc.	First Lien Term Loan, LIBOR+5.00% cash due 8/11/2028	7.94 %	Leisure Products	7,444	7,369	6,029	
Global Medical Response, Inc.	First Lien Term Loan, LIBOR+4.25% cash due 3/14/2025	7.37 %	Health Care Services	1,979	1,979	1,722	(4)
Global Medical Response, Inc.	First Lien Term Loan, LIBOR+4.25% cash due 10/2/2025	6.81 %	Health Care Services	2,192	2,165	1,912	
Total Global Medical Response, Inc.				4,171	4,144	3,634	
Harbor Purchaser Inc.	First Lien Term Loan, SOFR+5.25% cash due 4/9/2029	8.38 %	Education Services	8,000	7,774	7,310	(4)
Indivior Finance S.À.R.L.	First Lien Term Loan, SOFR+5.25% cash due 6/30/2026	8.80 %	Pharmaceuticals	7,406	7,293	7,286	
INW Manufacturing, LLC	First Lien Term Loan, LIBOR+5.75% cash due 3/25/2027	9.42 %	Personal Products	9,500	9,282	8,408	(4)
Iris Holding, Inc.	First Lien Term Loan, SOFR+4.75% cash due 6/28/2028	7.89 %	Metal & Glass Containers	5,000	4,624	4,610	
LaserAway Intermediate Holdings II, LLC	First Lien Term Loan, LIBOR+5.75% cash due 10/14/2027	8.23 %	Health Care Services	7,444	7,318	7,323	
Lightbox Intermediate, L.P.	First Lien Term Loan, LIBOR+5.00% cash due 5/9/2026	8.67 %	Real Estate Services	7,367	7,315	7,109	(4)
LogMeIn, Inc.	First Lien Term Loan, LIBOR+4.75% cash due 8/31/2027	7.80 %	Application Software	7,860	7,751	5,494	
LTI Holdings, Inc.	First Lien Term Loan, LIBOR+3.25% cash due 9/6/2025	6.37 %	Electronic Components	7,366	7,282	6,835	
Mindbody, Inc.	First Lien Term Loan, LIBOR+7.00% cash 1.50% PIK due 2/14/2025	10.64 %	Internet Services & Infrastructure	4,687	4,651	4,570	(4)
Mindbody, Inc.	First Lien Revolver, LIBOR+8.00% cash due 2/14/2025		Internet Services & Infrastructure	—	(4)	(12)	(4)(5)
Total Mindbody, Inc.				4,687	4,647	4,558	
MRI Software LLC	First Lien Term Loan, LIBOR+5.50% cash due 2/10/2026	9.17 %	Application Software	6,139	6,104	5,966	(4)
MRI Software LLC	First Lien Revolver, LIBOR+5.50% cash due 2/10/2026		Application Software	—	(3)	(10)	(4)(5)
Total MRI Software LLC				6,139	6,101	5,956	
Northern Star Industries Inc.	First Lien Term Loan, LIBOR+4.75% cash due 3/31/2025	7.87 %	Electrical Components & Equipment	6,685	6,673	6,484	
OEConnection LLC	First Lien Term Loan, LIBOR+4.00% cash due 9/25/2026	7.12 %	Application Software	7,777	7,741	7,505	(4)
Park Place Technologies, LLC	First Lien Term Loan, SOFR+5.00% cash due 11/10/2027	8.13 %	Internet Services & Infrastructure	4,925	4,781	4,687	(4)
Peloton Interactive, Inc.	First Lien Term Loan, SOFR+6.50% cash due 5/25/2027	8.35 %	Leisure Products	5,486	5,251	5,371	

OAKTREE SPECIALTY LENDING CORPORATION
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
(in thousands, except share and per share amounts, percentages and as otherwise indicated)

<u>Portfolio Company</u>	<u>Investment Type</u>	<u>Cash Interest Rate (1)(2)</u>	<u>Industry</u>	<u>Principal</u>	<u>Cost</u>	<u>Fair Value (3)</u>	<u>Notes</u>
Planview Parent, Inc.	Second Lien Term Loan, LIBOR+7.25% cash due 12/18/2028	10.92 %	Application Software	\$ 4,503	\$ 4,435	\$ 4,323	(4)
Pluralsight, LLC	First Lien Term Loan, LIBOR+8.00% cash due 4/6/2027	10.68 %	Application Software	6,796	6,694	6,582	(4)
Pluralsight, LLC	First Lien Revolver, LIBOR+8.00% cash due 4/6/2027		Application Software	—	(6)	(13)	(4)(5)
Total Pluralsight, LLC				6,796	6,688	6,569	
RevSpring, Inc.	First Lien Term Loan, LIBOR+4.00% cash due 10/11/2025	7.67 %	Commercial Printing	9,625	9,607	9,304	
Sabert Corporation	First Lien Term Loan, LIBOR+4.50% cash due 12/10/2026	7.63 %	Metal & Glass Containers	2,536	2,511	2,435	(4)
SHO Holding I Corporation	First Lien Term Loan, LIBOR+5.25% cash due 4/27/2024	8.06 %	Footwear	8,201	8,194	7,176	
SHO Holding I Corporation	First Lien Term Loan, LIBOR+5.23% cash due 4/27/2024	8.04 %	Footwear	138	138	121	
Total SHO Holding I Corporation				8,339	8,332	7,297	
Sorenson Communications, LLC	First Lien Term Loan, LIBOR+5.50% cash due 3/17/2026	9.17 %	Communications Equipment	2,553	2,528	2,454	
Spanx, LLC	First Lien Term Loan, LIBOR+5.25% cash due 11/20/2028	8.30 %	Apparel Retail	8,933	8,776	8,721	(4)
SPX Flow, Inc.	First Lien Term Loan, SOFR+4.50% cash due 4/5/2029	7.63 %	Industrial Machinery	7,500	7,184	6,966	(4)
Supermoose Borrower, LLC	First Lien Term Loan, LIBOR+3.75% cash due 8/29/2025	7.42 %	Application Software	7,743	7,479	6,827	(4)
Surgery Center Holdings, Inc.	First Lien Term Loan, LIBOR+3.75% cash due 8/31/2026	6.51 %	Health Care Facilities	3,377	3,365	3,213	
TIBCO Software Inc.	First Lien Term Loan, SOFR+4.50% cash due 3/20/2029	8.15 %	Application Software	6,256	5,693	5,629	(4)
Touchstone Acquisition, Inc.	First Lien Term Loan, LIBOR+6.00% cash due 12/29/2028	9.12 %	Health Care Supplies	7,285	7,155	7,140	(4)
Veritas US Inc.	First Lien Term Loan, LIBOR+5.00% cash due 9/1/2025	8.67 %	Application Software	6,365	6,290	5,087	
Windstream Services II, LLC	First Lien Term Loan, LIBOR+6.25% cash due 9/21/2027	9.37 %	Integrated Telecommunication Services	7,818	7,596	7,115	(4)
WP CPP Holdings, LLC	Second Lien Term Loan, LIBOR+7.75% cash due 4/30/2026	10.56 %	Aerospace & Defense	6,000	5,972	5,070	(4)
WP CPP Holdings, LLC	First Lien Term Loan, LIBOR+3.75% cash due 4/30/2025	6.56 %	Aerospace & Defense	1,985	1,910	1,783	(4)
Total WP CPP Holdings, LLC				7,985	7,882	6,853	
Zayo Group Holdings, Inc.	First Lien Term Loan, LIBOR+3.00% cash due 3/9/2027	6.12 %	Alternative Carriers	2,155	2,000	1,812	
Total Portfolio Investments				\$ 383,194	\$ 382,673	\$ 359,625	

(1) Represents the interest rate as of September 30, 2022. All interest rates are payable in cash, unless otherwise noted.

(2) The interest rate on the principal balance outstanding for most of the floating rate loans is indexed to LIBOR and/or an alternate base rate (e.g., prime rate), which typically resets semi-annually, quarterly, or monthly at the borrower's option. Certain loans may also be indexed to SOFR. The borrower may also elect to have multiple interest reset periods for each loan. For each of these loans, the Company has provided the applicable margin over the reference rates based on each respective credit agreement and the cash interest rate as of period end. All the LIBOR shown above is in U.S. dollars. As of September 30, 2022, the reference rates for SLF JV I's variable rate loans were the 30-day LIBOR at 3.12%, the 90-day LIBOR at 3.67%, the 30-day SOFR at 3.03%, the 90-day SOFR at 3.55% and the 180-day SOFR at 3.98%. Most loans include an interest floor, which generally ranges from 0% to 1%. SOFR based contracts may include a credit spread adjustment that is charged in addition to the base rate and the stated spread.

(3) Represents the current determination of fair value as of September 30, 2022 utilizing a similar technique as the Company in accordance with ASC 820. However, the determination of such fair value is not included in the valuation process described elsewhere herein.

(4) This investment was held by both the Company and SLF JV I as of September 30, 2022.

(5) Investment had undrawn commitments. Unamortized fees are classified as unearned income which reduces cost basis, which may result in a negative cost basis. A negative fair value may result from the unfunded commitment being valued below par.

OAKTREE SPECIALTY LENDING CORPORATION
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
(in thousands, except share and per share amounts, percentages and as otherwise indicated)

Both the cost and fair value of the Company's SLF JV I Notes were \$112.7 million as of December 31, 2022. Both the cost and fair value of the Company's SLF JV I Notes were \$96.3 million as of September 30, 2022. The Company earned interest income of \$2.6 million and \$2.0 million on the SLF JV I Notes for the three months ended December 31, 2022 and 2021, respectively. As of December 31, 2022, the SLF JV I Notes bore interest at a rate of one-month LIBOR plus 7.00% per annum with a LIBOR floor of 1.00% and will mature on December 29, 2028.

The cost and fair value of the LLC equity interests in SLF JV I held by the Company were \$54.8 million and \$24.1 million, respectively, as of December 31, 2022, and \$49.3 million and \$20.7 million, respectively, as of September 30, 2022. The Company earned \$1.1 million and \$0.5 million in dividend income for the three months ended December 31, 2022 and December 31, 2021, respectively, with respect to its investment in the LLC equity interests of SLF JV I. The LLC equity interests of SLF JV I are generally dividend producing to the extent SLF JV I has residual cash to be distributed on a quarterly basis.

Below is certain summarized financial information for SLF JV I as of December 31, 2022 and September 30, 2022 and for the three months ended December 31, 2022 and 2021:

	December 31, 2022	September 30, 2022
Selected Balance Sheet Information:		
Investments at fair value (cost December 31, 2022: \$380,682; cost September 30, 2022: \$382,673)	\$ 355,427	\$ 359,625
Cash and cash equivalents	39,259	14,274
Restricted cash	6,612	5,642
Other assets	8,106	5,686
Total assets	\$ 409,404	\$ 385,227
Senior credit facility payable	\$ 226,000	\$ 230,000
SLF JV I Notes payable at fair value (proceeds December 31, 2022: \$128,750; proceeds September 30, 2022: \$110,000)	128,750	110,000
Other liabilities	27,094	21,539
Total liabilities	\$ 381,844	\$ 361,539
Members' equity	27,560	23,688
Total liabilities and members' equity	\$ 409,404	\$ 385,227
	Three months ended	Three months ended
	December 31, 2022	December 31, 2021
Selected Statements of Operations Information:		
Interest income	\$ 8,781	\$ 5,423
Other income	—	11
Total investment income	8,781	5,434
Senior credit facility interest expense	3,709	1,514
SLF JV I Notes interest expense	2,982	2,249
Other expenses	69	79
Total expenses (1)	6,760	3,842
Net investment income	2,021	1,592
Net unrealized appreciation (depreciation)	(2,207)	(525)
Net realized gains (losses)	(992)	374
Net income (loss)	\$ (1,178)	\$ 1,441

(1) There are no management fees or incentive fees charged at SLF JV I.

SLF JV I has elected to fair value the SLF JV I Notes issued to the Company and Kemper under FASB ASC Topic 825, *Financial Instruments - Fair Value Option ("ASC 825")*. The SLF JV I Notes are valued based on the total assets less the total liabilities senior to the SLF JV I Notes in an amount not exceeding par under the EV technique.

During the three months ended December 31, 2022, the Company sold \$13.5 million of senior secured debt investments to SLF JV I for \$12.9 million cash consideration, which represented the fair value at the time of sale. A loss of \$0.1 million was recognized by the Company on these transactions. During the three months ended December 31, 2021, the Company sold \$9.7 million of senior secured debt investments to SLF JV I for \$9.7 million cash consideration, which represented the fair value at the time of sale. A gain of \$0.5 million was recognized by the Company on these transactions.

OAKTREE SPECIALTY LENDING CORPORATION
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
(in thousands, except share and per share amounts, percentages and as otherwise indicated)

OCSI Glick JV LLC

On March 19, 2021, the Company became party to the LLC agreement of Glick JV. The Company co-invests primarily in senior secured loans of middle-market companies with GF Equity Funding through the Glick JV. The Glick JV is managed by a four person Board of Directors, two of whom are selected by the Company and two of whom are selected by GF Equity Funding. The Glick JV is capitalized as transactions are completed, and portfolio decisions and investment decisions in respect of the Glick JV must be approved by the Glick JV investment committee, which consists of one representative selected by the Company and one representative selected by GF Equity Funding (with approval from a representative of each required). Since the Company does not have a controlling financial interest in the Glick JV, the Company does not consolidate the Glick JV.

The members provide capital to the Glick JV in exchange for LLC equity interests, and the Company and GF Debt Funding 2014 LLC ("GF Debt Funding"), an entity advised by affiliates of GF Equity Funding, provide capital to the Glick JV in exchange for subordinated notes issued by the Glick JV (the "Glick JV Notes"). As of December 31, 2022 and September 30, 2022, the Company and GF Equity Funding owned 87.5% and 12.5%, respectively, of the outstanding LLC equity interests, and the Company and GF Debt Funding owned 87.5% and 12.5%, respectively, of the Glick JV Notes. The Glick JV is not an "eligible portfolio company" as defined in section 2(a)(46) of the Investment Company Act.

The Glick JV has a senior revolving credit facility with Deutsche Bank AG, New York Branch (the "Glick JV Deutsche Bank Facility"), which, as of December 31, 2022, had a reinvestment period end date and maturity date of May 3, 2023 and May 3, 2028, respectively, and permitted borrowings of up to \$90.0 million (subject to borrowing base and other limitations). Borrowings under the Glick JV Deutsche Bank Facility are secured by all of the assets of the Glick JV and all of the equity interests in the Glick JV and, as of December 31, 2022, bore interest at a rate equal to 3-month LIBOR plus 2.25% per annum during the reinvestment period, 3-month LIBOR plus 2.40% for the first year after the end of the reinvestment period, 3-month LIBOR plus 2.50% for the following year and 3-month LIBOR plus 2.75% thereafter, in each case with a 0.125% LIBOR floor. \$76.1 million and \$82.1 million of borrowings were outstanding under the Glick JV Deutsche Bank Facility as of December 31, 2022 and September 30, 2022, respectively.

As of December 31, 2022 and September 30, 2022, the Glick JV had total assets of \$137.5 million and \$146.8 million, respectively. The Glick JV's portfolio consisted of middle-market and other corporate debt securities of 40 and 43 portfolio companies as of December 31, 2022 and September 30, 2022, respectively. The portfolio companies in the Glick JV are in industries similar to those in which the Company may invest directly. The Company's investment in the Glick JV consisted of LLC equity interests and Glick JV Notes of \$49.5 million and \$50.3 million in the aggregate at fair value as of December 31, 2022 and September 30, 2022, respectively. The Glick JV Notes are junior in right of payment to the repayment of temporary contributions made by the Company to fund investments of the Glick JV that are repaid when GF Equity Funding and GF Debt Funding make their capital contributions and fund their Glick JV Notes, respectively.

As of each of December 31, 2022 and September 30, 2022, the Glick JV had total capital commitments of \$100.0 million, \$87.5 million of which was from the Company and the remaining \$12.5 million of which was from GF Equity Funding and GF Debt Funding. Approximately \$84.0 million in aggregate commitments were funded as of each of December 31, 2022 and September 30, 2022, of which \$73.5 million was from the Company. As of each of December 31, 2022 and September 30, 2022, the Company had commitments to fund Glick JV Notes of \$78.8 million, of which \$12.4 million were unfunded. As of each of December 31, 2022 and September 30, 2022, the Company had commitments to fund LLC equity interests in the Glick JV of \$8.7 million, of which \$1.6 million were unfunded.

OAKTREE SPECIALTY LENDING CORPORATION
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
(in thousands, except share and per share amounts, percentages and as otherwise indicated)

Below is a summary of the Glick JV's portfolio, followed by a listing of the individual loans in the Glick JV's portfolio as of December 31, 2022 and September 30, 2022:

	December 31, 2022	September 30, 2022
Senior secured loans (1)	\$134,080	\$143,225
Weighted average current interest rate on senior secured loans (2)	9.86%	8.52%
Number of borrowers in the Glick JV	40	43
Largest loan exposure to a single borrower (1)	\$7,476	\$6,562
Total of five largest loan exposures to borrowers (1)	\$29,830	\$28,973

(1) At principal amount.

(2) Computed using the weighted average annual interest rate on accruing senior secured loans at fair value.

Glick JV Portfolio as of December 31, 2022

Portfolio Company	Investment Type	Cash Interest Rate (1)(2)	Industry	Principal	Cost	Fair Value (3)	Notes
ADB Companies, LLC	First Lien Term Loan, SOFR+6.25% cash due 12/18/2025	11.34%	Construction & Engineering	\$ 4,589	\$ 4,528	\$ 4,510	(4)
Alvogen Pharma Inc	First Lien Term Loan, SOFR+7.50% cash due 6/30/2025	12.23%	Pharmaceuticals	6,479	6,413	6,447	(4)
Alvogen Pharma Inc	First Lien Term Loan, LIBOR+4.00% cash due 6/9/2028	8.38%	Diversified Metals & Mining	997	918	941	
Total Alvogen Pharma Inc				7,476	7,331	7,388	
American Tire Distributors, Inc.	First Lien Term Loan, LIBOR+6.25% cash due 10/20/2028	10.61%	Distributors	2,882	2,846	2,652	(4)
Amplify Finco Pty Ltd.	First Lien Term Loan, LIBOR+4.25% cash due 11/26/2026	8.98%	Movies & Entertainment	2,918	2,888	2,813	(4)
Anastasia Parent, LLC	First Lien Term Loan, LIBOR+3.75% cash due 8/11/2025	8.48%	Personal Products	914	711	685	(4)
ASP-R-PAC Acquisition Co LLC	First Lien Revolver, LIBOR+6.00% cash due 12/29/2027		Paper Packaging	—	(3)	(8)	(5)
ASP-R-PAC Acquisition Co LLC	First Lien Term Loan, LIBOR+6.00% cash due 12/29/2027	10.38%	Paper Packaging	1,729	1,701	1,666	
Total ASP-R-PAC Acquisition Co LLC				1,729	1,698	1,658	
Astra Acquisition Corp.	First Lien Term Loan, LIBOR+5.25% cash due 10/25/2028	9.63%	Application Software	2,078	2,034	1,844	(4)
Asurion, LLC	First Lien Term Loan, SOFR+4.00% cash due 8/19/2028	8.68%	Property & Casualty Insurance	1,995	1,901	1,785	
Asurion, LLC	Second Lien Term Loan, LIBOR+5.25% cash due 1/20/2029	9.63%	Property & Casualty Insurance	2,423	2,220	1,898	
Total Asurion, LLC				4,418	4,121	3,683	
Aurora Lux Finco S.À.R.L.	First Lien Term Loan, LIBOR+6.00% cash due 12/24/2026	10.32%	Airport Services	3,647	3,595	3,468	(4)
BAART Programs, Inc.	First Lien Term Loan, LIBOR+5.00% cash due 6/11/2027	9.07%	Health Care Services	3,389	3,357	3,294	
BAART Programs, Inc.	First Lien Term Loan, LIBOR+5.00% cash due 6/11/2027	9.73%	Health Care Services	806	798	768	(4)(5)
Total BAART Programs, Inc.				4,195	4,155	4,062	
BYJU's Alpha, Inc.	First Lien Term Loan, LIBOR+6.00% cash due 11/24/2026	10.70%	Application Software	3,960	3,912	3,193	
Covetrus, Inc.	First Lien Term Loan, SOFR+5.00% cash due 9/20/2029	9.58%	Health Care Distributors	2,280	2,143	2,142	(4)
Curium Bidco S.à.r.l.	First Lien Term Loan, LIBOR+4.00% cash due 7/9/2026	8.73%	Biotechnology	2,863	2,842	2,806	
DirecTV Financing, LLC	First Lien Term Loan, LIBOR+5.00% cash due 8/2/2027	9.38%	Cable & Satellite	2,663	2,636	2,598	(4)
Domtar Corporation	First Lien Term Loan, LIBOR+5.50% cash due 11/30/2028	9.79%	Paper Products	2,497	2,472	2,397	
DTI Holdco, Inc.	First Lien Term Loan, SOFR+4.75% cash due 4/26/2029	8.84%	Research & Consulting Services	2,993	2,938	2,764	(4)

OAKTREE SPECIALTY LENDING CORPORATION
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
(in thousands, except share and per share amounts, percentages and as otherwise indicated)

<u>Portfolio Company</u>	<u>Investment Type</u>	<u>Cash Interest Rate (1)(2)</u>	<u>Industry</u>	<u>Principal</u>	<u>Cost</u>	<u>Fair Value (3)</u>	<u>Notes</u>
eResearch Technology, Inc.	First Lien Term Loan, LIBOR+4.50% cash due 2/4/2027	8.88%	Application Software	\$ 2,438	\$ 2,413	\$ 2,158	
Gibson Brands, Inc.	First Lien Term Loan, LIBOR+5.00% cash due 8/11/2028	9.13%	Leisure Products	3,960	3,920	2,930	
Harbor Purchaser Inc.	First Lien Term Loan, SOFR+5.25% cash due 4/9/2029	9.67%	Education Services	3,990	3,882	3,807	(4)
Indivior Finance S.À.R.L.	First Lien Term Loan, SOFR+5.25% cash due 6/30/2026	10.09%	Pharmaceuticals	3,940	3,884	3,881	
INW Manufacturing, LLC	First Lien Term Loan, LIBOR+5.75% cash due 3/25/2027	10.48%	Personal Products	2,344	2,293	2,004	(4)
Iris Holding, Inc.	First Lien Term Loan, SOFR+4.75% cash due 6/28/2028	8.94%	Metal & Glass Containers	1,995	1,849	1,819	
LaserAway Intermediate Holdings II, LLC	First Lien Term Loan, LIBOR+5.75% cash due 10/14/2027	9.76%	Health Care Services	3,960	3,897	3,891	
LTI Holdings, Inc.	First Lien Term Loan, LIBOR+3.50% cash due 9/6/2025	7.88%	Electronic Components	1,355	1,203	1,300	
MRI Software LLC	First Lien Revolver, LIBOR+5.50% cash due 2/10/2026		Application Software	—	(1)	(6)	(4)(5)
MRI Software LLC	First Lien Term Loan, LIBOR+5.50% cash due 2/10/2026	10.23%	Application Software	1,642	1,629	1,583	(4)
Total MRI Software LLC				1,642	1,628	1,577	
Northern Star Industries Inc.	First Lien Term Loan, LIBOR+4.50% cash due 3/31/2025	9.23%	Electrical Components & Equipment	5,239	5,230	5,082	
OEConnection LLC	First Lien Term Loan, SOFR+4.00% cash due 9/25/2026	8.42%	Application Software	3,878	3,861	3,705	(4)
Planview Parent, Inc.	First Lien Term Loan, LIBOR+4.00% cash due 12/17/2027	8.73%	Application Software	688	649	643	
Planview Parent, Inc.	Second Lien Term Loan, LIBOR+7.25% cash due 12/18/2028	11.98%	Application Software	2,842	2,799	2,551	(4)
Total Planview Parent, Inc.				3,530	3,448	3,194	
Pluralsight, LLC	First Lien Term Loan, LIBOR+8.00% cash due 4/6/2027	11.83%	Application Software	4,465	4,401	4,354	(4)
Pluralsight, LLC	First Lien Revolver, LIBOR+8.00% cash due 4/6/2027	12.36%	Application Software	158	153	150	(4)(5)
Total Pluralsight, LLC				4,623	4,554	4,504	
SHO Holding I Corporation	First Lien Term Loan, LIBOR+5.25% cash due 4/27/2024	9.66%	Footwear	6,078	6,068	4,710	
SHO Holding I Corporation	First Lien Term Loan, LIBOR+5.23% cash due 4/27/2024	9.64%	Footwear	102	102	89	
Total SHO Holding I Corporation				6,180	6,170	4,799	
Spanx, LLC	First Lien Term Loan, LIBOR+5.25% cash due 11/20/2028	9.64%	Apparel Retail	4,950	4,867	4,833	(4)
SPX Flow, Inc.	First Lien Term Loan, SOFR+4.50% cash due 4/5/2029	8.92%	Industrial Machinery	5,985	5,730	5,605	(4)
Supermoose Borrower, LLC	First Lien Term Loan, LIBOR+3.75% cash due 8/29/2025	8.48%	Application Software	2,813	2,714	2,436	(4)
Surgery Center Holdings, Inc.	First Lien Term Loan, LIBOR+3.75% cash due 8/31/2026	8.05%	Health Care Facilities	3,044	3,034	3,014	
TIBCO Software Inc.	First Lien Term Loan, SOFR+4.50% cash due 3/20/2029	9.18%	Application Software	2,654	2,423	2,377	(4)
Touchstone Acquisition, Inc.	First Lien Term Loan, LIBOR+6.00% cash due 12/29/2028	10.38%	Health Care Supplies	3,016	2,964	2,948	(4)
Tribe Buyer LLC	First Lien Term Loan, LIBOR+4.50% cash due 2/16/2024	8.88%	Human Resource & Employment Services	1,578	1,578	987	
Windstream Services II, LLC	First Lien Term Loan, SOFR+6.25% cash due 9/21/2027	10.67%	Integrated Telecommunication Services	4,874	4,742	4,433	(4)
WP CPP Holdings, LLC	Second Lien Term Loan, LIBOR+7.75% cash due 4/30/2026	12.17%	Aerospace & Defense	3,000	2,987	2,528	(4)
WP CPP Holdings, LLC	First Lien Term Loan, LIBOR+3.75% cash due 4/30/2025	8.17%	Aerospace & Defense	990	956	864	(4)
Total WP CPP Holdings, LLC				3,990	3,943	3,392	
Total Portfolio Investments				\$ 134,080	\$ 131,077	\$ 123,339	

OAKTREE SPECIALTY LENDING CORPORATION
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
(in thousands, except share and per share amounts, percentages and as otherwise indicated)

(1) Represents the interest rate as of December 31, 2022. All interest rates are payable in cash, unless otherwise noted.

(2) The interest rate on the principal balance outstanding for most of the floating rate loans is indexed to LIBOR and/or an alternate base rate (e.g., prime rate), which typically resets semi-annually, quarterly, or monthly at the borrower's option. Certain loans may also be indexed to SOFR. The borrower may also elect to have multiple interest reset periods for each loan. For each of these loans, the Company has provided the applicable margin over the reference rates based on each respective credit agreement and the cash interest rate as of period end. All LIBOR shown above is in U.S. dollars. As of December 31, 2022, the reference rates for the Glick JV's variable rate loans were the 30-day LIBOR at 4.38%, the 90-day LIBOR at 4.73%, the 30-day SOFR at 4.32% and the 90-day SOFR at 4.58%. Most loans include an interest floor, which generally ranges from 0% to 1%. SOFR based contracts may include a credit spread adjustment that is charged in addition to the base rate and the stated spread.

(3) Represents the current determination of fair value as of December 31, 2022 utilizing a similar technique as the Company in accordance with ASC 820. However, the determination of such fair value is not included in the valuation process described elsewhere herein.

(4) This investment was held by both the Company and the Glick JV as of December 31, 2022.

(5) Investment had undrawn commitments. Unamortized fees are classified as unearned income which reduces cost basis, which may result in a negative cost basis. A negative fair value may result from the unfunded commitment being valued below par.

Glick JV Portfolio as of September 30, 2022

<u>Portfolio Company</u>	<u>Investment Type</u>	<u>Cash Interest Rate (1)(2)</u>	<u>Industry</u>	<u>Principal</u>	<u>Cost</u>	<u>Fair Value (3)</u>	<u>Notes</u>
ADB Companies, LLC	First Lien Term Loan, SOFR+6.25% cash due 12/18/2025	9.80%	Construction & Engineering	\$ 4,647	\$ 4,579	\$ 4,567	(4)
Alvogen Pharma Inc	First Lien Term Loan, SOFR+7.50% cash due 6/30/2025	11.20%	Pharmaceuticals	6,562	6,489	6,529	(4)
American Tire Distributors, Inc.	First Lien Term Loan, LIBOR+6.25% cash due 10/20/2028	9.03%	Distributors	2,889	2,853	2,714	(4)
Amplify Finco Pty Ltd.	First Lien Term Loan, LIBOR+4.25% cash due 11/26/2026	7.92%	Movies & Entertainment	2,925	2,896	2,823	(4)
Anastasia Parent, LLC	First Lien Term Loan, LIBOR+3.75% cash due 8/11/2025	7.42%	Personal Products	917	712	734	(4)
ASP-R-PAC Acquisition Co LLC	First Lien Term Loan, LIBOR+6.00% cash due 12/29/2027	9.67%	Paper Packaging	1,734	1,704	1,694	
ASP-R-PAC Acquisition Co LLC	First Lien Revolver, LIBOR+6.00% cash due 12/29/2027		Paper Packaging	—	(4)	(5)	(5)
Total ASP-R-PAC Acquisition Co LLC				1,734	1,700	1,689	
Astra Acquisition Corp.	First Lien Term Loan, LIBOR+5.25% cash due 10/25/2028	8.37%	Application Software	2,078	2,033	1,777	(4)
Asurion, LLC	First Lien Term Loan, SOFR+4.00% cash due 8/19/2028	7.70%	Property & Casualty Insurance	2,000	1,901	1,711	
Asurion, LLC	Second Lien Term Loan, LIBOR+5.25% cash due 1/20/2029	8.37%	Property & Casualty Insurance	2,423	2,212	1,866	
Total Asurion, LLC				4,423	4,113	3,577	
Aurora Lux Finco S.À.R.L.	First Lien Term Loan, LIBOR+6.00% cash due 12/24/2026	8.78%	Airport Services	3,656	3,601	3,476	(4)
BAART Programs, Inc.	First Lien Term Loan, LIBOR+5.00% cash due 6/11/2027	8.12%	Health Care Services	3,398	3,366	3,279	
BAART Programs, Inc.	First Lien Delayed Draw Term Loan, LIBOR+5.00% cash due 6/11/2027	8.12%	Health Care Services	808	800	760	(4)(5)
Total BAART Programs, Inc.				4,206	4,166	4,039	
BYJU's Alpha, Inc.	First Lien Term Loan, LIBOR+6.00% cash due 11/24/2026	8.98%	Application Software	3,970	3,919	2,909	
CITGO Petroleum Corp.	First Lien Term Loan, LIBOR+6.25% cash due 3/28/2024	9.37%	Oil & Gas Refining & Marketing	3,519	3,484	3,529	(4)
City Football Group Limited	First Lien Term Loan, LIBOR+3.50% cash due 7/21/2028	6.48%	Movies & Entertainment	2,481	2,469	2,372	
Covetrus, Inc.	First Lien Term Loan, SOFR+5.00% cash due 9/20/2029	7.65%	Health Care Distributors	2,280	2,143	2,136	(4)
Curium Bidco S.à.r.l.	First Lien Term Loan, LIBOR+4.00% cash due 7/9/2026	7.67%	Biotechnology	2,870	2,849	2,756	
DirecTV Financing, LLC	First Lien Term Loan, LIBOR+5.00% cash due 8/2/2027	8.12%	Cable & Satellite	2,730	2,703	2,549	(4)
Domtar Corporation	First Lien Term Loan, LIBOR+5.50% cash due 11/30/2028	8.26%	Paper Products	2,503	2,478	2,394	
DTI Holdeo, Inc.	First Lien Term Loan, SOFR+4.75% cash due 4/26/2029	7.33%	Research & Consulting Services	3,000	2,943	2,856	(4)

OAKTREE SPECIALTY LENDING CORPORATION
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
(in thousands, except share and per share amounts, percentages and as otherwise indicated)

<u>Portfolio Company</u>	<u>Investment Type</u>	<u>Cash Interest Rate (1)(2)</u>	<u>Industry</u>	<u>Principal</u>	<u>Cost</u>	<u>Fair Value (3)</u>	<u>Notes</u>
Eagle Parent Corp.	First Lien Term Loan, SOFR+4.25% cash due 4/1/2029	7.80%	Industrial Machinery	\$ 2,488	\$ 2,429	\$ 2,426	
eResearch Technology, Inc.	First Lien Term Loan, LIBOR+4.50% cash due 2/4/2027	7.62%	Application Software	2,444	2,419	2,286	
Gibson Brands, Inc.	First Lien Term Loan, LIBOR+5.00% cash due 8/11/2028	7.94%	Leisure Products	3,970	3,930	3,216	
Harbor Purchaser Inc.	First Lien Term Loan, SOFR+5.25% cash due 4/9/2029	8.38%	Education Services	4,000	3,887	3,655	(4)
Indivior Finance S.À.R.L.	First Lien Term Loan, LIBOR+5.25% cash due 6/30/2026	8.80%	Pharmaceuticals	3,950	3,890	3,886	
INW Manufacturing, LLC	First Lien Term Loan, LIBOR+5.75% cash due 3/25/2027	9.42%	Personal Products	2,375	2,320	2,102	(4)
Iris Holding, Inc.	First Lien Term Loan, SOFR+4.75% cash due 6/28/2028	7.89%	Metal & Glass Containers	2,000	1,846	1,844	
LaserAway Intermediate Holdings II, LLC	First Lien Term Loan, LIBOR+5.75% cash due 10/14/2027	8.23%	Health Care Services	3,970	3,903	3,905	
LTI Holdings, Inc.	First Lien Term Loan, LIBOR+3.25% cash due 9/6/2025	6.37%	Electronic Components	1,358	1,192	1,260	
MRI Software LLC	First Lien Term Loan, LIBOR+5.50% cash due 2/10/2026	9.17%	Application Software	1,647	1,632	1,600	(4)
MRI Software LLC	First Lien Revolver, LIBOR+5.50% cash due 2/10/2026		Application Software	—	(1)	(4)	(4)(5)
Total MRI Software LLC				1,647	1,631	1,596	
Northern Star Industries Inc.	First Lien Term Loan, LIBOR+4.75% cash due 3/31/2025	7.87%	Electrical Components & Equipment	5,252	5,243	5,095	
OEConnection LLC	First Lien Term Loan, LIBOR+4.00% cash due 9/25/2026	7.12%	Application Software	3,888	3,871	3,752	(4)
Planview Parent, Inc.	Second Lien Term Loan, LIBOR+7.25% cash due 12/18/2028	10.92%	Application Software	2,842	2,799	2,728	(4)
Pluralsight, LLC	First Lien Term Loan, LIBOR+8.00% cash due 4/6/2027	10.68%	Application Software	4,465	4,398	4,325	(4)
Pluralsight, LLC	First Lien Revolver, LIBOR+8.00% cash due 4/6/2027		Application Software	—	(5)	(10)	(4)(5)
Total Pluralsight, LLC				4,465	4,393	4,315	
Sabert Corporation	First Lien Term Loan, LIBOR+4.50% cash due 12/10/2026	7.63%	Metal & Glass Containers	1,691	1,674	1,623	(4)
SHO Holding I Corporation	First Lien Term Loan, LIBOR+5.25% cash due 4/27/2024	8.06%	Footwear	6,094	6,082	5,332	
SHO Holding I Corporation	First Lien Term Loan, LIBOR+5.23% cash due 4/27/2024	8.04%	Footwear	102	102	90	
Total SHO Holding I Corporation				6,196	6,184	5,422	
Spanx, LLC	First Lien Term Loan, LIBOR+5.25% cash due 11/20/2028	8.30%	Apparel Retail	4,962	4,876	4,845	(4)
SPX Flow, Inc.	First Lien Term Loan, SOFR+4.50% cash due 4/5/2029	7.63%	Industrial Machinery	6,000	5,734	5,572	(4)
Supermoose Borrower, LLC	First Lien Term Loan, LIBOR+3.75% cash due 8/29/2025	7.42%	Application Software	2,820	2,712	2,487	(4)
Surgery Center Holdings, Inc.	First Lien Term Loan, LIBOR+3.75% cash due 8/31/2026	6.51%	Health Care Facilities	3,377	3,365	3,213	
TIBCO Software Inc.	First Lien Term Loan, SOFR+4.50% cash due 3/20/2029	8.15%	Application Software	2,654	2,415	2,388	(4)
Touchstone Acquisition, Inc.	First Lien Term Loan, LIBOR+6.00% cash due 12/29/2028	9.12%	Health Care Supplies	3,024	2,970	2,963	(4)
Tribe Buyer LLC	First Lien Term Loan, LIBOR+4.50% cash due 2/16/2024	7.62%	Human Resource & Employment Services	1,583	1,582	1,266	
Windstream Services II, LLC	First Lien Term Loan, LIBOR+6.25% cash due 9/21/2027	9.37%	Integrated Telecommunication Services	4,886	4,747	4,447	(4)
WP CPP Holdings, LLC	First Lien Term Loan, LIBOR+3.75% cash due 4/30/2025	6.56%	Aerospace & Defense	993	955	892	(4)
WP CPP Holdings, LLC	Second Lien Term Loan, LIBOR+7.75% cash due 4/30/2026	10.56%	Aerospace & Defense	3,000	2,986	2,534	(4)
Total WP CPP Holdings, LLC				3,993	3,941	3,426	
Total Portfolio Investments				\$ 143,225	\$ 140,083	\$ 133,144	

OAKTREE SPECIALTY LENDING CORPORATION
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
(in thousands, except share and per share amounts, percentages and as otherwise indicated)

(1) Represents the interest rate as of September 30, 2022. All interest rates are payable in cash, unless otherwise noted.

(2) The interest rate on the principal balance outstanding for most of the floating rate loans is indexed to LIBOR and/or an alternate base rate (e.g., prime rate), which typically resets semi-annually, quarterly, or monthly at the borrower's option. Certain loans may also be indexed to SOFR. The borrower may also elect to have multiple interest reset periods for each loan. For each of these loans, the Company has provided the applicable margin over the reference rates based on each respective credit agreement and the cash interest rate as of period end. All LIBOR shown above is in U.S. dollars. As of September 30, 2022, the reference rates for the Glick JV's variable rate loans were the 30-day LIBOR at 3.12%, the 90-day LIBOR at 3.67%, the 30-day SOFR at 3.03% and the 90-day SOFR at 3.55%. Most loans include an interest floor, which generally ranges from 0% to 1%. SOFR based contracts may include a credit spread adjustment that is charged in addition to the base rate and the stated spread.

(3) Represents the current determination of fair value as of September 30, 2022 utilizing a similar technique as the Company in accordance with ASC 820. However, the determination of such fair value is not included in the valuation process described elsewhere herein.

(4) This investment was held by both the Company and the Glick JV as of September 30, 2022.

(5) Investment had undrawn commitments. Unamortized fees are classified as unearned income which reduces cost basis, which may result in a negative cost basis. A negative fair value may result from the unfunded commitment being valued below par.

The cost and fair value of the Company's aggregate investment in the Glick JV was \$50.0 million and \$49.5 million, respectively, as of December 31, 2022. The cost and fair value of the Company's aggregate investment in the Glick JV was \$50.2 million and \$50.3 million, respectively, as of September 30, 2022. For the three months ended December 31, 2022 and December 31, 2021, the Company's investment in the Glick JV Notes earned interest income of \$1.6 million and \$1.1 million, respectively. The Company did not earn dividend income for the three months ended December 31, 2022 and December 31, 2021 with respect to its investment in the LLC equity interest of the Glick JV. As of December 31, 2022, the Glick JV Notes bore interest at a rate of one-month LIBOR plus 4.50% per annum and will mature on October 20, 2028.

Below is certain summarized financial information for the Glick JV as of December 31, 2022 and September 30, 2022 and for the three months ended December 31, 2022 and December 31, 2021:

	December 31, 2022	September 30, 2022
Selected Balance Sheet Information:		
Investments at fair value (cost December 31, 2022: \$131,077; September 30, 2022: \$140,083)	\$ 123,339	\$ 133,144
Cash and cash equivalents	9,777	7,021
Restricted cash	1,747	1,788
Other assets	2,592	4,855
Total assets	\$ 137,455	\$ 146,808
Senior credit facility payable	\$ 76,082	\$ 82,082
Glick JV Notes payable at fair value (proceeds December 31, 2022: \$67,485; September 30, 2022: \$68,185)	56,614	57,463
Other liabilities	4,759	7,263
Total liabilities	\$ 137,455	\$ 146,808
Members' equity	—	—
Total liabilities and members' equity	\$ 137,455	\$ 146,808
	For the three months ended December 31, 2022	For the three months ended December 31, 2021
Selected Statements of Operations Information:		
Interest income	\$ 3,403	\$ 2,160
Fee income	—	—
Total investment income	3,403	2,160
Senior credit facility interest expense	1,285	510
Glick JV Notes interest expense	1,324	818
Other expenses	53	39
Total expenses (1)	2,662	1,367
Net investment income	741	793
Net unrealized appreciation (depreciation)	(651)	(882)
Realized gain (loss)	(90)	89
Net income (loss)	\$ —	\$ —

(1) There are no management fees or incentive fees charged at the Glick JV.

OAKTREE SPECIALTY LENDING CORPORATION
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
(in thousands, except share and per share amounts, percentages and as otherwise indicated)

The Glick JV has elected to fair value the Glick JV Notes issued to the Company and GF Debt Funding under ASC 825. The Glick JV Notes are valued based on the total assets less the liabilities senior to the Glick JV Notes in an amount not exceeding par under the EV technique.

During the three months ended December 31, 2022 and 2021, the Company did not sell any debt investments to the Glick JV.

Note 4. Fee Income

For the three months ended December 31, 2022 and 2021, the Company recorded total fee income of \$2.0 million and \$0.9 million, respectively, of which \$0.2 million and \$0.2 million, respectively, was recurring in nature. Recurring fee income primarily consisted of servicing fees and certain exit fees.

Note 5. Share Data and Net Assets

The share and per share information disclosed in Note 5 have been retrospectively adjusted to reflect the Company's 1-for-3 reverse stock split completed on January 20, 2023 and effective as of the commencement of trading on January 23, 2023.

Earnings per Share

The following table sets forth the computation of basic and diluted earnings per share, pursuant to ASC Topic 260-10, *Earnings per Share*, for the three months ended December 31, 2022 and 2021:

<i>(Share amounts in thousands)</i>	Three months ended December 31, 2022	Three months ended December 31, 2021
Earnings (loss) per common share — basic and diluted:		
Net increase (decrease) in net assets resulting from operations	\$ 13,172	\$ 39,408
Weighted average common shares outstanding — basic and diluted	61,142	60,127
Earnings (loss) per common share — basic and diluted	\$ 0.22	\$ 0.66

Changes in Net Assets

The following table presents the changes in net assets for the three months ended December 31, 2022:

<i>(Share amounts in thousands)</i>	Common Stock		Additional paid-in- capital	Accumulated Overdistributed Earnings	Total Net Assets
	Shares	Par Value			
Balance as of September 30, 2022	61,125	\$ 611	\$ 1,827,721	\$ (582,769)	\$ 1,245,563
Net investment income	—	—	—	38,808	38,808
Net unrealized appreciation (depreciation)	—	—	—	(22,982)	(22,982)
Net realized gains (losses)	—	—	—	(3,203)	(3,203)
(Provision) benefit for taxes on realized and unrealized gains (losses)	—	—	—	549	549
Distributions to stockholders	—	—	—	(58,679)	(58,679)
Issuance of common stock under dividend reinvestment plan	95	1	1,932	—	1,933
Balance as of December 31, 2022	61,220	\$ 612	\$ 1,829,653	\$ (628,276)	\$ 1,201,989

OAKTREE SPECIALTY LENDING CORPORATION
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
(in thousands, except share and per share amounts, percentages and as otherwise indicated)

The following table presents the changes in net assets for the three months ended December 31, 2021:

	Common Stock		Additional paid-in-capital	Accumulated Overdistributed Earnings	Total Net Assets
	Shares	Par Value			
Balance as of September 30, 2021	60,120	\$ 601	\$ 1,805,557	\$ (493,335)	\$ 1,312,823
Net investment income	—	—	—	32,295	32,295
Net unrealized appreciation (depreciation)	—	—	—	(4,586)	(4,586)
Net realized gains (losses)	—	—	—	9,321	9,321
(Provision) benefit for taxes on realized and unrealized gains (losses)	—	—	—	2,378	2,378
Distributions to stockholders	—	—	—	(27,956)	(27,956)
Issuance of common stock under dividend reinvestment plan	36	1	785	—	786
Balance as of December 31, 2021	60,156	\$ 602	\$ 1,806,342	\$ (481,883)	\$ 1,325,061

Distributions

Distributions to common stockholders are recorded on the ex-dividend date. The amount to be paid out as a dividend is determined by the Board of Directors and is based on management's estimate of the Company's annual taxable income. Net realized capital gains, if any, may be distributed to stockholders or retained for reinvestment.

The Company has adopted a dividend reinvestment plan ("DRIP") that provides for reinvestment of any distributions the Company declares in cash on behalf of its stockholders, unless a stockholder elects to receive cash. As a result, if the Company's Board of Directors declares a cash distribution, then the Company's stockholders who have not "opted out" of the Company's DRIP will have their cash distribution automatically reinvested in additional shares of the Company's common stock, rather than receiving the cash distribution. If the Company's shares are trading at a premium to net asset value, the Company typically issues new shares to implement the DRIP with such shares issued at the greater of the most recently computed net asset value per share of common stock or 95% of the current market price per share of common stock on the payment date for such distribution. If the Company's shares are trading at a discount to net asset value, the Company typically purchases shares in the open market in connection with the Company's obligations under the DRIP.

For income tax purposes, the Company estimated its distributions for the 2022 calendar year will be composed primarily of ordinary income. The character of such distributions will be appropriately reported to the Internal Revenue Service and stockholders for the 2022 calendar year. To the extent the Company's taxable earnings for a fiscal and taxable year fall below the amount of distributions paid for the fiscal and taxable year, a portion of the total amount of the Company's distributions for the fiscal and taxable year is deemed a return of capital for U.S. federal income tax purposes to the Company's stockholders.

The following table reflects the distributions per share that the Company has paid, including shares issued under the DRIP, on its common stock during the three months ended December 31, 2022 and 2021:

Distribution	Date Declared	Record Date	Payment Date	Amount per Share	Cash Distribution	DRIP Shares Issued	DRIP Shares Value
Quarterly	November 10, 2022	December 15, 2022	December 30, 2022	\$ 0.54	\$ 32.0 million	53,369 (1)	\$ 1.1 million
Special	November 10, 2022	December 15, 2022	December 30, 2022	\$ 0.42	\$ 24.8 million	41,510 (1)	\$ 0.8 million
Total for the three months ended December 31, 2022				\$ 0.96	\$ 56.8 million	94,879	\$ 1.9 million
Distribution	Date Declared	Record Date	Payment Date	Amount per Share	Cash Distribution	DRIP Shares Issued	DRIP Shares Value
Quarterly	October 13, 2021	December 15, 2021	December 31, 2021	\$ 0.465	\$ 27.2 million	35,990 (1)	\$ 0.8 million
Total for the three months ended December 31, 2021				\$ 0.465	\$ 27.2 million	35,990	\$ 0.8 million

(1) New shares were issued and distributed.

Common Stock Issuances

During the three months ended December 31, 2022 and 2021, the Company issued of 94,879 and 35,990, respectively, of shares of common stock as part of the DRIP.

On February 7, 2022, the Company entered into an equity distribution agreement by and among the Company, Oaktree, Oaktree Administrator and Keefe, Bruyette & Woods, Inc., JMP Securities LLC, Raymond James & Associates, Inc. and

OAKTREE SPECIALTY LENDING CORPORATION
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
(in thousands, except share and per share amounts, percentages and as otherwise indicated)

SMBC Nikko Securities America, Inc., as placement agents, in connection with the issuance and sale by the Company of shares of common stock, having an aggregate offering price of up to \$125.0 million. Sales of the common stock may be made in negotiated transactions or transactions that are deemed to be "at the market," as defined in Rule 415 under the Securities Act of 1933, as amended, including sales made directly on the Nasdaq Global Select Market or similar securities exchanges or sales made to or through a market maker other than on an exchange, at prices related to the prevailing market prices or at negotiated prices.

In connection with the "at the market" offering, the Company did not issue or sell any shares of common stock during the three months ended December 31, 2022.

Note 6. Borrowings

Syndicated Facility

On November 30, 2017, the Company entered into a senior secured revolving credit facility (as amended and restated, the "Syndicated Facility") pursuant to a Senior Secured Revolving Credit Agreement with the lenders party thereto, ING Capital LLC, as administrative agent, ING Capital LLC, JPMorgan Chase Bank, N.A., BofA Securities, Inc. and MUFG Union Bank, N.A., as joint lead arrangers and joint bookrunners, and JPMorgan Chase Bank, N.A. and Bank of America, N.A., as syndication agents. The Syndicated Facility provides that the Company may use the proceeds of the loans and issuances of letters of credit under the Syndicated Facility for general corporate purposes, including acquiring and funding leveraged loans, mezzanine loans, high-yield securities, convertible securities, preferred stock, common stock and other investments. The Syndicated Facility further allows the Company to request letters of credit from ING Capital LLC, as the issuing bank.

As of December 31, 2022, the size of the Syndicated Facility was \$1.0 billion. In addition, pursuant to an "accordion" feature, the Company may increase the size of the facility to up to the greater of \$1.25 billion and the Company's net worth, as defined in the facility, under certain circumstances.

As of December 31, 2022, (i) the period during which the Company may make drawings will expire on May 4, 2025 and the maturity date is May 4, 2026 and (ii) the interest rate margin for (a) LIBOR loans (which may be 1-, 2-, 3- or 6-month, at the Company's option) was 2.00% and (b) alternate base rate loans was 1.00%.

The Syndicated Facility is secured by substantially all of the Company's assets (excluding, among other things, investments held in and by certain subsidiaries of the Company (including OCSL Senior Funding II LLC) or investments in certain portfolio companies of the Company) and guaranteed by certain subsidiaries of the Company. As of December 31, 2022, except for assets that were held by OCSL Senior Funding II LLC and certain immaterial subsidiaries, substantially all of the Company's assets are pledged as collateral under the Syndicated Facility.

The Syndicated Facility requires the Company to, among other things, (i) make representations and warranties regarding the collateral as well as each of the Company's portfolio companies' businesses, (ii) agree to certain indemnification obligations, and (iii) comply with various affirmative and negative covenants, reporting requirements and other customary requirements for similar revolving credit facilities, including covenants related to: (A) limitations on the incurrence of additional indebtedness and liens, (B) limitations on certain investments, (C) limitations on certain asset transfers and restricted payments, (D) maintaining a certain minimum stockholders' equity, (E) maintaining a ratio of total assets (less total liabilities) to total indebtedness, of the Company and its subsidiaries (subject to certain exceptions), of not less than 1.50 to 1.00, (F) maintaining a ratio of consolidated EBITDA to consolidated interest expense, of the Company and its subsidiaries (subject to certain exceptions), of not less than 2.25 to 1.00, (G) maintaining a minimum liquidity and net worth, and (H) limitations on the creation or existence of agreements that prohibit liens on certain properties of the Company and certain of its subsidiaries. The Syndicated Facility also includes usual and customary default provisions such as the failure to make timely payments under the facility, the occurrence of a change in control, and the failure by the Company to materially perform under the agreements governing the facility, which, if not complied with, could accelerate repayment under the facility. As of December 31, 2022, the Company was in compliance with all financial covenants under the Syndicated Facility. In addition to the asset coverage ratio described above, borrowings under the Syndicated Facility (and the incurrence of certain other permitted debt) are subject to compliance with a borrowing base that will apply different advance rates to different types of assets in the Company's portfolio. Each loan or letter of credit originated or assumed under the Syndicated Facility is subject to the satisfaction of certain conditions.

As of December 31, 2022 and September 30, 2022, the Company had \$695.0 million and \$540.0 million of borrowings outstanding under the Syndicated Facility, respectively, which had a fair value of \$695.0 million and \$540.0 million, respectively. The Company's borrowings under the Syndicated Facility bore interest at a weighted average interest rate of 5.849% and 2.174% for the three months ended December 31, 2022 and 2021, respectively. For the three months ended

OAKTREE SPECIALTY LENDING CORPORATION
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
(in thousands, except share and per share amounts, percentages and as otherwise indicated)

December 31, 2022 and 2021, the Company recorded interest expense (inclusive of fees) of \$10.0 million and \$3.8 million, respectively, related to the Syndicated Facility.

Citibank Facility

On March 19, 2021, the Company became party to a revolving credit facility (as amended and/or restated from time to time, the "Citibank Facility") with OCSL Senior Funding II LLC (formerly OCSI Senior Funding II LLC), the Company's wholly-owned, special purpose financing subsidiary, as the borrower, the Company, as collateral manager and seller, each of the lenders from time to time party thereto, Citibank, N.A., as administrative agent, and Wells Fargo Bank, National Association, as collateral agent and custodian.

As of December 31, 2022, the Company was able to borrow up to \$200 million under the Citibank Facility (subject to borrowing base and other limitations). As of December 31, 2022, the reinvestment period under the Citibank Facility was scheduled to expire on November 18, 2023 and the maturity date for the Citibank Facility was November 18, 2024.

As of December 31, 2022, borrowings under the Citibank Facility are subject to certain customary advance rates and accrue interest at a rate equal to LIBOR plus between 1.25% and 2.20% per annum on broadly syndicated loans, subject to observable market depth and pricing, and LIBOR plus 2.25% per annum on all other eligible loans during the reinvestment period. In addition, as of December 31, 2022, for the duration of the reinvestment period there is a non-usage fee payable of 0.50% per annum on the undrawn amount under the Citibank Facility. The minimum asset coverage ratio applicable to the Company under the Citibank Facility is 150% as determined in accordance with the requirements of the Investment Company Act. Borrowings under the Citibank Facility are secured by all of the assets of OCSL Senior Funding II LLC and all of the Company's equity interests in OCSL Senior Funding II LLC. The Company may use the Citibank Facility to fund a portion of its loan origination activities and for general corporate purposes. Each loan origination under the Citibank Facility is subject to the satisfaction of certain conditions.

As of December 31, 2022 and September 30, 2022, the Company had \$165.0 million and \$160.0 million outstanding under the Citibank Facility, respectively, which had a fair value of \$165.0 million and \$160.0 million, respectively. The Company's borrowings under the Citibank Facility bore interest at a weighted average interest rate of 6.508% and 1.830% for the three months ended December 31, 2022 and 2021, respectively. For the three months ended December 31, 2022 and 2021, the Company recorded interest expense (inclusive of fees) of \$2.7 million and \$0.8 million, respectively, related to the Citibank Facility.

2025 Notes

On February 25, 2020, the Company issued \$300.0 million in aggregate principal amount of the 2025 Notes for net proceeds of \$293.8 million after deducting OID of \$2.5 million, underwriting commissions and discounts of \$3.0 million and offering costs of \$0.7 million. The OID on the 2025 Notes is amortized based on the effective interest method over the term of the 2025 Notes.

The 2025 Notes were issued pursuant to an indenture, dated April 30, 2012, as supplemented by the fifth supplemental indenture, dated February 25, 2020 (collectively, the "2025 Notes Indenture"), between the Company and Deutsche Bank Trust Company Americas (the "Trustee"). The 2025 Notes are the Company's general unsecured obligations that rank senior in right of payment to all of the Company's existing and future indebtedness that is expressly subordinated in right of payment to the 2025 Notes. The 2025 Notes rank equally in right of payment with all of the Company's existing and future liabilities that are not so subordinated. The 2025 Notes effectively rank junior to any of the Company's secured indebtedness (including unsecured indebtedness that the Company later secures) to the extent of the value of the assets securing such indebtedness. The 2025 Notes rank structurally junior to all existing and future indebtedness (including trade payables) incurred by the Company's subsidiaries, financing vehicles or similar facilities.

Interest on the 2025 Notes is paid semi-annually on February 25 and August 25 at a rate of 3.500% per annum. The 2025 Notes mature on February 25, 2025 and may be redeemed in whole or in part at any time or from time to time at the Company's option prior to maturity at par plus a "make-whole" premium, if applicable. In addition, holders of the 2025 Notes can require the Company to repurchase the 2025 Notes at 100% of their principal amount upon the occurrence of certain change of control events as described in the 2025 Notes Indenture. The 2025 Notes were issued in minimum denominations of \$2,000 and integral multiples of \$1,000 in excess thereof. During the three months ended December 31, 2022, the Company did not repurchase any of the 2025 Notes in the open market.

The 2025 Notes Indenture contains certain covenants, including covenants requiring the Company's compliance with the asset coverage requirements set forth in Section 18(a)(1)(A) as modified by Section 61(a)(1) and (2) of the Investment Company Act or any successor provisions (but giving effect to any exemptive relief granted to the Company by the U.S. Securities and Exchange Commission ("SEC")), as well as covenants requiring the Company to provide financial information to

OAKTREE SPECIALTY LENDING CORPORATION
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
(in thousands, except share and per share amounts, percentages and as otherwise indicated)

the holders of the 2025 Notes and the Trustee if the Company ceases to be subject to the reporting requirements of the Securities Exchange Act of 1934, as amended (the "Exchange Act"). These covenants are subject to limitations and exceptions that are described in the 2025 Notes Indenture.

2027 Notes

On May 18, 2021, the Company issued \$350.0 million in aggregate principal amount of the 2027 Notes for net proceeds of \$344.8 million after deducting OID of \$1.0 million, underwriting commissions and discounts of \$3.5 million and offering costs of \$0.7 million. The OID on the 2027 Notes is amortized based on the effective interest method over the term of the 2027 Notes.

The 2027 Notes were issued pursuant to an indenture, dated April 30, 2012, as supplemented by the sixth supplemental indenture, dated May 18, 2021 (collectively, the "2027 Notes Indenture"), between the Company and the Trustee. The 2027 Notes are the Company's general unsecured obligations that rank senior in right of payment to all of the Company's existing and future indebtedness that is expressly subordinated in right of payment to the 2027 Notes. The 2027 Notes rank equally in right of payment with all of the Company's existing and future liabilities that are not so subordinated. The 2027 Notes effectively rank junior to any of the Company's secured indebtedness (including unsecured indebtedness that the Company later secures) to the extent of the value of the assets securing such indebtedness. The 2027 Notes rank structurally junior to all existing and future indebtedness (including trade payables) incurred by the Company's subsidiaries, financing vehicles or similar facilities.

Interest on the 2027 Notes is paid semi-annually on January 15 and July 15, beginning on January 15, 2022, at a rate of 2.700% per annum. The 2027 Notes mature on January 15, 2027 and may be redeemed in whole or in part at any time or from time to time at the Company's option prior to maturity at par plus a "make-whole" premium, if applicable. In addition, holders of the 2027 Notes can require the Company to repurchase the 2027 Notes at 100% of their principal amount upon the occurrence of certain change of control events as described in the 2027 Notes Indenture. The 2027 Notes were issued in minimum denominations of \$2,000 and integral multiples of \$1,000 in excess thereof. During the three months ended December 31, 2022, the Company did not repurchase any of the 2027 Notes in the open market.

The 2027 Notes Indenture contains certain covenants, including covenants requiring the Company's compliance with the asset coverage requirements set forth in Section 18(a)(1)(A) as modified by Section 61(a)(1) and (2) of the Investment Company Act or any successor provisions (but giving effect to any exemptive relief granted to the Company by the SEC), as well as covenants requiring the Company to provide financial information to the holders of the 2027 Notes and the Trustee if the Company ceases to be subject to the reporting requirements of the Exchange Act. These covenants are subject to limitations and exceptions that are described in the 2027 Notes Indenture.

In connection with the 2027 Notes, the Company entered into an interest rate swap to more closely align the interest rates of its liabilities with its investment portfolio, which consists of predominately floating rate loans. Under the interest rate swap agreement, the Company receives a fixed interest rate of 2.700% and pays a floating interest rate of the three-month LIBOR plus 1.658% on a notional amount of \$350 million. The Company designated the interest rate swap as the hedging instrument in an effective hedge accounting relationship. See Note 12 for more information regarding the interest rate swap.

OAKTREE SPECIALTY LENDING CORPORATION
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
(in thousands, except share and per share amounts, percentages and as otherwise indicated)

The below table presents the components of the carrying value of the 2025 Notes and the 2027 Notes as of December 31, 2022 and September 30, 2022:

(\$ in millions)	As of December 31, 2022		As of September 30, 2022	
	2025 Notes	2027 Notes	2025 Notes	2027 Notes
Principal	\$ 300.0	\$ 350.0	\$ 300.0	\$ 350.0
Unamortized financing costs	(1.6)	(3.1)	(1.8)	(3.2)
Unaccreted discount	(1.1)	(0.7)	(1.2)	(0.7)
Interest rate swap fair value adjustment	—	(39.9)	—	(42.0)
Net carrying value	\$ 297.3	\$ 306.3	\$ 297.0	\$ 304.1
Fair Value	\$ 286.7	\$ 296.8	\$ 283.1	\$ 294.0

The below table presents the components of interest and other debt expenses related to the 2025 Notes and the 2027 Notes for the three months ended December 31, 2022:

(\$ in millions)	2025 Notes	2027 Notes
Coupon interest	\$ 2.6	\$ 2.4
Amortization of financing costs and discount	0.3	0.2
Effect of interest rate swap	—	2.5
Total interest expense	\$ 2.9	\$ 5.1
Coupon interest rate (net of effect of interest rate swap for 2027 Notes)	3.500 %	5.586 %

The below table presents the components of interest and other debt expenses related to the 2025 Notes and the 2027 Notes for the three months ended December 31, 2021:

(\$ in millions)	2025 Notes	2027 Notes
Coupon interest	\$ 2.6	\$ 2.4
Amortization of financing costs and discount	0.3	0.2
Effect of interest rate swap	—	(0.7)
Total interest expense	\$ 2.9	\$ 1.9
Coupon interest rate (net of effect of interest rate swap for 2027 Notes)	3.500 %	1.782 %

Note 7. Taxable/Distributable Income and Dividend Distributions

Taxable income differs from net increase (decrease) in net assets resulting from operations primarily due to: (1) unrealized appreciation (depreciation) on investments and foreign currency, as gains and losses are not included in taxable income until they are realized; (2) origination and exit fees received in connection with investments in portfolio companies; (3) organizational costs; (4) income or loss recognition on exited investments; and (5) recognition of interest income on certain loans.

As of September 30, 2022, the Company had net capital loss carryforwards of \$523.7 million to offset net capital gains that will not expire, to the extent available and permitted by U.S. federal income tax law, of which \$64.5 million are available to offset future short-term capital gains and \$459.2 million are available to offset future long-term capital gains. A portion of such net capital loss carryforwards represented a realized loss under sections 382 and 383 of the Code, which is carried forward to future years to offset future gains subject to certain limitations.

OAKTREE SPECIALTY LENDING CORPORATION
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
(in thousands, except share and per share amounts, percentages and as otherwise indicated)

Listed below is a reconciliation of "net increase (decrease) in net assets resulting from operations" to taxable income for the three months ended December 31, 2022 and 2021.

	Three months ended December 31, 2022	Three months ended December 31, 2021
Net increase (decrease) in net assets resulting from operations	\$ 13,172	\$ 39,408
Net unrealized (appreciation) depreciation	22,982	4,586
Book/tax difference due to organizational costs	—	(22)
Book/tax difference due to capital losses utilized	8,013	(10,531)
Other book/tax differences	(12,910)	(11,171)
Taxable/Distributable Income (1)	\$ 31,257	\$ 22,270

(1) The Company's taxable income for the three months ended December 31, 2022 is an estimate and will not be finally determined until the Company files its tax return for the fiscal year ending September 30, 2023. Therefore, the final taxable income may be different than the estimate.

The Company uses the liability method to account for its taxable subsidiaries' income taxes. Using this method, the Company recognizes deferred tax assets and liabilities for the estimated future tax effects attributable to temporary differences between financial reporting and tax bases of assets and liabilities. In addition, the Company recognizes deferred tax benefits associated with net loss carry forwards that it may use to offset future tax obligations. The Company measures deferred tax assets and liabilities using the enacted tax rates expected to apply to taxable income in the years in which it expects to recover or settle those temporary differences.

When assessing the realizability of deferred tax assets, the Company considers whether it is probable that some or all of the deferred tax assets will not be realized. In determining whether the deferred tax assets are realizable, the Company considers the period of expiration of the tax asset, historical and projected taxable income and tax liabilities for the tax jurisdiction in which the tax asset is located. The deferred tax asset recognized by the Company, as it relates to the higher tax basis in the carrying value of certain assets compared to the book basis of those assets, will be recognized in future years by these taxable entities. Deferred tax assets are based on the amount of the tax benefit that the Company's management has determined is more likely than not to be realized in future periods. In determining the realizability of this tax benefit, management considered numerous factors that will give rise to pre-tax income in future periods. Among these are the historical and expected future book and tax basis pre-tax income of the Company and unrealized gains in the Company's assets at the determination date. Based on these and other factors, the Company determined that, as of December 31, 2022, \$11.4 million of the \$13.1 million deferred tax assets would not more likely than not be realized in future periods. As of December 31, 2022, the Company recorded a net deferred tax asset of \$1.7 million on the Consolidated Statements of Assets and Liabilities.

For the three months ended December 31, 2022, the Company recognized a total benefit for income tax related to realized and unrealized losses of \$0.5 million, which was primarily all current income tax benefit.

For the three months ended December 31, 2021, the Company recognized a total benefit for income tax related to realized and unrealized losses of \$2.4 million, which was composed of (i) a current income tax benefit of approximately \$1.4 million, and (ii) a deferred income tax benefit of approximately \$1.0 million, which resulted from unrealized depreciation on investments held by the Company's wholly-owned taxable subsidiaries. For the three months ended December 31, 2021, the Company recognized a provision for income tax related to net investment income of \$3.3 million, which was all current income tax expense.

As of September 30, 2022, the Company's last tax year end, the components of accumulated overdistributed earnings on a tax basis were as follows:

Undistributed ordinary income, net	\$ (43,624)
Net realized capital losses	473,274
Unrealized losses, net	153,119
Accumulated overdistributed earnings	\$ 582,769

The aggregate cost of investments for U.S. federal income tax purposes was \$2,654.3 million as of September 30, 2022. As of September 30, 2022, the aggregate gross unrealized appreciation for all investments in which there was an excess of value over cost for U.S. federal income tax purposes was \$466.9 million. As of September 30, 2022, the aggregate gross unrealized depreciation for all investments in which there was an excess of cost for U.S. federal income tax purposes over value was

OAKTREE SPECIALTY LENDING CORPORATION
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
(in thousands, except share and per share amounts, percentages and as otherwise indicated)

\$620.0 million. Net unrealized depreciation based on the aggregate cost of investments for U.S. federal income tax purposes was \$153.1 million.

Note 8. Realized Gains or Losses and Net Unrealized Appreciation or Depreciation

Realized Gains or Losses

Realized gains or losses are measured by the difference between the net proceeds from the sale or redemption and the cost basis of the investment without regard to unrealized appreciation or depreciation previously recognized, and include investments written-off during the period, net of recoveries. Realized losses may also be recorded in connection with the Company's determination that certain investments are considered worthless securities and/or meet the conditions for loss recognition per the applicable tax rules.

During the three months ended December 31, 2022, the Company recorded an aggregate net realized loss of \$3.2 million, which consisted of the following:

(\$ in millions)	
Portfolio Company	Net Realized Gain (Loss)
Foreign currency forward contracts	\$ 4.4
Carvana Co.	(2.8)
ASP Unifrax Holdings Inc.	(2.1)
Global Medical Response Inc.	(1.0)
Other, net	(1.7)
Total, net	\$ (3.2)

During the three months ended December 31, 2021, the Company recorded an aggregate net realized gain of \$9.3 million, which consisted of the following:

(\$ in millions)	
Portfolio Company	Net Realized Gain (Loss)
Foreign currency forward contracts	\$ 3.0
OmniSYS Acquisition Corporation	2.0
First Star Speir Aviation Limited	1.9
Other, net	2.4
Total, net	\$ 9.3

Net Unrealized Appreciation or Depreciation

Net unrealized appreciation or depreciation reflects the net change in the valuation of the portfolio pursuant to the Company's valuation guidelines and the reclassification of any prior period unrealized appreciation or depreciation.

During the three months ended December 31, 2022 and 2021, the Company recorded net unrealized depreciation of \$23.0 million and \$4.6 million, respectively. For the three months ended December 31, 2022, this consisted of \$18.7 million of net unrealized depreciation on debt investments and \$11.0 million of net unrealized depreciation of foreign currency forward contracts, partially offset by \$3.9 million of net unrealized appreciation related to exited investments (a portion of which resulted in a reclassification to realized losses) and \$2.8 million of net unrealized appreciation on equity investments. For the three months ended December 31, 2021, this consisted of \$4.7 million of net unrealized depreciation related to exited investments (a portion of which resulted in a reclassification to realized gains), \$1.8 million of net unrealized depreciation on debt investments and \$0.8 million of net unrealized depreciation of foreign currency forward contracts, partially offset by \$2.8 million of net unrealized appreciation on equity investments.

Note 9. Concentration of Credit Risks

The Company deposits its cash with financial institutions and at times such balances may be in excess of the FDIC insurance limit. The Company limits its exposure to credit loss by depositing its cash with high credit quality financial institutions and monitoring their financial stability.

Note 10. Related Party Transactions

As of December 31, 2022 and September 30, 2022, the Company had a liability on its Consolidated Statements of Assets and Liabilities in the amount of \$16.9 million and \$15.9 million, respectively, reflecting the unpaid portion of the base management fees and incentive fees payable to Oaktree.

Investment Advisory Agreement

The Company is party to the Investment Advisory Agreement. Under the Investment Advisory Agreement, the Company pays Oaktree a fee for its services under the Investment Advisory Agreement consisting of two components: a base management fee and an incentive fee. The cost of both the base management fee payable to Oaktree and any incentive fees earned by Oaktree is ultimately borne by common stockholders of the Company.

From October 17, 2017 through May 3, 2020, the Company was externally managed by OCM pursuant to an investment advisory agreement. On May 4, 2020, OCM effected the novation of such investment advisory agreement to Oaktree. Immediately following such novation, the Company and Oaktree entered into a new investment advisory agreement with the same terms, including fee structure, as the investment advisory agreement with OCM. The investment advisory agreement with Oaktree was subsequently amended and restated on March 19, 2021 in connection with the closing of the OCSI Merger and on January 23, 2023 in connection with the OSI2 Merger. The term "Investment Advisory Agreement" refers collectively to the agreements with Oaktree and, prior to its novation, with OCM.

Unless earlier terminated as described below, the Investment Advisory Agreement will remain in effect from year-to-year if approved annually by the Board of Directors of the Company or by the affirmative vote of the holders of a majority of the Company's outstanding voting securities, including, in either case, approval by a majority of the directors of the Company who are not interested persons. The Investment Advisory Agreement will automatically terminate in the event of its assignment. The Investment Advisory Agreement may be terminated by either party without penalty upon 60 days' written notice to the other. The Investment Advisory Agreement may also be terminated, without penalty, upon the vote of a majority of the outstanding voting securities of the Company.

Base Management Fee

Under the Investment Advisory Agreement, the base management fee is calculated at an annual rate of 1.50% of total gross assets, including any investment made with borrowings, but excluding cash and cash equivalents. The base management fee is payable quarterly in arrears and the fee for any partial month or quarter is appropriately prorated. Effective May 3, 2019, the base management fee on the Company's gross assets, including any investments made with borrowings, but excluding any cash and cash equivalents, that exceed the product of (A) 200% and (B) the Company's net asset value will be 1.00%. For the avoidance of doubt, the 200% will be calculated in accordance with the Investment Company Act and will give effect to exemptive relief the Company received from the SEC with respect to debentures issued by a small business investment company subsidiary. In connection with the OCSI Merger, Oaktree waived an aggregate of \$6 million of base management fees otherwise payable to Oaktree in the two years following the closing of the OCSI Merger on March 19, 2021 at a rate of \$750,000 per quarter (with such amount appropriately prorated for any partial quarter). In connection with the OSI2 Merger, Oaktree waived an aggregate of \$9.0 million of base management fees payable to Oaktree as follows: \$6.0 million at a rate of \$1.5 million per quarter (with such amount appropriately prorated for any partial quarter) in the first year following closing of the OSI2 Merger on January 23, 2023 and \$3.0 million at a rate of \$750,000 per quarter (with such amount appropriately prorated for any partial quarter) in the second year following closing of the OSI2 Merger.

For the three months ended December 31, 2022 and 2021, the base management fee incurred under the Investment Advisory Agreement was \$9.2 million (net of waiver) and \$9.2 million (net of waiver), respectively.

Incentive Fee

The incentive fee consists of two parts. Under the Investment Advisory Agreement, the first part of the incentive fee (the "incentive fee on income" or "Part I incentive fee") is calculated and payable quarterly in arrears based upon the "pre-incentive fee net investment income" of the Company for the immediately preceding quarter. The payment of the incentive fee on income

OAKTREE SPECIALTY LENDING CORPORATION
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
(in thousands, except share and per share amounts, percentages and as otherwise indicated)

is subject to payment of a preferred return to investors each quarter (i.e., a “hurdle rate”), expressed as a rate of return on the value of the Company’s net assets at the end of the most recently completed quarter, of 1.50%, subject to a “catch up” feature.

For this purpose, “pre-incentive fee net investment income” means interest income, dividend income and any other income (including any other fees such as commitment, origination, structuring, diligence and consulting fees or other fees that the Company receives from portfolio companies, other than fees for providing managerial assistance) accrued during the fiscal quarter, minus the Company’s operating expenses for the quarter (including the base management fee, expenses payable under the Administration Agreement and any interest expense and dividends paid on any issued and outstanding preferred stock, but excluding the incentive fee). Pre-incentive fee net investment income includes, in the case of investments with a deferred interest feature (such as OID debt, instruments with PIK interest and zero coupon securities), accrued income that the Company has not yet received in cash. Pre-incentive fee net investment income does not include any realized capital gains, realized capital losses or unrealized capital appreciation or depreciation. In addition, pre-incentive fee net investment income does not include any amortization or accretion of any purchase premium or purchase discount to interest income resulting solely from merger-related accounting adjustments in connection with the assets acquired in the OCSI Merger or in the OSI2 Merger, in each case, including any premium or discount paid for the acquisition of such assets, solely to the extent that the inclusion of such merger-related accounting adjustments, in the aggregate, would result in an increase in pre-incentive fee net investment income.

Under the Investment Advisory Agreement, the calculation of the incentive fee on income for each quarter is as follows:

- No incentive fee is payable to Oaktree in any quarter in which the Company’s pre-incentive fee net investment income does not exceed the preferred return rate of 1.50% (the “preferred return”) on net assets;
- 100% of the Company’s pre-incentive fee net investment income, if any, that exceeds the preferred return but is less than or equal to 1.8182% in any fiscal quarter is payable to Oaktree. This portion of the incentive fee on income is referred to as the “catch-up” provision, and it is intended to provide Oaktree with an incentive fee of 17.5% on all of the Company’s pre-incentive fee net investment income when the Company’s pre-incentive fee net investment income exceeds 1.8182% on net assets in any fiscal quarter; and
- For any quarter in which the Company’s pre-incentive fee net investment income exceeds 1.8182% on net assets, the incentive fee on income is equal to 17.5% of the amount of the Company’s pre-incentive fee net investment income, as the preferred return and catch-up will have been achieved.

There is no accumulation of amounts on the hurdle rate from quarter to quarter and accordingly there is no clawback of amounts previously paid if subsequent quarters are below the quarterly hurdle.

For the three months ended December 31, 2022 and 2021, the first part of the incentive fee (incentive fee on income) incurred under the Investment Advisory Agreement was \$7.7 million and \$6.5 million, respectively.

Under the Investment Advisory Agreement, the second part of the incentive fee (the “capital gains incentive fee”) is determined and payable in arrears as of the end of each fiscal year (or upon termination of the Investment Advisory Agreement, as of the termination date) commencing with the fiscal year ended September 30, 2019 and equals 17.5% of the Company’s realized capital gains, if any, on a cumulative basis from the beginning of the fiscal year ended September 30, 2019 through the end of each subsequent fiscal year, computed net of all realized capital losses and unrealized capital depreciation on a cumulative basis, less the aggregate amount of any previously paid capital gain incentive fees under the Investment Advisory Agreement. Any realized capital gains, realized capital losses, unrealized capital appreciation and unrealized capital depreciation with respect to the Company’s portfolio as of the end of the fiscal year ended September 30, 2018 are excluded from the calculations of the second part of the incentive fee. In addition, the calculation of realized capital gains, realized capital losses and unrealized capital depreciation does (1) not include any such amounts resulting solely from merger-related accounting adjustments in connection with the assets acquired in the OCSI Merger or in the OSI2 Merger, in each case, including any premium or discount paid for the acquisition of such assets, solely to the extent that the inclusion of such merger-related accounting adjustments, in the aggregate, would result in an increase in the capital gains incentive fee, (2) include any such amounts associated with the investments acquired in the OCSI Merger for the period from October 1, 2018 to the date of closing of the OCSI Merger, solely to the extent that the exclusion of such amounts, in the aggregate, would result in an increase in the capital gains incentive fee and (3) include any such amounts associated with the investments acquired in the OSI2 Merger for the period from August 6, 2018 to the date of closing of the OSI2 Merger, solely to the extent that the exclusion of such amounts, in the aggregate, would result in an increase in the capital gains incentive fee. As of December 31, 2022, the Company paid \$9.6 million of capital gains incentive fees cumulatively under the Investment Advisory Agreement (net of waivers). Part II incentive fees are contractually calculated and paid at the end of the fiscal year in accordance with the Investment Advisory Agreement, which, as described above, differs from Part II incentive fees accrued under GAAP. Hypothetically, if Part II incentive fees were calculated as of December 31, 2022 under the Investment Advisory Agreement, no Part II incentive fees would be payable.

OAKTREE SPECIALTY LENDING CORPORATION
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
(in thousands, except share and per share amounts, percentages and as otherwise indicated)

GAAP requires that the capital gains incentive fee accrual consider the cumulative aggregate unrealized capital appreciation in the calculation, as a capital gains incentive fee would be payable if such unrealized capital appreciation were realized on a theoretical "liquidation basis." A fee so calculated and accrued would not be payable under applicable law and may never be paid based upon the computation of capital gains incentive fees in subsequent periods. Amounts ultimately paid under the Investment Advisory Agreement will be consistent with the formula reflected in the Investment Advisory Agreement. This GAAP accrual is calculated using the aggregate cumulative realized capital gains and losses and aggregate cumulative unrealized capital depreciation included in the calculation of the capital gains incentive fee plus the aggregate cumulative unrealized capital appreciation. Any realized capital gains and losses and cumulative unrealized capital appreciation and depreciation with respect to the Company's portfolio as of the end of the fiscal year ended September 30, 2018 are excluded from the GAAP accrual. If such amount is positive at the end of a period, then GAAP requires the Company to record a capital gains incentive fee equal to 17.5% of such cumulative amount, less the aggregate amount of actual capital gains incentive fees payable or capital gains incentive fees accrued under GAAP in all prior periods. The resulting accrual for any capital gains incentive fee under GAAP in a given period may result in an additional expense if such cumulative amount is greater than in the prior period or a reversal of previously recorded expense if such cumulative amount is less than in the prior period. If such cumulative amount is negative, then there is no accrual. There can be no assurance that such unrealized capital appreciation will be realized in the future or any accrued capital gains incentive fee will become payable under the Investment Advisory Agreement. For the three months ended December 31, 2022, there were no accrued capital gains incentive fees. For the three months ended December 31, 2021, \$1.8 million of accrued capital gains incentive fees were expensed. As of December 31, 2022, the total accrued capital gains incentive fee liability was zero.

Indemnification

The Investment Advisory Agreement provides that, absent willful misfeasance, bad faith or gross negligence in the performance of their respective duties or by reason of the reckless disregard of their respective duties and obligations, Oaktree and its officers, managers, partners, members (and their members, including the owners of their members), agents, employees, controlling persons and any other person or entity affiliated with it, are entitled to indemnification from the Company for any damages, liabilities, costs and expenses (including reasonable attorneys' fees and amounts reasonably paid in settlement) arising from the rendering of Oaktree's services under the Investment Advisory Agreement or otherwise as investment adviser.

Administrative Services

The Company is party to the Administration Agreement with Oaktree Administrator. Pursuant to the Administration Agreement, Oaktree Administrator provides administrative services to the Company necessary for the operations of the Company, which include providing office facilities, equipment, clerical, bookkeeping and record keeping services at such facilities and such other services as Oaktree Administrator, subject to review by the Company's Board of Directors, shall from time to time deem to be necessary or useful to perform its obligations under the Administration Agreement. Oaktree Administrator may, on behalf of the Company, conduct relations and negotiate agreements with custodians, trustees, depositories, attorneys, underwriters, brokers and dealers, corporate fiduciaries, insurers, banks and such other persons in any such other capacity deemed to be necessary or desirable. Oaktree Administrator makes reports to the Company's Board of Directors of its performance of obligations under the Administration Agreement and furnishes advice and recommendations with respect to such other aspects of the Company's business and affairs, in each case, as it shall determine to be desirable or as reasonably required by the Company's Board of Directors; provided that Oaktree Administrator shall not provide any investment advice or recommendation.

Oaktree Administrator also provides portfolio collection functions for interest income, fees and warrants and is responsible for the financial and other records that the Company is required to maintain and prepares, prints and disseminates reports to the Company's stockholders and all other materials filed with the SEC. In addition, Oaktree Administrator assists the Company in determining and publishing the Company's net asset value, overseeing the preparation and filing of the Company's tax returns, and generally overseeing the payment of the Company's expenses and the performance of administrative and professional services rendered to the Company by others. Oaktree Administrator may also offer to provide, on the Company's behalf, managerial assistance to the Company's portfolio companies.

For providing these services, facilities and personnel, the Company reimburses Oaktree Administrator the allocable portion of overhead and other expenses incurred by Oaktree Administrator in performing its obligations under the Administration Agreement, including the Company's allocable portion of the rent of the Company's principal executive offices (which are located in a building owned by a Brookfield affiliate) at market rates and the Company's allocable portion of the costs of compensation and related expenses of its Chief Financial Officer, Chief Compliance Officer, their staffs and other non-

OAKTREE SPECIALTY LENDING CORPORATION
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
(in thousands, except share and per share amounts, percentages and as otherwise indicated)

investment professionals at Oaktree that perform duties for the Company. Such reimbursement is at cost, with no profit to, or markup by, Oaktree Administrator. The Administration Agreement may be terminated by either party without penalty upon 60 days' written notice to the other. The Administration Agreement may also be terminated, without penalty, upon the vote of a majority of the Company's outstanding voting securities.

For the three months ended December 31, 2022 and 2021, the Company accrued administrative expenses of \$0.4 million and \$0.5 million, respectively, including \$0.1 million and \$0.1 million of general and administrative expenses, respectively.

As of December 31, 2022 and September 30, 2022, \$3.3 million and \$3.2 million, respectively, was included in "Due to affiliate" in the Consolidated Statements of Assets and Liabilities, reflecting the unpaid portion of administrative expenses and other reimbursable expenses payable to Oaktree Administrator.

OAKTREE SPECIALTY LENDING CORPORATION
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
(in thousands, except share and per share amounts, percentages and as otherwise indicated)

Note 11. Financial Highlights

<i>(Share amounts in thousands)</i>	Three months ended December 31, 2022 (8)	Three months ended December 31, 2021 (8)
Net asset value per share at beginning of period	\$20.38	\$21.84
Net investment income (1)	0.63	0.54
Net unrealized appreciation (depreciation) (1)	(0.38)	(0.08)
Net realized gains (losses) (1)	(0.05)	0.16
(Provision) benefit for taxes on realized and unrealized gains (losses) (1)	0.01	0.04
Distributions of net investment income to stockholders	(0.96)	(0.47)
Net asset value per share at end of period	\$19.63	\$22.03
Per share market value at beginning of period (7)	\$18.00	\$21.18
Per share market value at end of period (7)	\$20.61	\$22.38
Total return (2)	19.90%	7.92%
Common shares outstanding at beginning of period	61,125	60,120
Common shares outstanding at end of period	61,220	60,156
Net assets at beginning of period	\$1,245,563	\$1,312,823
Net assets at end of period	\$1,201,989	\$1,325,061
Average net assets (3)	\$1,241,806	\$1,327,934
Ratio of net investment income to average net assets (4)	12.40%	9.65%
Ratio of total expenses to average net assets (4)	13.11%	8.99%
Ratio of net expenses to average net assets (4)	12.87%	8.77%
Ratio of portfolio turnover to average investments at fair value	4.24%	9.14%
Weighted average outstanding debt (5)	\$1,441,326	\$1,331,141
Average debt per share (1)	\$23.57	\$22.14
Asset coverage ratio at end of period (6)	176.31%	200.81%

-
- (1) Calculated based upon weighted average shares outstanding for the period.
- (2) Total return equals the increase or decrease of ending market value over beginning market value, plus distributions, divided by the beginning market value, assuming dividend reinvestment prices obtained under the Company's DRIP. Total return does not include sales load.
- (3) Calculated based upon the weighted average net assets for the period.
- (4) Interim periods are annualized.
- (5) Calculated based upon the weighted average of principal debt outstanding for the period.
- (6) Based on outstanding senior securities of \$1,514.4 million and \$1,300.0 million as of December 31, 2022 and 2021, respectively.
- (7) Per share market values are adjusted to reflect the 1-for-3 reverse stock split of the Company's common stock completed on January 20, 2023 and effective as of the commencement of trading on January 23, 2023.
- (8) The share and per share information disclosed in this table has been retrospectively adjusted to reflect the Company's 1-for-3 reverse stock split completed on January 20, 2023 and effective as of the commencement of trading on January 23, 2023.

OAKTREE SPECIALTY LENDING CORPORATION
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
(in thousands, except share and per share amounts, percentages and as otherwise indicated)

Note 12. Derivative Instruments

The Company enters into foreign currency forward contracts from time to time to help mitigate the impact that an adverse change in foreign exchange rates would have on the value of the Company's investments denominated in foreign currencies. In order to better define its contractual rights and to secure rights that will help the Company mitigate its counterparty risk, the Company entered into an International Swaps and Derivatives Association, Inc. Master Agreement (the "ISDA Master Agreement") with its derivative counterparty, JPMorgan Chase Bank, N.A. The ISDA Master Agreement permits a single net payment in the event of a default or similar event. As of December 31, 2022, no cash collateral has been pledged to cover obligations and no cash collateral has been received from the counterparty with respect to the Company's forward currency contracts.

In connection with the issuance of the 2027 Notes, the Company entered into an interest rate swap agreement with the Royal Bank of Canada pursuant to an ISDA Master Agreement. As of December 31, 2022, the Company paid \$39.8 million to the Royal Bank of Canada to cover collateral obligations under the terms of the interest swap agreement, which is included in due from broker on the Consolidated Statement of Assets and Liabilities.

Certain information related to the Company's foreign currency forward contracts is presented below as of December 31, 2022.

Description	Notional Amount to be Purchased	Notional Amount to be Sold	Maturity Date	Gross Amount of Recognized Assets	Gross Amount of Recognized Liabilities	Balance Sheet Location of Net Amounts
Foreign currency forward contract	\$ 44,825	€ 44,224	2/9/2023	\$ —	\$ (2,499)	Derivative liability
Foreign currency forward contract	\$ 46,412	£ 39,965	2/9/2023	\$ —	\$ (1,712)	Derivative liability
				<u>\$ —</u>	<u>\$ (4,211)</u>	

Certain information related to the Company's foreign currency forward contracts is presented below as of September 30, 2022.

Description	Notional Amount to be Purchased	Notional Amount to be Sold	Maturity Date	Gross Amount of Recognized Assets	Gross Amount of Recognized Liabilities	Balance Sheet Location of Net Amounts
Foreign currency forward contract	\$ 43,179	€ 41,444	11/10/2022	\$ 2,466	\$ —	Derivative asset
Foreign currency forward contract	\$ 45,692	£ 37,033	11/10/2022	\$ 4,323	\$ —	Derivative asset
				<u>\$ 6,789</u>	<u>\$ —</u>	

Certain information related to the Company's interest rate swap is presented below as of December 31, 2022.

Description	Notional Amount	Maturity Date	Gross Amount of Recognized Assets	Gross Amount of Recognized Liabilities	Balance Sheet Location of Net Amounts
Interest rate swap	\$ 350,000	1/15/2027	\$ —	\$ 39,928	Derivative liability
			<u>\$ —</u>	<u>\$ 39,928</u>	

Certain information related to the Company's interest rate swap is presented below as of September 30, 2022.

Description	Notional Amount	Maturity Date	Gross Amount of Recognized Assets	Gross Amount of Recognized Liabilities	Balance Sheet Location of Net Amounts
Interest rate swap	\$ 350,000	1/15/2027	\$ —	\$ 41,969	Derivative liability
			<u>\$ —</u>	<u>\$ 41,969</u>	

Note 13. Commitments and Contingencies

Off-Balance Sheet Arrangements

The Company may be a party to financial instruments with off-balance sheet risk in the normal course of business to meet the financial needs of its portfolio companies. As of December 31, 2022, the Company's only off-balance sheet arrangements consisted of \$198.9 million of unfunded commitments, which was comprised of \$171.8 million to provide debt and equity financing to certain of its portfolio companies and \$27.1 million to provide financing to the JVs. As of September 30, 2022, the Company's only off-balance sheet arrangements consisted of \$224.2 million of unfunded commitments, which was comprised of \$175.2 million to provide debt and equity financing to certain of its portfolio companies and \$49.0 million to provide financing to the JVs. Such commitments are subject to the portfolio companies' satisfaction of certain financial and nonfinancial covenants and may involve, to varying degrees, elements of credit risk in excess of the amount recognized in the Consolidated Statements of Assets and Liabilities.

OAKTREE SPECIALTY LENDING CORPORATION
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
(in thousands, except share and per share amounts, percentages and as otherwise indicated)

A list of unfunded commitments by investment (consisting of revolving, term loans with delayed draw components, subordinated notes and LLC equity interests in the JVs, preferred stock and limited partnership interests) as of December 31, 2022 and September 30, 2022 is shown in the table below:

	December 31, 2022	September 30, 2022
Delta Leasing SPV II LLC	\$ 23,004	\$ 27,187
Fairbridge Strategic Capital Funding LLC	15,995	22,150
OCSI Glick JV LLC	13,998	13,998
Senior Loan Fund JV I, LLC	13,125	35,000
BioXcel Therapeutics, Inc.	11,785	11,785
Dominion Diagnostics, LLC	11,148	11,148
BAART Programs, Inc.	7,675	8,645
iCIMS, Inc.	6,930	6,930
Marinus Pharmaceuticals, Inc.	5,734	5,734
scPharmaceuticals Inc.	5,212	—
Assembled Brands Capital LLC	5,035	2,008
RumbleOn, Inc.	4,822	4,822
MRI Software LLC	4,427	5,196
107 Fair Street LLC	4,322	—
Grove Hotel Parcel Owner, LLC	4,293	4,293
Accupac, Inc.	4,197	4,605
Innocoll Pharmaceuticals Limited	4,195	4,195
Avalara, Inc.	4,147	—
Mindbody, Inc.	4,000	4,000
OTG Management, LLC	3,789	3,789
Mesoblast, Inc.	3,553	3,553
Establishment Labs Holdings Inc.	3,384	5,075
112-126 Van Houten Real22 LLC	3,174	—
ADC Therapeutics SA	3,020	3,020
Spanx, LLC	2,762	2,226
PRGX Global, Inc.	2,518	2,518
SCP Eye Care Services, LLC	2,356	—
Relativity ODA LLC	2,218	2,218
Berner Food & Beverage, LLC	2,197	1,392
Salus Workers' Compensation, LLC	2,171	—
Pluralsight, LLC	1,766	3,532
Tahoe Bidco B.V.	1,741	1,741
CorEvitas, LLC	1,526	915
Coyote Buyer, LLC	1,333	1,333
MHE Intermediate Holdings, LLC	1,229	1,429
Kings Buyer, LLC	1,208	1,537
Liquid Environmental Solutions Corporation	1,115	1,115
Acquia Inc.	923	1,326
Apptio, Inc.	892	1,338
Digital.AI Software Holdings, Inc.	826	826
Telestream Holdings Corporation	528	528
GKD Index Partners, LLC	320	320
PFNY Holdings, LLC	275	1,527
Ardonagh Midco 3 PLC	—	4,372
Dialyze Holdings, LLC	—	3,431
Thrasio, LLC	—	2,578
109 Montgomery Owner LLC	—	477
LSL Holdco, LLC	—	427
Total	\$ 198,868	\$ 224,239

Note 14. Subsequent Events

The Company's management evaluated subsequent events through the date of issuance of the Consolidated Financial Statements. There have been no subsequent events that occurred during such period that would require disclosure in, or would be required to be recognized in the Consolidated Financial Statements as of and for the three months ended December 31, 2022, except as discussed below.

Distribution Declaration

On January 27, 2023, the Company's Board of Directors declared a quarterly distribution of \$0.55 per share, payable in cash on March 31, 2023 to stockholders of record on March 15, 2023.

Investment Advisory Agreement

On January 23, 2023, in connection with the consummation of the OSI2 Merger, the Company entered into an amended and restated investment advisory agreement with Oaktree to amend and restate the prior investment advisory agreement, dated as of March 19, 2021, by and between the Company and Oaktree to (1) waive an aggregate of \$9.0 million of base management fees otherwise payable to the Oaktree in the two years following the closing of the OSI2 Merger and (2) revise the calculation of the incentive fees to eliminate certain unintended consequences of the accounting treatment of the OSI2 Merger on the incentive fees payable to Oaktree. None of the other terms were changed, and the services to be provided by Oaktree and the term of the Investment Advisory Agreement remain the same.

OSI2 Merger

On January 23, 2023, the Company completed the OSI2 Merger. In accordance with the terms of the OSI2 Merger Agreement, at the effective time of the OSI2 Merger, each outstanding share of OSI2 common stock was converted into the right to receive 0.9115 shares of the Company's common stock (with OSI2's stockholders receiving cash in lieu of fractional shares of the Company's common stock). As a result of the OSI2 Merger, the Company issued an aggregate of 15,860,200 shares of its common stock to former OSI2 stockholders. Following completion of the OSI2 Merger, the Company had 77,079,805 shares of common stock outstanding.

OSI2 Citibank Facility

On January 23, 2023, as a result of the consummation of the OSI2 Merger, the Company became party to the OSI2 Citibank Facility (as described below).

OSI 2 Senior Lending SPV, LLC ("OSI 2 SPV"), the Company's wholly-owned and consolidated subsidiary, is party to a loan and security agreement dated as of July 26, 2019, which was subsequently amended on September 20, 2019, July 2, 2020, December 31, 2020, March 31, 2021 and December 2, 2022 (as amended, the "OSI2 Citibank Loan Agreement"), with the lenders from time to time party thereto and the other parties referenced below. Under the terms of the OSI2 Citibank Loan Agreement, the Company serves as the collateral manager and seller and OSI 2 SPV serves as borrower with Citibank, N.A., as administrative agent, and Deutsche Bank Trust Company Americas, as collateral agent.

The OSI2 Citibank Loan Agreement provides for a senior secured revolving credit facility (the "OSI2 Citibank Facility") of up to \$250 million (the "Citibank Maximum Commitment") in aggregate principal amount, subject to the lesser of (i) the borrowing base, which is an amount based on advance rates that vary depending on the class of assets and the value assigned to such assets under the OSI2 Citibank Loan Agreement and (ii) the Citibank Maximum Commitment. The OSI2 Citibank Facility has a reinvestment period through May 26, 2023, during which advances may be made, and matures on January 26, 2025. Following the reinvestment period, OSI 2 SPV will be required to make certain mandatory amortization payments. Borrowings under the OSI2 Citibank Facility bear interest payable quarterly at a rate per year equal to (a) in the case of a lender that is identified as a conduit lender under the OSI2 Citibank Loan Agreement, the lesser of (i) the applicable commercial paper rate for such conduit lender and (ii) LIBOR for a three month maturity and (b) for all other lenders under the OSI2 Citibank Facility, LIBOR, plus, in each case, an applicable spread. During the reinvestment period, the applicable spread is the greater of (i) a weighted average rate of (x) 1.65% per year for broadly syndicated loans and (y) 2.25% per year for all other eligible loans and (ii) 1.85%. After the reinvestment period, the applicable spread is 3.00% per year. There is also a non-usage fee of 0.50% per year on the unused portion of the OSI2 Citibank Facility, payable quarterly; provided that if the unused portion of the OSI2 Citibank Facility is greater than 30% of the commitments under the OSI2 Citibank Facility, the non-usage fee will be based on an unused portion of 30% of the commitments under the OSI2 Citibank Facility.

OAKTREE SPECIALTY LENDING CORPORATION
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
(in thousands, except share and per share amounts, percentages and as otherwise indicated)

The OSI2 Citibank Facility is secured by a first priority security interest in substantially all of OSI 2 SPV's assets.

As part of the OSI2 Citibank Facility, OSI 2 SPV is subject to certain limitations as to how borrowed funds may be used and the types of loans that are eligible to be acquired by OSI 2 SPV including restrictions on sector concentrations, loan size, tenor and minimum investment ratings (or estimated ratings). The OSI2 Citibank Facility also contains certain requirements relating to interest coverage, collateral quality and portfolio performance, certain violations of which could result in the acceleration of the amounts due under the OSI2 Citibank Facility.

Under the OSI2 Citibank Facility, the Company and OSI 2 SPV, as applicable, have made customary representations and warranties, and are required to comply with various affirmative and negative covenants, reporting requirements and other customary requirements for similar credit facilities.

OSI 2 SPV's borrowings are non-recourse to the Company but are considered borrowings of the Company for purposes of complying with the asset coverage requirements under the Investment Company Act.

As of January 23, 2023, the Company had \$225.0 million outstanding under the OSI2 Citibank Facility.

Reverse Stock Split

On January 20, 2023, the Company amended its restated certificate of incorporation, as amended and corrected, to effect a 1-for-3 reverse stock split. Immediately following completion of the reverse stock split, the Company had 61,219,605 shares of common stock outstanding.

Oaktree Specialty Lending Corporation
Schedule of Investments in and Advances to Affiliates
(in thousands, except share and per share amounts, percentages and as otherwise indicated)
Three months ended December 31, 2022
(unaudited)

Portfolio Company/Type of Investment (1)	Cash Interest Rate	Industry	Principal	Net Realized Gain (Loss)	Amount of Interest, Fees or Dividends Credited in Income (2)	Fair Value as of October 1, 2022	Gross Additions (3)	Gross Reductions (4)	Fair Value as of December 31, 2022	% of Total Net Assets
Control Investments										
C5 Technology Holdings, LLC		Data Processing & Outsourced Services								
829 Common Units				\$ —	\$ —	\$ —	\$ —	\$ —	\$ —	— %
34,984,460.37 Preferred Units				—	—	27,638	—	—	27,638	2.3 %
Dominion Diagnostics, LLC		Health Care Services								
First Lien Term Loan, LIBOR+5.00% cash due 2/28/2024	9.73 %		\$ 14,297	—	331	14,333	—	(36)	14,297	1.2 %
First Lien Revolver, LIBOR+5.00% cash due 2/28/2024			—	—	14	—	—	—	—	— %
30,030.8 Common Units in DD Healthcare Services Holdings, LLC				—	—	4,946	—	(719)	4,227	0.4 %
OCSI Glick JV LLC (5)		Multi-Sector Holdings								
Subordinated Debt, LIBOR+4.50% cash due 10/20/2028	7.67 %		59,049	—	1,624	50,283	380	(1,127)	49,536	4.1 %
87.5% equity interest				—	—	—	—	—	—	— %
Senior Loan Fund JV I, LLC (6)		Multi-Sector Holdings								
Subordinated Debt, LIBOR+7.00% cash due 12/29/2028	10.17 %		112,656	—	2,611	96,250	16,406	—	112,656	9.4 %
87.5% LLC equity interest				—	1,050	20,715	5,469	(2,076)	24,108	2.0 %
Total Control Investments			<u>\$ 186,002</u>	<u>\$ —</u>	<u>\$ 5,630</u>	<u>\$ 214,165</u>	<u>\$ 22,255</u>	<u>\$ (3,958)</u>	<u>\$ 232,462</u>	<u>19.3 %</u>
Affiliate Investments										
Assembled Brands Capital LLC		Specialized Finance								
First Lien Revolver, LIBOR+6.75% cash due 10/17/2023	11.48 %		\$ 21,464	\$ —	\$ 646	\$ 24,225	\$ 55	\$ (3,028)	\$ 21,252	1.8 %
1,609,201 Class A Units				—	—	370	—	(16)	354	— %
1,019,168.80 Preferred Units, 6%				—	—	1,223	20	—	1,243	0.1 %
70,424,564.1 Class A Warrants (exercise price \$3.3778) expiration date 9/9/2029				—	—	—	—	—	—	— %
Caregiver Services, Inc.		Health Care Services								
1,080,399 shares of Series A Preferred Stock, 10%			—	—	—	378	—	(54)	324	— %
Total Affiliate Investments			<u>\$ 21,464</u>	<u>\$ —</u>	<u>\$ 646</u>	<u>\$ 26,196</u>	<u>\$ 75</u>	<u>\$ (3,098)</u>	<u>\$ 23,173</u>	<u>1.9 %</u>
Total Control & Affiliate Investments			<u>\$ 207,466</u>	<u>\$ —</u>	<u>\$ 6,276</u>	<u>\$ 240,361</u>	<u>\$ 22,330</u>	<u>\$ (7,056)</u>	<u>\$ 255,635</u>	<u>21.2 %</u>

This schedule should be read in connection with the Company's Consolidated Financial Statements, including the Consolidated Schedules of Investments and Notes to the Consolidated Financial Statements.

- (1) The principal amount and ownership detail are shown in the Company's Consolidated Schedules of Investments.
- (2) Represents the total amount of interest (net of non-accrual amounts), fees and dividends credited to income for the portion of the period an investment was included in the Control or Affiliate categories.
- (3) Gross additions include increases in the cost basis of investments resulting from new portfolio investments, follow-on investments, accrued PIK interest (net of non-accrual amounts) and the exchange of one or more existing securities for one or more new securities. Gross additions also include net increases in unrealized appreciation or net decreases in unrealized depreciation as well as the movement of an existing portfolio company into this category or out of a different category.
- (4) Gross reductions include decreases in the cost basis of investments resulting from principal payments or sales and exchanges of one or more existing securities for one or more new securities. Gross reductions also include net increases in unrealized depreciation or net decreases in unrealized appreciation as well as the movement of an existing portfolio company out of this category and into a different category.

- (5) Together with GF Equity Funding, the Company co-invests through Glick JV. Glick JV is capitalized as transactions are completed and all portfolio and investment decisions in respect to Glick JV must be approved by the Glick JV investment committee consisting of representatives of the Company and GF Equity Funding (with approval from a representative of each required).
- (6) Together with Kemper, the Company co-invests through SLF JV I. SLF JV I is capitalized as transactions are completed and all portfolio and investment decisions in respect to SLF JV I must be approved by the SLF JV I investment committee consisting of representatives of the Company and Kemper (with approval from a representative of each required).

Oaktree Specialty Lending Corporation
Schedule of Investments in and Advances to Affiliates
(in thousands, except share and per share amounts, percentages and as otherwise indicated)
Three months ended December 31, 2021
(unaudited)

Portfolio Company/Type of Investment (1)	Cash Interest Rate	Industry	Principal	Net Realized Gain (Loss)	Amount of Interest, Fees or Dividends Credited in Income (2)	Fair Value as of October 1, 2021	Gross Additions (3)	Gross Reductions (4)	Fair Value as of December 31, 2021	% of Total Net Assets
Control Investments										
C5 Technology Holdings, LLC		Data Processing & Outsourced Services								
829 Common Units				\$ —	\$ —	\$ —	\$ —	\$ —	\$ —	— %
34,984,460.37 Preferred Units				—	—	27,638	—	—	27,638	2.1 %
Dominion Diagnostics, LLC		Health Care Services								
First Lien Term Loan, LIBOR+5.00% cash due 2/28/2024	6.00 %		\$ 23,201	—	430	27,381	—	(4,180)	23,201	1.8 %
First Lien Revolver, LIBOR+5.00% cash due 2/28/2024			—	—	14	—	—	—	—	— %
30,030.8 Common Units in DD Healthcare Services Holdings, LLC				—	3,308	18,065	—	—	18,065	1.4 %
First Star Speir Aviation Limited (5)		Airlines								
First Lien Term Loan, 9.00% cash due 12/15/2025			—	7,500	—	7,500	—	(7,500)	—	— %
100% equity interest				(5,632)	158	698	—	(698)	—	— %
OCSI Glick JV LLC (6)		Multi-Sector Holdings								
Subordinated Debt, LIBOR+4.50% cash due 10/20/2028	4.58 %		61,237	—	1,081	55,582	745	(473)	55,854	4.2 %
87.5% equity interest				—	—	—	—	—	—	— %
Senior Loan Fund JV I, LLC (7)		Multi-Sector Holdings								
Subordinated Debt, LIBOR+7.00% cash due 12/29/2028	8.00 %		96,250	—	1,967	96,250	—	—	96,250	7.3 %
87.5% LLC equity interest				—	451	37,651	810	—	38,461	2.9 %
Total Control Investments			\$ 180,688	\$ 1,868	\$ 7,409	\$ 270,765	\$ 1,555	\$ (12,851)	\$ 259,469	19.6 %
Affiliate Investments										
Assembled Brands Capital LLC		Specialized Finance								
First Lien Revolver, LIBOR+6.75% cash due 10/17/2023	7.75 %		\$ 15,982	\$ —	\$ 339	\$ 15,712	\$ 3,499	\$ (3,487)	\$ 15,724	1.2 %
1,609,201 Class A Units				—	—	587	—	(201)	386	— %
1,019,168.80 Preferred Units, 6%				—	—	1,152	20	—	1,172	0.1 %
70,424.5641 Class A Warrants (exercise price \$3.3778) expiration date 9/9/2029				—	—	—	—	—	—	— %
Caregiver Services, Inc.		Health Care Services								
1,080,399 shares of Series A Preferred Stock, 10%			—	—	—	838	—	—	838	0.1 %
Total Affiliate Investments			\$ 15,982	\$ —	\$ 339	\$ 18,289	\$ 3,519	\$ (3,688)	\$ 18,120	1.4 %
Total Control & Affiliate Investments			\$ 196,670	\$ 1,868	\$ 7,748	\$ 289,054	\$ 5,074	\$ (16,539)	\$ 277,589	21.0 %

This schedule should be read in connection with the Company's Consolidated Financial Statements, including the Consolidated Schedules of Investments and Notes to the Consolidated Financial Statements.

- (1) The principal amount and ownership detail are shown in the Company's Consolidated Schedules of Investments included in the Company's quarterly report on Form 10-Q for the quarter ended December 31, 2021.
- (2) Represents the total amount of interest (net of non-accrual amounts), fees and dividends credited to income for the portion of the period an investment was included in the Control or Affiliate categories.
- (3) Gross additions include increases in the cost basis of investments resulting from new portfolio investments, follow-on investments, accrued PIK interest (net of non-accrual amounts) and the exchange of one or more existing securities for one or more new securities. Gross additions also include net increases in unrealized appreciation or net decreases in unrealized depreciation as well as the movement of an existing portfolio company into this category or out of a different category.

- (4) Gross reductions include decreases in the cost basis of investments resulting from principal payments or sales and exchanges of one or more existing securities for one or more new securities. Gross reductions also include net increases in unrealized depreciation or net decreases in unrealized appreciation as well as the movement of an existing portfolio company out of this category and into a different category.
- (5) First Star Speir Aviation Limited is a wholly-owned holding company formed by the Company in order to facilitate its investment strategy. In accordance with ASU 2013-08, the Company has deemed the holding company to be an investment company under GAAP and therefore deemed it appropriate to consolidate the financial results and financial position of the holding company and to recognize dividend income versus a combination of interest income and dividend income. Accordingly, the debt and equity investments in the wholly-owned holding company are disregarded for accounting purposes since the economic substance of these instruments are equity investments in the operating entities.
- (6) Together with GF Equity Funding, the Company co-invests through Glick JV. Glick JV is capitalized as transactions are completed and all portfolio and investment decisions in respect to Glick JV must be approved by the Glick JV investment committee consisting of representatives of the Company and GF Equity Funding (with approval from a representative of each required).
- (7) Together with Kemper, the Company co-invests through SLF JV I. SLF JV I is capitalized as transactions are completed and all portfolio and investment decisions in respect to SLF JV I must be approved by the SLF JV I investment committee consisting of representatives of the Company and Kemper (with approval from a representative of each required).

Item 2. *Management's Discussion and Analysis of Financial Condition and Results of Operations*

The following discussion should be read in connection with our Consolidated Financial Statements and the notes thereto included elsewhere in this quarterly report on Form 10-Q.

Some of the statements in this quarterly report on Form 10-Q constitute forward-looking statements because they relate to future events or our future performance or financial condition. The forward-looking statements contained in this quarterly report on Form 10-Q may include statements as to:

- our future operating results and distribution projections;
- the ability of Oaktree Fund Advisors, LLC, or Oaktree, to reposition our portfolio and to implement Oaktree's future plans with respect to our business;
- the ability of Oaktree and its affiliates to attract and retain highly talented professionals;
- our business prospects and the prospects of our portfolio companies;
- the impact of the investments that we expect to make;
- the ability of our portfolio companies to achieve their objectives;
- our expected financings and investments and additional leverage we may seek to incur in the future;
- the adequacy of our cash resources and working capital;
- the timing of cash flows, if any, from the operations of our portfolio companies; and
- the cost or potential outcome of any litigation to which we may be a party.

In addition, words such as “anticipate,” “believe,” “expect,” “seek,” “plan,” “should,” “estimate,” “project” and “intend” indicate forward-looking statements, although not all forward-looking statements include these words. The forward-looking statements contained in this quarterly report on Form 10-Q involve risks and uncertainties. Our actual results could differ materially from those implied or expressed in the forward-looking statements for any reason, including the factors set forth in “Item 1A. Risk Factors” in our annual report on Form 10-K for the year ended September 30, 2022 and elsewhere in this quarterly report on Form 10-Q.

Other factors that could cause actual results to differ materially include:

- changes or potential disruptions in our operations, the economy, financial markets or political environment, including the impacts of inflation and rising interest rates;
- risks associated with possible disruption in our operations or the economy generally due to terrorism, war or other geopolitical conflict (including the current conflict between Russia and Ukraine), natural disasters or pandemics;
- future changes in laws or regulations (including the interpretation of these laws and regulations by regulatory authorities) and conditions in our operating areas, particularly with respect to Business Development Companies or, regulated investment companies, or RICs;
- the ability to realize the benefits of the OSI2 Merger (as defined below); and
- other considerations that may be disclosed from time to time in our publicly disseminated documents and filings.

We have based the forward-looking statements included in this quarterly report on Form 10-Q on information available to us on the date of this quarterly report, and we assume no obligation to update any such forward-looking statements. Although we undertake no obligation to revise or update any forward-looking statements, whether as a result of new information, future events or otherwise, you are advised to consult any additional disclosures that we may make directly to you or through reports that we in the future may file with the Securities and Exchange Commission, or the SEC, including annual reports on Form 10-K, quarterly reports on Form 10-Q and current reports on Form 8-K.

All dollar amounts in tables are in thousands, except share and per share amounts and as otherwise indicated.

Business Overview

We are a specialty finance company dedicated to providing customized, one-stop credit solutions to companies with limited access to public or syndicated capital markets. We are a closed-end, externally managed, non-diversified management investment company that has elected to be regulated as a Business Development Company under the Investment Company Act of 1940, as amended, or the Investment Company Act. In addition, we have qualified and elected to be treated as a RIC under the Internal Revenue Code of 1986, as amended, or the Code, for U.S. federal income tax purposes.

We are externally managed by Oaktree pursuant to an investment advisory agreement, as amended from time to time, or the Investment Advisory Agreement. Oaktree Fund Administration, LLC, or Oaktree Administrator, an affiliate of Oaktree, provides certain administrative and other services necessary for us to operate pursuant to an administration agreement, as amended from time to time, or the Administration Agreement.

Our investment objective is to generate current income and capital appreciation by providing companies with flexible and innovative financing solutions, including first and second lien loans, unsecured and mezzanine loans, bonds, preferred equity and certain equity co-investments. We may also seek to generate capital appreciation and income through secondary investments at discounts to par in either private or syndicated transactions. Our portfolio may also include certain structured finance and other non-traditional structures. We invest in companies that typically possess resilient business models with strong underlying fundamentals. We intend to deploy capital across credit and economic cycles with a focus on long-term results, which we believe will enable us to build lasting partnerships with financial sponsors and management teams, and we may seek to opportunistically take advantage of dislocations in the financial markets and other situations that may benefit from Oaktree's credit and structuring expertise. Sponsors may include financial sponsors, such as an institutional investor or a private equity firm, or a strategic entity seeking to invest in a portfolio company. Oaktree is generally focused on middle-market companies, which we define as companies with enterprise values of between \$100 million and \$750 million. We generally invest in securities that are rated below investment grade by rating agencies or that would be rated below investment grade if they were rated. Below investment grade securities, which are often referred to as "high yield" and "junk," have predominantly speculative characteristics with respect to the issuer's capacity to pay interest and repay principal.

In the current market environment, Oaktree intends to focus on the following area, in which Oaktree believes there is less competition and thus potential for greater returns, for our new investment opportunities: (1) situational lending, which we define to include directly originated loans to non-sponsor companies that are hard to understand and value using traditional underwriting techniques, (2) select sponsor lending, which we define to include financing to support leveraged buyouts of companies with specialized sponsors that have expertise in certain industries, and (3) stressed sector and rescue lending, which we define to include opportunistic private loans in industries experiencing stress or limited access to capital.

Oaktree intends to continue to rotate our portfolio into investments that are better aligned with Oaktree's overall approach to credit investing and that it believes have the potential to generate attractive returns across market cycles (which we call "core investments"). Oaktree has performed a comprehensive review of our portfolio and categorized our portfolio into core investments, non-core performing investments and underperforming investments. Certain additional information on such categorization and our portfolio composition is included in investor presentations that we file with the SEC. Since an Oaktree affiliate became our investment adviser in October 2017, Oaktree and its affiliates have reduced the investments identified as non-core by approximately \$800 million at fair value. Over time, Oaktree intends to rotate us out of the remaining non-core investments, which were approximately \$71 million at fair value as of December 31, 2022. Oaktree periodically reviews designations of investments as core and non-core and may change such designations over time.

On March 19, 2021, we acquired Oaktree Strategic Income Corporation, or OCSI, pursuant to an agreement and plan of merger, or the OCSI Merger Agreement, dated as of October 28, 2020, by and among OCSI, us, Lion Merger Sub, Inc., our wholly-owned subsidiary, and, solely for the limited purposes set forth therein, Oaktree. Pursuant to the OCSI Merger Agreement, OCSI was merged with and into us in a two-step transaction with us as the surviving company, or the OCSI Merger.

On January 23, 2023, we acquired Oaktree Strategic Income II, Inc., or OSI2, pursuant to that certain Agreement and Plan of Merger, or the OSI2 Merger Agreement, dated as of September 14, 2022, by and among OSI2, us, Project Superior Merger Sub, Inc., a wholly-owned subsidiary of us, and, solely for the limited purposes set forth therein, Oaktree. Pursuant to the OSI2 Merger Agreement, OSI2 was merged with and into us in a two-step transaction with us as the surviving company, or the OSI2 Merger.

Business Environment and Developments

Global financial markets have experienced an increase in volatility as concerns about the impact of higher inflation, rising interest rates, a potential recession and the current conflict in Ukraine have weighed on market participants. These factors have created disruptions in supply chains and economic activity and have had a particularly adverse impact on certain companies in the energy, raw materials and transportation sectors, among others. These uncertainties can ultimately impact the overall supply and demand of the market through changing spreads, deal terms and structures and equity purchase price multiples.

We are unable to predict the full effects of these macroeconomic events or how long any further market disruptions or volatility might last. We continue to closely monitor the impact these events have on our business, industry and portfolio companies and will provide constructive solutions where necessary.

Against this uncertain macroeconomic backdrop, we believe attractive risk-adjusted returns can be achieved by making loans to middle market companies that typically possess resilient business models with strong underlying fundamentals. Given the breadth of the investment platform and decades of credit investing experience of Oaktree and its affiliates, we believe that we have the resources and experience to source, diligence and structure investments in these companies and are well placed to generate attractive returns for investors.

As of December 31, 2022, 87.3% of our debt investment portfolio (at fair value) and 87.2% of our debt investment portfolio (at cost) bore interest at floating rates. Most of our floating rate loans are indexed to the London Interbank Offered Rate, or LIBOR, and/or an alternate base rate (e.g., prime rate), which typically resets semi-annually, quarterly or monthly at the borrower's option. Certain loans may also be indexed to the Secured Overnight Financing Rate, or SOFR, or the Sterling Overnight Index Average, or SONIA. Most U.S. dollar LIBOR rates will continue to be published through June 30, 2023. The FCA no longer compels panel banks to continue to contribute to LIBOR and the Federal Reserve Board, the Office of the Comptroller of the Currency, and the Federal Deposit Insurance Corporation have encouraged banks to cease entering into new contracts that use U.S. dollar LIBOR as a reference rate. The U.S. Federal Reserve, in conjunction with the Alternative Reference Rates Committee, a steering committee comprised of large U.S. financial institutions, supports replacing U.S.-dollar LIBOR with SOFR. Although there are an increasing number of issuances utilizing SOFR or SONIA, these alternative reference rates may not attain market acceptance as replacements for LIBOR. In anticipation of the cessation of LIBOR, we may need to renegotiate any credit agreements extending beyond the applicable phase out date with our prospective portfolio companies that utilize LIBOR as a factor in determining the interest rate. Certain of the loan agreements with our portfolio companies have included fallback language in the event that LIBOR becomes unavailable. This language generally provides that the administrative agent may identify a replacement reference rate, typically with the consent of (or prior consultation with) the borrower. In certain cases, the administrative agent will be required to obtain the consent of either a majority of the lenders under the facility, or the consent of each lender, prior to identifying a replacement reference rate. Certain of the loan agreements with our portfolio companies do not include any fallback language providing a mechanism for the parties to negotiate a new reference interest rate and will instead revert to the base rate in the event LIBOR ceases to exist.

Critical Accounting Estimates

Investment Valuation

We value our investments in accordance with Financial Accounting Standards Board, or FASB, Accounting Standards Codification, or ASC, Topic 820, *Fair Value Measurements and Disclosures*, or ASC 820, which defines fair value as the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. A liability's fair value is defined as the amount that would be paid to transfer the liability to a new obligor, not the amount that would be paid to settle the liability with the creditor. ASC 820 prioritizes the use of observable market prices over entity-specific inputs. Where observable prices or inputs are not available or reliable, valuation techniques are applied. These valuation techniques involve some level of management estimation and judgment, the degree of which is dependent on the price transparency for the investments or market and the investments' complexity.

Hierarchical levels, defined by ASC 820 and directly related to the amount of subjectivity associated with the inputs to fair valuation of these assets and liabilities, are as follows:

- Level 1 — Unadjusted, quoted prices in active markets for identical assets or liabilities as of the measurement date.
- Level 2 — Observable inputs other than Level 1 prices, such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data at the measurement date for substantially the full term of the assets or liabilities.
- Level 3 — Unobservable inputs that reflect Oaktree's best estimate of what market participants would use in pricing the asset or liability at the measurement date. Consideration is given to the risk inherent in the valuation technique and the risk inherent in the inputs to the model.

If inputs used to measure fair value fall into different levels of the fair value hierarchy, an investment's level is based on the lowest level of input that is significant to the fair value measurement. Oaktree's assessment of the significance of a particular input to the fair value measurement in its entirety requires judgment and considers factors specific to the investment. This includes investment securities that are valued using "bid" and "ask" prices obtained from independent third party pricing services or directly from brokers. These investments may be classified as Level 3 because the quoted prices may be indicative in nature for securities that are in an inactive market, may be for similar securities or may require adjustments for investment-specific factors or restrictions.

Financial instruments with readily available quoted prices generally will have a higher degree of market price observability and a lesser degree of judgment inherent in measuring fair value. As such, Oaktree obtains and analyzes readily available market quotations provided by pricing vendors and brokers for all of our investments for which quotations are available. In determining the fair value of a particular investment, pricing vendors and brokers use observable market information, including both binding and non-binding indicative quotations.

Oaktree seeks to obtain at least two quotations for the subject or similar securities, typically from pricing vendors. If Oaktree is unable to obtain two quotes from pricing vendors, or if the prices obtained from pricing vendors are not within our set threshold, Oaktree seeks to obtain a quote directly from a broker making a market for the asset. Oaktree evaluates the

quotations provided by pricing vendors and brokers based on available market information, including trading activity of the subject or similar securities, or by performing a comparable security analysis to ensure that fair values are reasonably estimated. Oaktree also performs back-testing of valuation information obtained from pricing vendors and brokers against actual prices received in transactions. In addition to ongoing monitoring and back-testing, Oaktree performs due diligence procedures over pricing vendors to understand their methodology and controls to support their use in the valuation process. Generally, Oaktree does not adjust any of the prices received from these sources.

If the quotations obtained from pricing vendors or brokers are determined to not be reliable or are not readily available, Oaktree values such investments using any of three different valuation techniques. The first valuation technique is the transaction precedent technique, which utilizes recent or expected future transactions of the investment to determine fair value, to the extent applicable. The second valuation technique is an analysis of the enterprise value, or EV, of the portfolio company. EV means the entire value of the portfolio company to a market participant, including the sum of the values of debt and equity securities used to capitalize the enterprise at a point in time. The EV analysis is typically performed to determine (i) the value of equity investments, (ii) whether there is credit impairment for debt investments and (iii) the value for debt investments that we are deemed to control under the Investment Company Act. To estimate the EV of a portfolio company, Oaktree analyzes various factors, including the portfolio company's historical and projected financial results, macroeconomic impacts on the company and competitive dynamics in the company's industry. Oaktree also utilizes some or all of the following information based on the individual circumstances of the portfolio company: (i) valuations of comparable public companies, (ii) recent sales of private and public comparable companies in similar industries or having similar business or earnings characteristics, (iii) purchase prices as a multiple of their earnings or cash flow, (iv) the portfolio company's ability to meet its forecasts and its business prospects, (v) a discounted cash flow analysis, (vi) estimated liquidation or collateral value of the portfolio company's assets and (vii) offers from third parties to buy the portfolio company. Oaktree may probability weight potential sale outcomes with respect to a portfolio company when uncertainty exists as of the valuation date. Under the EV technique, the significant unobservable input used in the fair value measurement of our investments in debt or equity securities is the EBITDA, revenue or asset multiple, as applicable. Increases or decreases in the valuation multiples in isolation may result in a higher or lower fair value measurement, respectively. The third valuation technique is a market yield technique, which is typically performed for non-credit impaired debt investments. In the market yield technique, a current price is imputed for the investment based upon an assessment of the expected market yield for a similarly structured investment with a similar level of risk, and we consider the current contractual interest rate, the capital structure and other terms of the investment relative to risk of the company and the specific investment. A key determinant of risk, among other things, is the leverage through the investment relative to the EV of the portfolio company. As debt investments held by us are substantially illiquid with no active transaction market, Oaktree depends on primary market data, including newly funded transactions and industry-specific market movements, as well as secondary market data with respect to high yield debt instruments and syndicated loans, as inputs in determining the appropriate market yield, as applicable. Under the market yield technique, the significant unobservable input used in the fair value measurement of our investments in debt securities is the market yield. Increases or decreases in the market yield may result in a lower or higher fair value measurement, respectively.

In accordance with ASC 820-10, certain investments that qualify as investment companies in accordance with ASC 946 may be valued using net asset value as a practical expedient for fair value. Consistent with FASB guidance under ASC 820, these investments are excluded from the hierarchical levels. These investments are generally not redeemable.

Oaktree estimates the fair value of certain privately held warrants using a Black Scholes pricing model, which includes an analysis of various factors and subjective assumptions, including the current stock price (by using an EV analysis as described above), the expected period until exercise, expected volatility of the underlying stock price, expected dividends and the risk-free rate. Changes in the subjective input assumptions can materially affect the fair value estimates.

The fair value of our investments as of December 31, 2022 and September 30, 2022 was determined by Oaktree, as our valuation designee. We have and will continue to engage independent valuation firms to provide assistance regarding the determination of the fair value of a portion of our portfolio securities for which market quotations are not readily available or are readily available but deemed not reflective of the fair value of the investment each quarter. As of December 31, 2022, 92.1% of our portfolio at fair value was valued either based on market quotations, the transactions precedent approach or corroborated by independent valuation firms.

Certain factors that may be considered in determining the fair value of our investments include the nature and realizable value of any collateral, the portfolio company's earnings and its ability to make payments on its indebtedness, the markets in which the portfolio company does business, comparison to comparable publicly-traded companies, discounted cash flow and other relevant factors. Because such valuations, and particularly valuations of private securities and private companies, are inherently uncertain, may fluctuate over short periods of time and may be based on estimates, our determinations of fair value may differ materially from the values that would have been used if a ready market for these securities existed. Due to these uncertainties, Oaktree's fair value determinations may cause our net asset value on a given date to materially understate or overstate the value that we may ultimately realize upon the sale of one or more of our investments.

As of December 31, 2022, we held \$2,642.9 million of investments at fair value, up from \$2,494.1 million held at September 30, 2022, primarily driven by new originations outpacing the rate of repayments. As of December 31, 2022 and September 30, 2022, approximately 95.5% and 94.2%, respectively, of our total assets represented investments at fair value.

Revenue Recognition

Interest Income

Interest income, adjusted for accretion of original issue discount, or OID, is recorded on an accrual basis to the extent that such amounts are expected to be collected. We stop accruing interest on investments when it is determined that interest is no longer collectible. Investments that are expected to pay regularly scheduled interest in cash are generally placed on non-accrual status when there is reasonable doubt that principal or interest cash payments will be collected. Cash interest payments received on investments may be recognized as income or a return of capital depending upon management's judgment. A non-accrual investment is restored to accrual status if past due principal and interest are paid in cash, and the portfolio company, in management's judgment, is likely to continue timely payment of its remaining obligations. As of each of December 31, 2022 and September 30, 2022, there were no investments on non-accrual status.

In connection with our investment in a portfolio company, we sometimes receive nominal cost equity that is valued as part of the negotiation process with the portfolio company. When we receive nominal cost equity, we allocate our cost basis in the investment between debt securities and the nominal cost equity at the time of origination. Any resulting discount from recording the loan, or otherwise purchasing a security at a discount, is accreted into interest income over the life of the loan.

PIK Interest Income

Our investments in debt securities may contain payment-in-kind, or PIK, interest provisions. PIK interest, which typically represents contractually deferred interest added to the loan balance that is generally due at the end of the loan term, is generally recorded on the accrual basis to the extent such amounts are expected to be collected. We generally cease accruing PIK interest if there is insufficient value to support the accrual or if we do not expect the portfolio company to be able to pay all principal and interest due. Our decision to cease accruing PIK interest on a loan or debt security involves subjective judgments and determinations based on available information about a particular portfolio company, including whether the portfolio company is current with respect to its payment of principal and interest on its loans and debt securities; financial statements and financial projections for the portfolio company; our assessment of the portfolio company's business development success; information obtained by us in connection with periodic formal update interviews with the portfolio company's management and, if appropriate, the private equity sponsor; and information about the general economic and market conditions in which the portfolio company operates. Our determination to cease accruing PIK interest is generally made well before our full write-down of a loan or debt security. In addition, if it is subsequently determined that we will not be able to collect any previously accrued PIK interest, the fair value of the loans or debt securities would be reduced by the amount of such previously accrued, but uncollectible, PIK interest. The accrual of PIK interest on our debt investments increases the recorded cost bases of these investments in our Consolidated Financial Statements including for purposes of computing the capital gains incentive fee payable by us to Oaktree. To maintain our status as a RIC, certain income from PIK interest may be required to be distributed to our stockholders, even though we have not yet collected the cash and may never do so.

Portfolio Composition

Our investments principally consist of loans, common and preferred equity and warrants in privately-held companies, Senior Loan Fund JV I, LLC, or SLF JV I, a joint venture through which we and Trinity Universal Insurance Company, a subsidiary of Kemper Corporation, or Kemper, co-invest in senior secured loans of middle-market companies and other corporate debt securities, and OCSI Glick JV LLC, or the Glick JV, a joint venture through which we and GF Equity Funding 2014 LLC, or GF Equity Funding, co-invest primarily in senior secured loans of middle-market companies. We refer to SLF JV I and the Glick JV collectively as the JVs. Our loans are typically secured by a first, second or subordinated lien on the assets of the portfolio company and generally have terms of up to ten years (but an expected average life of between three and four years).

During the three months ended December 31, 2022, we originated \$250.3 million of investment commitments in 18 new and seven existing portfolio companies and funded \$274.4 million of investments.

During the three months ended December 31, 2022, we received \$104.4 million of proceeds from prepayments, exits, other paydowns and sales and exited 11 portfolio companies.

A summary of the composition of our investment portfolio at cost and fair value as a percentage of total investments is shown in the following tables:

	December 31, 2022	September 30, 2022
Cost:		
Senior secured debt	84.94 %	85.08 %
Debt investments in the JVs	5.85	5.59
Preferred equity	3.16	3.26
Subordinated debt	2.48	2.57
LLC equity interests of the JVs	1.97	1.88
Common equity and warrants	1.60	1.62
Total	100.00 %	100.00 %

	December 31, 2022	September 30, 2022
Fair value:		
Senior secured debt	86.32 %	86.86 %
Debt investments in the JVs	6.14	5.88
Preferred equity	3.05	3.19
Subordinated debt	2.35	2.28
Common equity and warrants	1.23	0.96
LLC equity interests of the JVs	0.91	0.83
Total	100.00 %	100.00 %

The industry composition of our portfolio at cost and fair value as a percentage of total investments was as follows:

	December 31, 2022	September 30, 2022
Cost:		
Application Software	15.66 %	14.98 %
Multi-Sector Holdings (1)	8.27	7.48
Pharmaceuticals	4.73	4.83
Data Processing & Outsourced Services	4.25	4.60
Biotechnology	4.02	4.20
Health Care Technology	3.97	3.82
Specialized Finance	3.15	3.09
Industrial Machinery	2.93	3.12
Health Care Services	2.37	2.24
Internet & Direct Marketing Retail	2.36	2.59
Aerospace & Defense	2.23	2.37
Construction & Engineering	2.19	2.33
Health Care Distributors	2.10	2.18
Other Diversified Financial Services	2.06	1.12
Personal Products	1.91	2.03
Automotive Retail	1.86	2.26
Auto Parts & Equipment	1.84	0.48
Real Estate Operating Companies	1.80	1.82
Fertilizers & Agricultural Chemicals	1.77	1.88
Internet Services & Infrastructure	1.77	2.07
Metal & Glass Containers	1.70	1.82
Home Improvement Retail	1.63	1.75
Soft Drinks	1.58	1.31
Airport Services	1.57	1.65
Leisure Facilities	1.48	1.52
Insurance Brokers	1.41	1.36
Diversified Support Services	1.37	1.45
Specialty Chemicals	1.34	1.43
Health Care Supplies	1.32	1.39
Real Estate Services	1.30	1.54
Integrated Telecommunication Services	1.25	1.32
Electrical Components & Equipment	1.22	1.29
Advertising	0.99	1.08
Movies & Entertainment	0.94	1.00
Distributors	0.91	0.97
Airlines	0.87	—
Health Care Equipment	0.79	0.93
Environmental & Facilities Services	0.76	0.80
Oil & Gas Storage & Transportation	0.72	0.85
Home Furnishings	0.70	0.75
Systems Software	0.54	0.57
Consumer Finance	0.52	0.55
Hotels, Resorts & Cruise Lines	0.50	0.53
IT Consulting & Other Services	0.42	0.45
Restaurants	0.34	0.36
Education Services	0.33	0.35
Cable & Satellite	0.29	0.79
Research & Consulting Services	0.28	0.35
Apparel, Accessories & Luxury Goods	0.19	0.20
Air Freight & Logistics	0.18	0.28
Integrated Oil & Gas	0.18	0.19
Apparel Retail	0.17	0.20
Food Distributors	0.17	0.18
Specialized REITs	0.16	0.16
Real Estate Development	0.15	—
Diversified Banks	0.13	0.13
Technology Distributors	0.11	0.12
Construction Materials	0.08	0.09
Housewares & Specialties	0.08	0.09
Electronic Components	0.08	0.08
Alternative Carriers	0.01	0.01
Oil & Gas Refining & Marketing	—	0.33
Trading Companies & Distributors	—	0.29
Total	100.00 %	100.00 %

	December 31, 2022	September 30, 2022
Fair value:		
Application Software	15.95 %	15.43 %
Multi-Sector Holdings (1)	7.53	6.71
Pharmaceuticals	4.82	4.79
Biotechnology	4.37	4.35
Data Processing & Outsourced Services	4.02	4.46
Health Care Technology	3.92	3.90
Industrial Machinery	3.02	3.25
Specialized Finance	3.02	2.93
Internet & Direct Marketing Retail	2.50	2.82
Aerospace & Defense	2.33	2.48
Construction & Engineering	2.31	2.45
Health Care Distributors	2.08	2.19
Other Diversified Financial Services	2.05	0.98
Fertilizers & Agricultural Chemicals	1.98	2.08
Health Care Services	1.94	1.84
Automotive Retail	1.92	2.31
Real Estate Operating Companies	1.90	1.93
Auto Parts & Equipment	1.89	0.46
Internet Services & Infrastructure	1.85	2.16
Personal Products	1.85	2.01
Home Improvement Retail	1.71	1.82
Metal & Glass Containers	1.69	1.91
Soft Drinks	1.68	1.35
Airport Services	1.64	1.72
Leisure Facilities	1.54	1.57
Insurance Brokers	1.48	1.33
Health Care Supplies	1.43	1.47
Diversified Support Services	1.35	1.47
Real Estate Services	1.35	1.59
Electrical Components & Equipment	1.25	1.32
Integrated Telecommunication Services	1.21	1.29
Specialty Chemicals	1.19	1.36
Movies & Entertainment	1.00	1.07
Advertising	0.98	1.08
Airlines	0.98	—
Distributors	0.93	0.98
Health Care Equipment	0.86	0.97
Environmental & Facilities Services	0.78	0.83
Oil & Gas Storage & Transportation	0.69	0.84
Home Furnishings	0.68	0.73
Hotels, Resorts & Cruise Lines	0.53	0.56
Systems Software	0.46	0.51
Consumer Finance	0.43	0.53
Education Services	0.34	0.34
Restaurants	0.33	0.35
Cable & Satellite	0.30	0.78
Research & Consulting Services	0.27	0.34
IT Consulting & Other Services	0.26	0.34
Integrated Oil & Gas	0.18	0.20
Apparel Retail	0.18	0.21
Real Estate Development	0.16	—
Air Freight & Logistics	0.16	0.26
Food Distributors	0.14	0.13
Diversified Banks	0.13	0.14
Specialized REITs	0.12	0.13
Technology Distributors	0.11	0.12
Housewares & Specialties	0.09	0.10
Construction Materials	0.07	0.08
Electronic Components	0.06	0.08
Alternative Carriers	0.01	0.01
Oil & Gas Refining & Marketing	—	0.34
Trading Companies & Distributors	—	0.22
Total	100.00 %	100.00 %

(1) This industry includes our investments in the JVs.

The Joint Ventures

Senior Loan Fund JV I, LLC

In May 2014, we entered into a limited liability company, or LLC, agreement with Kemper to form SLF JV I. We co-invest in senior secured loans of middle-market companies and other corporate debt securities with Kemper through our investment in SLF JV I. SLF JV I is managed by a four person Board of Directors, two of whom are selected by us and two of whom are selected by Kemper. All portfolio decisions and investment decisions in respect of SLF JV I must be approved by the SLF JV I investment committee, which consists of one representative selected by us and one representative selected by Kemper (with approval from a representative of each required). Since we do not have a controlling financial interest in SLF JV I, we do not consolidate SLF JV I. SLF JV I is not an "eligible portfolio company" as defined in section 2(a)(46) of the Investment Company Act. SLF JV I is capitalized pro rata with LLC equity interests as transactions are completed and may be capitalized with additional subordinated notes issued to us and Kemper by SLF JV I. The subordinated notes issued by SLF JV I are referred to as the SLF JV I Notes. The SLF JV I Notes are senior in right of payment to SLF JV I LLC equity interests and subordinated in right of payment to SLF JV I's secured debt.

As of December 31, 2022 and September 30, 2022, we and Kemper owned, in the aggregate, 87.5% and 12.5%, respectively, of the LLC equity interests of SLF JV I and the outstanding SLF JV I Notes. As of December 31, 2022, we and Kemper had funded approximately \$190.5 million to SLF JV I, of which \$166.7 million was from us. As of September 30, 2022, we and Kemper had funded approximately \$165.5 million to SLF JV I, of which \$144.8 million was from us. As of December 31, 2022, we had aggregate commitments to fund SLF JV I of \$13.1 million, of which approximately \$9.8 million was to fund additional SLF JV I Notes and approximately \$3.3 million was to fund LLC equity interests in SLF JV I. During the three months ended December 31, 2022, we contributed \$16.4 million to fund additional SLF JV I Notes and approximately \$5.5 million to fund additional LLC equity interests in SLF JV I. As of September 30, 2022, we had aggregate commitments to fund SLF JV I of \$35.0 million, of which approximately \$26.2 million was to fund additional SLF JV I Notes and approximately \$8.8 million was to fund LLC equity interests in SLF JV I.

Both the cost and fair value of our SLF JV I Notes were \$112.7 million as of December 31, 2022. Both the cost and fair value of our SLF JV I Notes were \$96.3 million as of September 30, 2022. We earned interest income of \$2.6 million and \$2.0 million on the SLF JV I Notes for the three months ended December 31, 2022 and 2021, respectively. As of December 31, 2022, the SLF JV I Notes bore interest at a rate of one-month LIBOR plus 7.00% per annum with a LIBOR floor of 1.00% and will mature on December 29, 2028.

The cost and fair value of the LLC equity interests in SLF JV I held by us was \$54.8 million and \$24.1 million, respectively, as of December 31, 2022, and \$49.3 million and \$20.7 million, respectively, as of September 30, 2022. We earned \$1.1 million and \$0.5 million in dividend income for the three months ended December 31, 2022 and December 31, 2021, respectively, with respect to our investment in the LLC equity interests of SLF JV I.

Below is a summary of SLF JV I's portfolio as of December 31, 2022 and September 30, 2022:

	December 31, 2022	September 30, 2022
Senior secured loans (1)	\$382,148	\$383,194
Weighted average interest rate on senior secured loans (2)	9.55%	8.33%
Number of borrowers in SLF JV I	59	60
Largest exposure to a single borrower (1)	\$11,337	\$10,093
Total of five largest loan exposures to borrowers (1)	\$51,990	\$48,139

(1) At principal amount.

(2) Computed using the weighted average annual interest rate on accruing senior secured loans at fair value.

See "Note 3. Portfolio Investments" in the notes to the accompanying financial statements for more information on SLF JV I and its portfolio.

On March 19, 2021, we became party to the LLC agreement of the Glick JV. The Glick JV invests primarily in senior secured loans of middle-market companies. We co-invest in these securities with GF Equity Funding through the Glick JV. The Glick JV is managed by a four person Board of Directors, two of whom are selected by us and two of whom are selected by GF Equity Funding. All portfolio decisions and investment decisions in respect of the Glick JV must be approved by the Glick JV investment committee, consisting of one representative selected by us and one representative selected by GF Equity Funding (with approval from a representative of each required). Since we do not have a controlling financial interest in the Glick JV, we do not consolidate the Glick JV. The Glick JV is not an "eligible portfolio company" as defined in section 2(a)(46) of the Investment Company Act. The Glick JV is capitalized as transactions are completed. The members provide capital to the Glick JV in exchange for LLC equity interests, and we and GF Debt Funding, an entity advised by affiliates of GF Equity Funding, provide capital to the Glick JV in exchange for subordinated notes issued by the Glick JV, or the Glick JV Notes. The Glick JV Notes are junior in right of payment to the repayment of temporary contributions made by us to fund investments of the Glick JV that are repaid when GF Equity Funding and GF Debt Funding make their capital contributions and fund their Glick JV Notes, respectively.

As of December 31, 2022 and September 30, 2022, we and GF Equity Funding owned 87.5% and 12.5%, respectively, of the outstanding LLC equity interests, and we and GF Debt Funding owned 87.5% and 12.5%, respectively, of the Glick JV Notes. Approximately \$84.0 million in aggregate commitments was funded as of each of December 31, 2022 and September 30, 2022, of which \$73.5 million was from us. As of December 31, 2022 and September 30, 2022, we had commitments to fund Glick JV Notes of \$78.8 million, of which \$12.4 million was unfunded. As of each of December 31, 2022 and September 30, 2022, we had commitments to fund LLC equity interests in the Glick JV of \$8.7 million, of which \$1.6 million was unfunded.

The cost and fair value of our aggregate investment in the Glick JV was \$50.0 million and \$49.5 million, respectively, as of December 31, 2022. The cost and fair value of our aggregate investment in the Glick JV was \$50.2 million and \$50.3 million, respectively, as of September 30, 2022. For the three months ended December 31, 2022 and December 31, 2021, our investment in the Glick JV Notes earned interest income of \$1.6 million and \$1.1 million, respectively. We did not earn any dividend income for the three months ended December 31, 2022 and December 31, 2021 with respect to our investment in the LLC equity interests of the Glick JV.

Below is a summary of the Glick JV's portfolio as of December 31, 2022 and September 30, 2022:

	December 31, 2022	September 30, 2022
Senior secured loans (1)	\$134,080	\$143,225
Weighted average current interest rate on senior secured loans (2)	9.86%	8.52%
Number of borrowers in the Glick JV	40	43
Largest loan exposure to a single borrower (1)	\$7,476	\$6,562
Total of five largest loan exposures to borrowers (1)	\$29,830	\$28,973

(1) At principal amount.

(2) Computed using the weighted average annual interest rate on accruing senior secured loans at fair value.

See "Note 3. Portfolio Investments" in the notes to the accompanying financial statements for more information on the Glick JV and its portfolio.

Discussion and Analysis of Results and Operations

Results of Operations

Net increase (decrease) in net assets resulting from operations includes net investment income, net realized gains (losses) and net unrealized appreciation (depreciation). Net investment income is the difference between our income from interest, dividends and fees and net expenses. Net realized gains (losses) is the difference between the proceeds received from dispositions of investment related assets and liabilities and their stated costs. Net unrealized appreciation (depreciation) is the net change in the fair value of our investment related assets and liabilities carried at fair value during the reporting period, including the reversal of previously recorded unrealized appreciation (depreciation) when gains or losses are realized.

Comparison of three months ended December 31, 2022 and December 31, 2021

Total Investment Income

Total investment income includes interest on our investments, fee income and dividend income.

Total investment income for the three months ended December 31, 2022 and 2021 was \$79.2 million and \$64.9 million, respectively. For the three months ended December 31, 2022, this amount consisted of \$76.1 million of interest income from portfolio investments (which included \$6.1 million of PIK interest), \$2.0 million of fee income and \$1.1 million of dividend income. For the three months ended December 31, 2021, this amount consisted of \$60.1 million of interest income from portfolio investments (which included \$4.7 million of PIK interest), \$0.9 million of fee income and \$3.9 million of dividend income. The increase of \$14.2 million, or 21.9%, in our total investment income for the three months ended December 31, 2022, as compared to the three months ended December 31, 2021, was due primarily to (1) a \$16.0 million increase in interest income, which was primarily driven by the impact of rising reference rates on interest income and (2) a \$1.1 million increase in fee income primarily due to higher exit and amendment fees. This was partially offset by a \$2.9 million decrease in dividend income.

Expenses

Net expenses (expenses net of fee waivers) for the three months ended December 31, 2022 and 2021 were \$40.3 million and \$29.3 million, respectively. Net expenses increased for the three months ended December 31, 2022, as compared to the three months ended December 31, 2021, by \$11.0 million, or 37.3%, primarily due to (1) a \$11.3 million increase in interest expense due to higher borrowings outstanding and the impact of rising reference rates and (2) a \$1.2 million increase in Part I incentive fees mainly due to higher total investment income. These were partially offset by \$1.8 million of lower accrued Part II incentive fees.

Net Investment Income

Primarily as a result of the \$14.2 million increase in total investment income, the \$11.0 million increase in net expenses and a \$3.3 million decrease in the provision for taxes on net investment income, net investment income for the three months ended December 31, 2022 increased by \$6.5 million compared to the three months ended December 31, 2021.

Realized Gain (Loss)

Realized gains or losses are measured by the difference between the net proceeds from the sale or redemption of investments and foreign currency and the cost basis without regard to unrealized appreciation or depreciation previously recognized, and includes investments written-off during the period, net of recoveries. Realized losses may also be recorded in connection with our determination that certain investments are considered worthless securities and/or meet the conditions for loss recognition per the applicable tax rules.

During the three months ended December 31, 2022 and 2021, we recorded aggregate net realized gains (losses) of \$(3.2) million and \$9.3 million, respectively, in connection with the exits of various investments and foreign currency forward contracts. See “*Note 8. Realized Gains or Losses and Net Unrealized Appreciation or Depreciation*” in the notes to the accompanying Consolidated Financial Statements for more details regarding investment realization events for the three months ended December 31, 2022 and 2021.

Net Unrealized Appreciation (Depreciation)

Net unrealized appreciation or depreciation is the net change in the fair value of our investments and foreign currency during the reporting period, including the reversal of previously recorded unrealized appreciation or depreciation when gains or losses are realized.

During the three months ended December 31, 2022 and 2021, we recorded net unrealized depreciation of \$23.0 million and \$4.6 million, respectively. For the three months ended December 31, 2022, this consisted of \$18.7 million of net unrealized depreciation on debt investments and \$11.0 million of net unrealized depreciation of foreign currency forward contracts, partially offset by \$3.9 million of net unrealized appreciation related to exited investments (a portion of which resulted in a reclassification to realized losses) and \$2.8 million of net unrealized appreciation on equity investments. For the three months ended December 31, 2021, this consisted of \$4.7 million of net unrealized depreciation related to exited investments (a portion of which resulted in a reclassification to realized gains), \$1.8 million of net unrealized depreciation on debt investments and \$0.8 million of net unrealized depreciation of foreign currency forward contracts, partially offset by \$2.8 million of net unrealized appreciation on equity investments.

Financial Condition, Liquidity and Capital Resources

We have a number of alternatives available to fund our investment portfolio and our operations, including raising equity, increasing or refinancing debt and funding from operational cash flow. We generally expect to fund the growth of our investment portfolio through additional debt and equity capital, which may include securitizing a portion of our investments. We cannot assure you, however, that our efforts to grow our portfolio will be successful. For example, our common stock has generally traded at prices below net asset value for the past several years, and we may not be able to raise additional equity at prices below the then-current net asset value per share. We intend to continue to generate cash primarily from cash flows from operations, including interest earned, and future borrowings or equity offerings. We intend to fund our future distribution obligations through operating cash flow or with funds obtained through future equity and debt offerings or credit facilities, as we deem appropriate.

Our primary uses of funds are investments in our targeted asset classes and cash distributions to holders of our common stock. We may also from time to time repurchase or redeem some or all of our outstanding notes. At a special meeting of our stockholders held on June 28, 2019, our stockholders approved the application of the reduced asset coverage requirements in Section 61(a)(2) of the Investment Company Act to us effective as of June 29, 2019. As a result of the reduced asset coverage requirement, we can incur \$2 of debt for each \$1 of equity as compared to \$1 of debt for each \$1 of equity. As of December 31, 2022, we had \$1,514.4 million in senior securities and our asset coverage ratio was 176.3%. During the year ended September 30, 2022, we increased our target debt to equity ratio from 0.85x to 1.0x to 0.90x to 1.25x (i.e., one dollar of equity for each \$0.90 to \$1.25 of debt outstanding) to provide us with increased capacity to opportunistically deploy capital into the markets. As of December 31, 2022, our net debt to equity ratio was 1.24x.

For the three months ended December 31, 2022, we experienced a net decrease in cash and cash equivalents (including restricted cash) of \$7.1 million. During that period, net cash used in operating activities was \$109.9 million, primarily from funding \$261.4 million of investments and \$10.0 million of net decrease in payables from unsettled transactions, partially offset by \$108.8 million of principal payments and sale proceeds received, the cash activities related to \$38.8 million of net investment income and a \$16.3 million increase in due from portfolio companies. During the same period, net cash provided by financing activities was \$103.3 million, primarily consisting of \$160.0 million of net borrowings under the credit facilities, partially offset by \$56.7 million of cash distributions paid to our stockholders.

For the three months ended December 31, 2021, we experienced a net increase in cash and cash equivalents (including restricted cash) of \$14.4 million. During that period, we received \$23.2 million of net cash from operating activities, primarily from \$235.0 million of principal payments and sale proceeds received, \$15.0 million of net increases in payables from unsettled transactions and the cash activities related to \$32.3 million of net investment income, partially offset by funding \$246.6 million of investments. During the same period, net cash used by financing activities was \$7.5 million, primarily consisting of \$27.2 million of cash distributions paid to our stockholders and \$0.3 million of deferred financing costs paid, partially offset by \$20.0 million of net borrowings under the credit facilities.

As of December 31, 2022, we had \$19.2 million in cash and cash equivalents (including \$1.9 million of restricted cash), portfolio investments (at fair value) of \$2.6 billion, \$37.8 million of interest, dividends and fees receivable, \$6.2 million of due from portfolio companies, \$340.0 million of undrawn capacity on our credit facilities (subject to borrowing base and other limitations), \$12.3 million of net payables from unsettled transactions, \$860.0 million of borrowings outstanding under our credit facilities and \$603.6 million of unsecured notes payable (net of unamortized financing costs, unaccreted discount and interest rate swap fair value adjustment).

As of September 30, 2022, we had \$26.4 million in cash and cash equivalents (including \$2.8 million of restricted cash), portfolio investments (at fair value) of \$2.5 billion, \$35.6 million of interest, dividends and fees receivable, \$22.5 million of due from portfolio companies, \$500.0 million of undrawn capacity on our credit facilities (subject to borrowing base and other limitations), \$22.3 million of net payables from unsettled transactions, \$700.0 million of borrowings outstanding under our credit facilities and \$601.0 million of unsecured notes payable (net of unamortized financing costs, unaccreted discount and interest rate swap fair value adjustment).

We may be a party to financial instruments with off-balance sheet risk in the normal course of business to meet the financial needs of our portfolio companies. As of December 31, 2022, our only off-balance sheet arrangements consisted of \$198.9 million of unfunded commitments, which was comprised of \$171.8 million to provide debt and equity financing to certain of our portfolio companies and \$27.1 million to provide financing to the JVs. As of September 30, 2022, our only off-balance sheet arrangements consisted of \$224.2 million of unfunded commitments, which was comprised of \$175.2 million to provide debt and equity financing to certain of our portfolio companies and \$49.0 million to provide financing to the JVs.

As of December 31, 2022, we have analyzed cash and cash equivalents, availability under our credit facilities, the ability to rotate out of certain assets and amounts of unfunded commitments that could be drawn and believe our liquidity and capital resources are sufficient to take advantage of market opportunities in the current economic climate.

Contractual Obligations

The following table reflects information pertaining to our principal debt outstanding under the Syndicated Facility (as defined below), Citibank Facility (as defined below), our 3.500% notes due 2025, or the 2025 Notes, and our 2.700% notes due 2027, or the 2027 Notes:

	Debt Outstanding as of September 30, 2022	Debt Outstanding as of December 31, 2022	Weighted average debt outstanding for the three months ended December 31, 2022	Maximum debt outstanding for the three months ended December 31, 2022
Syndicated Facility	\$ 540,000	\$ 695,000	\$ 627,826	\$ 710,000
Citibank Facility	160,000	165,000	163,500	175,000
2025 Notes	300,000	300,000	300,000	300,000
2027 Notes	350,000	350,000	350,000	350,000
Total debt	\$ 1,350,000	\$ 1,510,000	\$ 1,441,326	

The following table reflects our contractual obligations arising from the Syndicated Facility, Citibank Facility, 2025 Notes and 2027 Notes:

Contractual Obligations	Payments due by period as of December 31, 2022			
	Total	Less than 1 year	1-3 years	3-5 years
Syndicated Facility	\$ 695,000	\$ —	\$ —	\$ 695,000
Interest due on Syndicated Facility	145,376	43,494	86,988	14,894
Citibank Facility	165,000	—	165,000	—
Interest due on Citibank Facility	20,573	10,915	9,658	—
2025 Notes	300,000	—	300,000	—
Interest due on 2025 Notes	22,640	10,500	12,140	—
2027 Notes	350,000	—	—	350,000
Interest due on 2027 Notes (a)	81,200	20,080	40,160	20,960
Total	\$ 1,779,789	\$ 84,989	\$ 613,946	\$ 1,080,854

(a) The interest due on the 2027 Notes was calculated net of the interest rate swap.

Equity Issuances

During the three months ended December 31, 2022 and 2021, we issued an aggregate of 94,879 and 35,990, respectively, shares of common stock as part of the DRIP.

On February 7, 2022, we entered into an equity distribution agreement by and among us, Oaktree, Oaktree Administrator and Keefe, Bruyette & Woods, Inc., JMP Securities LLC, Raymond James & Associates, Inc. and SMBC Nikko Securities America, Inc., as placement agents, in connection with the issuance and sale by us of shares of common stock, having an aggregate offering price of up to \$125.0 million. Sales of the common stock, if any, may be made in negotiated transactions or transactions that are deemed to be “at the market,” as defined in Rule 415 under the Securities Act of 1933, as amended, including sales made directly on the Nasdaq Global Select Market or similar securities exchanges or sales made to or through a market maker other than on an exchange, at prices related to the prevailing market prices or at negotiated prices.

In connection with the "at the market" offering, we did not issue or sell any shares of common stock during the three months ended December 31, 2022.

Distributions

The following table reflects the distributions per share that we have paid, including shares issued under our DRIP, on our common stock since October 1, 2020. The distributions per share and shares issued under our DRIP information disclosed in this table has been retrospectively adjusted to reflect our 1-for-3 reverse stock split completed on January 20, 2023 and effective as of the commencement of trading on January 23, 2023.

Distribution	Date Declared	Record Date	Payment Date	Amount per Share	Cash Distribution	DRIP Shares Issued (1)	DRIP Shares Value
Quarterly	November 13, 2020	December 15, 2020	December 31, 2020	\$ 0.33	\$ 15.0 million	31,321	\$ 0.5 million
Quarterly	January 29, 2021	March 15, 2021	March 31, 2021	0.36	16.4 million	27,234	0.5 million
Quarterly	April 30, 2021	June 15, 2021	June 30, 2021	0.39	22.9 million	25,660	0.5 million
Quarterly	July 30, 2021	September 15, 2021	September 30, 2021	0.435	25.5 million	28,358	0.6 million
Quarterly	October 13, 2021	December 15, 2021	December 31, 2021	0.465	27.2 million	35,990	0.8 million
Quarterly	January 28, 2022	March 15, 2022	March 31, 2022	0.48	28.5 million	34,804	0.8 million
Quarterly	April 29, 2022	June 15, 2022	June 30, 2022	0.495	29.4 million	43,676	0.9 million
Quarterly	July 29, 2022	September 15, 2022	September 30, 2022	0.51	30.2 million	51,181	1.0 million
Quarterly	November 10, 2022	December 15, 2022	December 30, 2022	0.54	32.0 million	53,369	1.1 million
Special	November 10, 2022	December 15, 2022	December 30, 2022	0.42	24.8 million	41,510	0.8 million

(1) Shares were purchased on the open market and distributed other than with respect to the distributions paid on December 31, 2021, March 31, 2022 and December 30, 2022. New shares were issued and distributed during the quarters ended December 31, 2021, March 31, 2022 and December 31, 2022.

Indebtedness

See "Note 6. Borrowings" in the Consolidated Financial Statements for more details regarding our indebtedness.

Syndicated Facility

As of December 31, 2022, (i) the size of our senior secured revolving credit facility, or, as amended and/or restated from time to time, the Syndicated Facility, pursuant to a senior secured revolving credit agreement, with the lenders, ING Capital LLC, as administrative agent, ING Capital LLC, JPMorgan Chase Bank, N.A., BofA Securities, Inc. and MUFG Union Bank, N.A. as joint lead arrangers and joint bookrunners, and JPMorgan Chase Bank, N.A. and Bank of America, N.A., as syndication agents, was \$1.0 billion (with an "accordion" feature that permits us, under certain circumstances, to increase the size of the facility to up to the greater of \$1.25 billion and our net worth (as defined in the Syndicated Facility) on the date of such increase), (ii) the period during which we may make drawings will expire on May 4, 2025 and the maturity date was May 4, 2026 and (iii) the interest rate margin for (a) LIBOR loans (which may be 1-, 2-, 3- or 6-month, at our option) was 2.00% and (b) alternate base rate loans was 1.00%.

Each loan or letter of credit originated or assumed under the Syndicated Facility is subject to the satisfaction of certain conditions. Borrowings under the Syndicated Facility are subject to the facility's various covenants and the leverage restrictions contained in the Investment Company Act. We cannot assure you that we will be able to borrow funds under the Syndicated Facility at any particular time or at all.

The following table describes significant financial covenants, as of December 31, 2022, with which we must comply under the Syndicated Facility on a quarterly basis:

Financial Covenant	Description	Target Value	September 30, 2022 Reported Value (1)
Minimum shareholders' equity	Net assets shall not be less than the sum of (x) \$600 million, plus (y) 50% of the aggregate net proceeds of all sales of equity interests after May 6, 2020	\$610 million	\$1,246 million
Asset coverage ratio	Asset coverage ratio shall not be less than the greater of 1.50:1 and the statutory test applicable to us	1.50:1	1.89:1
Interest coverage ratio	Interest coverage ratio shall not be less than 2.25:1	2.25:1	4.01:1
Minimum net worth	Net worth shall not be less than \$550 million	\$550 million	\$1,034 million

(1) As contractually required, we report financial covenants based on the last filed quarterly or annual report, in this case our Annual Report on Form 10-K for the year ended September 30, 2022. We were in compliance with all financial covenants under the Syndicated Facility based on the financial information contained in this Quarterly Report on Form 10-Q.

As of December 31, 2022 and September 30, 2022, we had \$695.0 million and \$540.0 million of borrowings outstanding under the Syndicated Facility, respectively, which had a fair value of \$695.0 million and \$540.0 million, respectively. Our borrowings under the Syndicated Facility bore interest at a weighted average interest rate of 5.849% and 2.174% for the three months ended December 31, 2022 and 2021, respectively. For the three months ended December 31, 2022 and 2021, we recorded interest expense (inclusive of fees) of \$10.0 million and \$3.8 million, respectively, related to the Syndicated Facility.

Citibank Facility

On March 19, 2021, we became party to a revolving credit facility, or, as amended and/or restated from time to time, the Citibank Facility, with OCSL Senior Funding II LLC, our wholly-owned, special purpose financing subsidiary, as the borrower, us, as collateral manager and seller, each of the lenders from time to time party thereto, Citibank, N.A., as administrative agent, and Wells Fargo Bank, National Association, as collateral agent and custodian. As of December 31, 2022, we were able to borrow up to \$200 million under the Citibank Facility (subject to borrowing base and other limitations). As of December 31, 2022, the reinvestment period under the Citibank Facility was scheduled to expire on November 18, 2023 and the maturity date for the Citibank Facility was November 18, 2024.

As of December 31, 2022, borrowings under the Citibank Facility are subject to certain customary advance rates and accrue interest at a rate equal to LIBOR plus between 1.25% and 2.20% per annum on broadly syndicated loans, subject to observable market depth and pricing, and LIBOR plus 2.25% per annum on all other eligible loans during the reinvestment period. In addition, as of December 31, 2022, for the duration of the reinvestment period there is a non-usage fee payable of 0.50% per annum on the undrawn amount under the Citibank Facility. The minimum asset coverage ratio applicable to us under the Citibank Facility is 150% as determined in accordance with the requirements of the Investment Company Act. Borrowings under the Citibank Facility are secured by all of the assets of OCSL Senior Funding II LLC and all of our equity interests in OCSL Senior Funding II LLC. We may use the Citibank Facility to fund a portion of our loan origination activities and for general corporate purposes. Each loan origination under the Citibank Facility is subject to the satisfaction of certain conditions.

As of December 31, 2022 and September 30, 2022, we had \$165.0 million and \$160.0 million outstanding under the Citibank Facility, respectively, which had a fair value of \$165.0 million and \$160.0 million, respectively. Our borrowings under the Citibank Facility bore interest at a weighted average interest rate of 6.508% and 1.830% for the three months ended December 31, 2022 and December 31, 2021, respectively. For the three months ended December 31, 2022 and December 31, 2021, we recorded interest expense (inclusive of fees) of \$2.7 million and \$0.8 million, respectively, related to the Citibank Facility.

2025 Notes

On February 25, 2020, we issued \$300.0 million in aggregate principal amount of the 2025 Notes for net proceeds of \$293.8 million after deducting OID of \$2.5 million, underwriting commissions and discounts of \$3.0 million and offering costs of \$0.7 million. The OID on the 2025 Notes is amortized based on the effective interest method over the term of the notes.

2027 Notes

On May 18, 2021, we issued \$350.0 million in aggregate principal amount of the 2027 Notes for net proceeds of \$344.8 million after deducting OID of \$1.0 million, underwriting commissions and discounts of \$3.5 million and offering costs of \$0.7 million. The OID on the 2027 Notes is amortized based on the effective interest method over the term of the notes.

In connection with the 2027 Notes, we entered into an interest rate swap to more closely align the interest rates of our liabilities with our investment portfolio, which consists of predominately floating rate loans. Under the interest rate swap

agreement, we receive a fixed interest rate of 2.700% and pay a floating interest rate of the three-month LIBOR plus 1.658% on a notional amount of \$350 million. We designated the interest rate swap as the hedging instrument in an effective hedge accounting relationship.

The below table presents the components of the carrying value of the 2025 Notes and the 2027 Notes as of December 31, 2022 and September 30, 2022:

(\$ in millions)	As of December 31, 2022		As of September 30, 2022	
	2025 Notes	2027 Notes	2025 Notes	2027 Notes
Principal	\$ 300.0	\$ 350.0	\$ 300.0	\$ 350.0
Unamortized financing costs	(1.6)	(3.1)	(1.8)	(3.2)
Unaccreted discount	(1.1)	(0.7)	(1.2)	(0.7)
Interest rate swap fair value adjustment	—	(39.9)	—	(42.0)
Net carrying value	\$ 297.3	\$ 306.3	\$ 297.0	\$ 304.1
Fair Value	\$ 286.7	\$ 296.8	\$ 283.1	\$ 294.0

The below table presents the components of interest and other debt expenses related to the 2025 Notes and the 2027 Notes for the three months ended December 31, 2022:

(\$ in millions)	2025 Notes	2027 Notes
Coupon interest	\$ 2.6	\$ 2.4
Amortization of financing costs and discount	0.3	0.2
Effect of interest rate swap	—	2.5
Total interest expense	\$ 2.9	\$ 5.1
Coupon interest rate (net of effect of interest rate swap for 2027 Notes)	3.500 %	5.586 %

The below table presents the components of interest and other debt expenses related to the 2025 Notes and the 2027 Notes for the three months ended December 31, 2021:

(\$ in millions)	2025 Notes	2027 Notes
Coupon interest	\$ 2.6	\$ 2.4
Amortization of financing costs and discount	0.3	0.2
Effect of interest rate swap	—	(0.7)
Total interest expense	\$ 2.9	\$ 1.9
Coupon interest rate (net of effect of interest rate swap for 2027 Notes)	3.500 %	1.782 %

Regulated Investment Company Status and Distributions

We have qualified and elected to be treated as a RIC under Subchapter M of the Code for U.S. federal income tax purposes. As long as we continue to qualify as a RIC, we will not be subject to tax on our investment company taxable income (determined without regard to any deduction for dividends paid) or realized net capital gains, to the extent that such taxable income or gains is distributed, or deemed to be distributed as dividends, to stockholders on a timely basis.

Taxable income generally differs from net income for financial reporting purposes due to temporary and permanent differences in the recognition of income and expenses, and generally excludes net unrealized appreciation or depreciation. Distributions declared and paid by us in a taxable year may differ from taxable income for that taxable year as such distributions may include the distribution of taxable income derived from the current taxable year or the distribution of taxable income derived from the prior taxable year carried forward into and distributed in the current taxable year. Distributions also may include returns of capital.

To maintain RIC tax treatment, we must, among other things, distribute dividends, with respect to each taxable year, of an amount at least equal to 90% of our investment company taxable income (i.e., our net ordinary income and our realized net short-term capital gains in excess of realized net long-term capital losses, if any), determined without regard to any deduction for dividends paid. As a RIC, we are also subject to a federal excise tax, based on distribution requirements of our taxable income on a calendar year basis. We anticipate timely distribution of our taxable income in accordance with tax rules. We did

not incur a U.S. federal excise tax for calendar year 2021. For the calendar year 2022, we incurred \$0.1 million of excise tax. We do not expect to incur a U.S. federal excise tax for calendar year 2023.

We intend to distribute at least 90% of our annual taxable income (which includes our taxable interest and fee income) to our stockholders. The covenants contained in our credit facilities may prohibit us from making distributions to our stockholders, and, as a result, could hinder our ability to satisfy the distribution requirement associated with our ability to be subject to tax as a RIC. In addition, we may retain for investment some or all of our net capital gains (i.e., realized net long-term capital gains in excess of realized net short-term capital losses) and treat such amounts as deemed distributions to our stockholders. If we do this, our stockholders will be treated as if they received actual distributions of the capital gains we retained and then reinvested the net after-tax proceeds in our common stock. Our stockholders also may be eligible to claim tax credits (or, in certain circumstances, tax refunds) equal to their allocable share of the tax we paid on the capital gains deemed distributed to them. To the extent our taxable earnings for a fiscal and taxable year fall below the total amount of our dividend distributions for that fiscal and taxable year, a portion of those distributions may be deemed a return of capital to our stockholders.

We may not be able to achieve operating results that will allow us to make distributions at a specific level or to increase the amount of these distributions from time to time. In addition, we may be limited in our ability to make distributions due to the asset coverage test for borrowings applicable to us as a Business Development Company under the Investment Company Act and due to provisions in our credit facilities and debt instruments. If we do not distribute a certain percentage of our taxable income annually, we will suffer adverse tax consequences, including possible loss of our ability to be subject to tax as a RIC. We cannot assure stockholders that they will receive any distributions or distributions at a particular level.

A RIC may treat a distribution of its own stock as fulfilling its RIC distribution requirements if each stockholder elects to receive his or her entire distribution in either cash or stock of the RIC, subject to certain limitations regarding the aggregate amount of cash to be distributed to all stockholders. If these and certain other requirements are met, for U.S. federal income tax purposes, the amount of the dividend paid in stock will be equal to the amount of cash that could have been received instead of stock.

We may generate qualified net interest income or qualified net short-term capital gains that may be exempt from U.S. withholding tax when distributed to foreign stockholders. A RIC is permitted to designate distributions of qualified net interest income and qualified short-term capital gains as exempt from U.S. withholding tax when paid to non-U.S. shareholders with proper documentation. The following table, which may be subject to change as we finalize our annual tax filings, lists the percentage of qualified net interest income and qualified short-term capital gains for the year ended September 30, 2022.

Year Ended	Qualified Net Interest Income	Qualified Short-Term Capital Gains
September 30, 2022	80.8 %	—

We have adopted a DRIP that provides for the reinvestment of any distributions that we declare in cash on behalf of our stockholders, unless a stockholder elects to receive cash. As a result, if our Board of Directors declares a cash distribution, then our stockholders who have not “opted out” of the DRIP will have their cash distributions automatically reinvested in additional shares of our common stock, rather than receiving a cash distribution. If our shares are trading at a premium to net asset value, we typically issue new shares to implement the DRIP, with such shares issued at the greater of the most recently computed net asset value per share of our common stock or 95% of the current market value per share of our common stock on the payment date for such distribution. If our shares are trading at a discount to net asset value, we typically purchase shares in the open market in connection with our obligations under the DRIP.

Related Party Transactions

We have entered into the Investment Advisory Agreement with Oaktree and the Administration Agreement with Oaktree Administrator, an affiliate of Oaktree. Mr. John B. Frank, an interested member of our Board of Directors, has an indirect pecuniary interest in Oaktree. Oaktree is a registered investment adviser under the Investment Advisers Act of 1940, as amended, that is partially and indirectly owned by Oaktree Capital Group, LLC. See “*Note 10. Related Party Transactions – Investment Advisory Agreement*” and “*– Administrative Services*” in the notes to the accompanying Consolidated Financial Statements.

Recent Developments

Distribution Declaration

On January 27, 2023, our Board of Directors declared a quarterly distribution of \$0.55 per share, payable in cash on March 31, 2023 to stockholders of record on March 15, 2023.

Investment Advisory Agreement

On January 23, 2023, in connection with the consummation of the OSI2 Merger, we entered into an amended and restated investment advisory agreement with Oaktree to amend and restate the prior investment advisory agreement, dated as of March 19, 2021, by and between us and Oaktree to (1) waive an aggregate of \$9.0 million of base management fees otherwise payable to the Oaktree in the two years following the closing of the OSI2 Merger and (2) revise the calculation of the incentive fees to eliminate certain unintended consequences of the accounting treatment of the OSI2 Merger on the incentive fees payable to Oaktree. None of the other terms were changed, and the services to be provided by Oaktree and the term of the Investment Advisory Agreement remain the same.

OSI2 Merger

On January 23, 2023, we completed the OSI2 Merger. In accordance with the terms of the OSI2 Merger Agreement, at the effective time of the OSI2 Merger, each outstanding share of OSI2 common stock was converted into the right to receive 0.9115 shares of our common stock (with OSI2's stockholders receiving cash in lieu of fractional shares of our common stock). As a result of the OSI2 Merger, we issued an aggregate of 15,860,200 shares of its common stock to former OSI2 stockholders. Following completion of the OSI2 Merger, we had 77,079,805 shares of common stock outstanding.

OSI2 Citibank Facility

On January 23, 2023, as a result of the consummation of the OSI2 Merger, we became party to the OSI2 Citibank Facility (as described below).

OSI 2 Senior Lending SPV, LLC, or OSI 2 SPV, our wholly-owned and consolidated subsidiary, is party to a loan and security agreement dated as of July 26, 2019, which was subsequently amended on September 20, 2019, July 2, 2020, December 31, 2020, March 31, 2021 and December 2, 2022, or, as amended, the OSI2 Citibank Loan Agreement, with the lenders from time to time party thereto and the other parties referenced below. Under the terms of the OSI2 Citibank Loan Agreement, we serve as the collateral manager and seller and OSI 2 SPV serves as borrower with Citibank, N.A., as administrative agent, and Deutsche Bank Trust Company Americas, as collateral agent.

The OSI2 Citibank Loan Agreement provides for a senior secured revolving credit facility, or the OSI2 Citibank Facility of up to \$250 million, or the Citibank Maximum Commitment, in aggregate principal amount, subject to the lesser of (i) the borrowing base, which is an amount based on advance rates that vary depending on the class of assets and the value assigned to such assets under the OSI2 Citibank Loan Agreement and (ii) the Citibank Maximum Commitment. The OSI2 Citibank Facility has a reinvestment period through May 26, 2023, during which advances may be made, and matures on January 26, 2025. Following the reinvestment period, OSI 2 SPV will be required to make certain mandatory amortization payments. Borrowings under the OSI2 Citibank Facility bear interest payable quarterly at a rate per year equal to (a) in the case of a lender that is identified as a conduit lender under the OSI2 Citibank Loan Agreement, the lesser of (i) the applicable commercial paper rate for such conduit lender and (ii) LIBOR for a three month maturity and (b) for all other lenders under the OSI2 Citibank Facility, LIBOR, plus, in each case, an applicable spread. During the reinvestment period, the applicable spread is the greater of (i) a weighted average rate of (x) 1.65% per year for broadly syndicated loans and (y) 2.25% per year for all other eligible loans and (ii) 1.85%. After the reinvestment period, the applicable spread is 3.00% per year. There is also a non-usage fee of 0.50% per year thereafter on the unused portion of the OSI2 Citibank Facility, payable quarterly; provided that if the unused portion of the OSI2 Citibank Facility is greater than 30% of the commitments under the OSI2 Citibank Facility, the non-usage fee will be based on an unused portion of 30% of the commitments under the OSI2 Citibank Facility.

The OSI2 Citibank Facility is secured by a first priority security interest in substantially all of OSI 2 SPV's assets.

As part of the OSI2 Citibank Facility, OSI 2 SPV is subject to certain limitations as to how borrowed funds may be used and the types of loans that are eligible to be acquired by OSI 2 SPV including restrictions on sector concentrations, loan size, tenor and minimum investment ratings (or estimated ratings). The OSI2 Citibank Facility also contains certain requirements relating to interest coverage, collateral quality and portfolio performance, certain violations of which could result in the acceleration of the amounts due under the OSI2 Citibank Facility.

Under the OSI2 Citibank Facility, we and OSI 2 SPV, as applicable, have made customary representations and warranties, and are required to comply with various affirmative and negative covenants, reporting requirements and other customary requirements for similar credit facilities.

OSI 2 SPV's borrowings are non-recourse to us but are considered our borrowings for purposes of complying with the asset coverage requirements under the Investment Company Act.

As of January 23, 2023, we had \$225.0 million outstanding under the OSI2 Citibank Facility.

Reverse Stock Split

On January 20, 2023, we amended our restated certificate of incorporation, as amended and corrected, to effect a 1-for-3 reverse stock split. Following completion of the reverse stock split, we had 61,219,605 shares of common stock outstanding.

Item 3. Quantitative and Qualitative Disclosures about Market Risk

We are subject to financial market risks, including changes in the valuations of our investment portfolio and interest rates.

Valuation Risk

Our investments may not have a readily available market price, and we value these investments at fair value as determined by Oaktree, as our valuation designee. There is no single standard for determining fair value in good faith and valuation methodologies involve a significant degree of management judgment. In addition, our valuation methodology utilizes discount rates in part in valuing our investments, and changes in those discount rates may have an impact on the valuation of our investments. Accordingly, valuations by Oaktree do not necessarily represent the amounts which may eventually be realized from sales or other dispositions of investments. Estimated fair values may differ from the values that would have been used had a ready market for the investment existed, and the differences could be material to the financial statements.

Interest Rate Risk

We are subject to financial market risks, including changes in interest rates. Changes in interest rates may affect both our cost of funding and our interest income from portfolio investments, cash and cash equivalents and idle fund investments. Our risk management procedures are designed to identify and analyze our risk, to set appropriate policies and to continually monitor these risks. Our investment income will be affected by changes in various interest rates, including LIBOR, SOFR, SONIA and prime rates, to the extent our debt investments include floating interest rates.

As of December 31, 2022, 87.3% of our debt investment portfolio (at fair value) and 87.2% of our debt investment portfolio (at cost) bore interest at floating rates. As of September 30, 2022, 86.5% of our debt investment portfolio (at fair value) and 86.3% of our debt investment portfolio (at cost) bore interest at floating rates. The composition of our floating rate debt investments by interest rate floor as of December 31, 2022 and September 30, 2022, was as follows:

(\$ in thousands)	December 31, 2022		September 30, 2022	
	Fair Value	% of Floating Rate Portfolio	Fair Value	% of Floating Rate Portfolio
0%	\$ 242,898	11.1 %	\$ 228,186	11.1 %
>0% and <1%	431,661	19.7 %	388,458	19.0 %
1%	1,397,099	63.9 %	1,364,668	66.6 %
>1%	116,535	5.3 %	68,332	3.3 %
Total Floating Rate Investments	\$ 2,188,193	100.0 %	\$ 2,049,644	100.0 %

Based on our Consolidated Statement of Assets and Liabilities as of December 31, 2022, the following table shows the approximate annualized net increase (decrease) in net assets resulting from operations (excluding the impact of any potential incentive fees) of hypothetical base rate changes in interest rates, assuming no changes in our investment and capital structure. However, there can be no assurances our portfolio companies will be able to meet their contractual obligations at any or all levels on increases in interest rates.

(\$ in thousands) Basis point increase	Increase in Interest Income	(Increase) in Interest Expense	Net increase in net assets resulting from operations
250	\$ 57,529	\$ (30,250)	\$ 27,279
200	46,020	(24,200)	21,820
150	34,512	(18,150)	16,362
100	23,004	(12,100)	10,904
50	11,498	(6,050)	5,448

(\$ in thousands) Basis point decrease	(Decrease) in Interest Income	Decrease in Interest Expense	Net (decrease) in net assets resulting from operations
50	\$ (11,471)	\$ 6,050	\$ (5,421)
100	(22,729)	12,100	(10,629)
150	(33,959)	18,150	(15,809)
200	(45,156)	24,200	(20,956)
250	(56,204)	30,250	(25,954)

We regularly measure exposure to interest rate risk. We assess interest rate risk and manage our interest rate exposure on an ongoing basis by comparing our interest rate sensitive assets to our interest rate sensitive liabilities. Based on this review, we determine whether or not any hedging transactions are necessary to mitigate exposure to changes in interest rates. The following table shows a comparison of the interest rate base for our interest-bearing cash and outstanding investments, at principal, and our outstanding borrowings as of December 31, 2022 and September 30, 2022:

(\$ in thousands)	December 31, 2022		September 30, 2022	
	Interest Bearing Cash and Investments	Borrowings	Interest Bearing Cash and Investments	Borrowings
Money market rate	\$ 3,421	\$ —	\$ 5,262	\$ —
Prime rate	305	—	2,618	—
LIBOR				
30 day	593,798	695,000	669,273	540,000
90 day (a)	1,030,274	515,000	928,978	510,000
180 day	91,244	—	199,301	—
EURIBOR				
30 day	€ 24,838	—	€ 24,838	—
90 day	30,810	—	16,911	—
180 day	14,304	—	1,964	—
SOFR				
30 day	\$ 142,913	—	\$ 50,099	—
90 day	285,690	—	190,799	—
180 day	47,323	—	18,390	—
SONIA	£ 40,137	—	£ 40,137	—
Fixed rate	\$ 338,548	300,000	\$ 341,749	300,000

(a) Borrowings include the 2027 Notes, which pay interest at a floating rate under the terms of the interest rate swap.

Item 4. Controls and Procedures

(a) Evaluation of Disclosure Controls and Procedures

Management, with the participation of our Chief Executive Officer and Chief Financial Officer, evaluated the effectiveness of our disclosure controls and procedures as of December 31, 2022. The term “disclosure controls and procedures,” as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended, or the Exchange Act, means controls and other procedures of a company that are designed to ensure that information required to be disclosed by a company in the reports that it files or submits under the Exchange Act is recorded, processed, summarized and reported, within the time periods specified in the Securities and Exchange Commission’s rules and forms. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed by a company in the reports that it files or submits under the Exchange Act is accumulated and communicated to the company’s management, including its chief executive officer and chief financial officer, as appropriate to allow timely decisions regarding required disclosure. Management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving their objectives. Based on the evaluation of our disclosure controls and procedures as of December 31, 2022, our Chief Executive Officer and Chief Financial Officer concluded that our disclosure controls and procedures were effective, at the reasonable assurance level, in timely identifying, recording, processing, summarizing and reporting any material information relating to us that is required to be disclosed in the reports we file or submit under the Exchange Act.

There were no changes in our internal control over financial reporting that occurred during the three months ended December 31, 2022 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

PART II

Item 1. Legal Proceedings

We are currently not a party to any pending material legal proceedings.

Item 1A. Risk Factors

There have been no material changes during the three months ended December 31, 2022 to the risk factors discussed in Item 1A. Risk Factors in our Annual Report on Form 10-K for the year ended September 30, 2022.

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds.

None.

Item 3. Defaults Upon Senior Securities

None.

Item 4. Mine Safety Disclosures

Not applicable.

Item 5. Other Information

None.

Item 6. Exhibits

<u>3.1</u>	Restated Certificate of Incorporation of the Registrant (incorporated by reference to Exhibit 3.1 filed with Registrant's Form 8-A (File No. 001-33901) filed on January 2, 2008).
<u>3.2</u>	Certificate of Amendment to the Registrant's Restated Certificate of Incorporation (incorporated by reference to Exhibit (a)(2) filed with Registrant's Registration Statement on Form N-2 (File No. 333-146743) filed on June 6, 2008).
<u>3.3</u>	Certificate of Correction to the Certificate of Amendment to the Registrant's Restated Certificate of Incorporation (Incorporated by reference to Exhibit (a)(3) filed with Registrant's Registration Statement on Form N-2 (File No. 333-146743) filed on June 6, 2008).
<u>3.4</u>	Certificate of Amendment to Registrant's Restated Certificate of Incorporation (incorporated by reference to Exhibit 3.1 filed with Registrant's Quarterly Report on Form 10-Q (File No. 001-33901) filed on May 5, 2010).
<u>3.5</u>	Certificate of Amendment to Registrant's Certificate of Incorporation (incorporated by reference to Exhibit (a)(5) filed with the Registrant's Registration Statement on Form N-2 (File No. 333-180267) filed on April 2, 2013).
<u>3.6</u>	Certificate of Amendment to the Restated Certificate of Incorporation of the Registrant, dated as of October 17, 2017 (incorporated by reference to Exhibit 3.1 filed with the Registrant's Form 8-K (File No. 814-00755) filed on October 17, 2017).
<u>3.7</u>	Certificate of Amendment to the Restated Certificate of Incorporation of the Registrant, dated as of January 20, 2023 (incorporated by reference to Exhibit 3.7 filed with the Registrant's Form 8-K (File No. 814-00755) filed on January 20, 2023).
<u>31.1*</u>	Certification of Chief Executive Officer Pursuant to Rule 13a-14(a) under the Securities Exchange Act of 1934.
<u>31.2*</u>	Certification of Chief Financial Officer Pursuant to Rule 13a-14(a) under the Securities Exchange Act of 1934.
<u>32.1*</u>	Certification of Chief Executive Officer Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 (18 U.S.C. 1350).
<u>32.2*</u>	Certification of Chief Financial Officer Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 (18 U.S.C. 1350).
<u>101.INS*</u>	Inline XBRL Instance Document - the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document.
<u>101.SCH*</u>	Inline XBRL Taxonomy Extension Schema Document.
<u>101.DEF*</u>	Inline XBRL Taxonomy Extension Definition Linkbase Document.
<u>101.LAB*</u>	Inline XBRL Taxonomy Extension Label Linkbase Document.
<u>101.PRE*</u>	Inline XBRL Taxonomy Extension Presentation Linkbase Document.
<u>104*</u>	Cover Page Interactive Data File (formatted as inline XBRL and contained in Exhibit 101)

* Filed herewith.

SIGNATURES

Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

OAKTREE SPECIALTY LENDING CORPORATION

By: /s/ Armen Panossian
Armen Panossian
Chief Executive Officer

By: /s/ Christopher McKown
Christopher McKown
Chief Financial Officer and Treasurer

Date: February 6, 2023

I, Armen Panossian, Chief Executive Officer of Oaktree Specialty Lending Corporation, certify that:

1. I have reviewed this quarterly report on Form 10-Q for the quarter ended December 31, 2022 of Oaktree Specialty Lending Corporation;
2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4. The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
 - (a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
 - (b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
 - (c) Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
 - (d) Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and
5. The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):
 - (a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and
 - (b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

Dated this 6th day of February, 2023.

By: /s/ Armen Panossian
 Armen Panossian
 Chief Executive Officer

I, Christopher McKown, Chief Financial Officer of Oaktree Specialty Lending Corporation, certify that:

1. I have reviewed this quarterly report on Form 10-Q for the quarter ended December 31, 2022 of Oaktree Specialty Lending Corporation;

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4. The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

(a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

(b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

(c) Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

(d) Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and

5. The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):

(a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and

(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

Dated this 6th day of February, 2023.

By: /s/ Christopher McKown

Christopher McKown
Chief Financial Officer

Certification of Chief Executive Officer
Pursuant to
Section 906 of the Sarbanes-Oxley Act of 2002 (18 U.S.C. 1350)

In connection with the quarterly report on Form 10-Q for the quarter ended **December 31, 2022** (the “Report”) of **Oaktree Specialty Lending Corporation** (the “Registrant”), as filed with the Securities and Exchange Commission on the date hereof, I, **Armen Panossian**, the Chief Executive Officer of the Registrant, hereby certify, to the best of my knowledge, that:

- (1) The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and
- (2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Registrant.

/s/ Armen Panossian

Name: Armen Panossian

Date: February 6, 2023

Certification of Chief Financial Officer
Pursuant to
Section 906 of the Sarbanes-Oxley Act of 2002 (18 U.S.C. 1350)

In connection with the quarterly report on Form 10-Q for the quarter ended **December 31, 2022** (the “Report”) of **Oaktree Specialty Lending Corporation** (the “Registrant”), as filed with the Securities and Exchange Commission on the date hereof, I, **Christopher McKown**, the Chief Financial Officer of the Registrant, hereby certify, to the best of my knowledge, that:

- (1) The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and
- (2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Registrant.

/s/ Christopher McKown

Name: Christopher McKown

Date: February 6, 2023